0001477932-13-002502.txt : 20130515 0001477932-13-002502.hdr.sgml : 20130515 20130515164523 ACCESSION NUMBER: 0001477932-13-002502 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130515 DATE AS OF CHANGE: 20130515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAIS ANALYTIC CORP CENTRAL INDEX KEY: 0001125699 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS MANUFACTURING INDUSTRIES [3990] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53554 FILM NUMBER: 13847928 BUSINESS ADDRESS: STREET 1: 11552 PROSPEROUS DRIVE CITY: ODESSA STATE: FL ZIP: 33556 10-Q 1 dais_10q.htm FORM 10-Q dais_10q.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q

x
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended March 31, 2013
 
¨
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the transition period from _____ to _____
 
Commission File No. 000-53554
 
DAIS ANALYTIC CORPORATION
(Exact name of Registrant as specified in its charter)
 
New York
 
14-1760865
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)
 
11552 Prosperous Drive, Odessa, FL 33556
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (727) 375-8484

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. Yes x   No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x   No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “accelerated filer, large accelerated filer and smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

There were 55,509,884 shares of the Registrant’s $0.01 par value common stock outstanding as of May 14, 2013.
 


 
 

 
 
Dais Analytic Corporation
INDEX
 
     
Page No.
 
Part I. Financial Information
         
Item 1.
Financial Statements
     
         
 
Balance Sheets as of March 31, 2013 (Unaudited) and December 31, 2012
   
3
 
           
 
Statements of Operations for the three months ended March 31, 2013 and 2012 (Unaudited)
   
4
 
           
 
Statement of Stockholders’ Deficit for the three months ended March 31, 2013 (Unaudited)
   
5
 
           
 
Statements of Cash Flows for the three months ended March 31, 2013 and 2012 (Unaudited)
   
6
 
           
 
Notes to Financial Statements (Unaudited)
   
7
 
           
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operation
   
17
 
           
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
   
23
 
           
Item 4T.
Controls and Procedures
   
23
 
           
Part II. Other Information
           
Item 1.
Legal Proceedings
   
24
 
           
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
   
24
 
           
Item 3.
Default Upon Senior Securities
   
24
 
           
Item 4.
Mine Safety Disclosures
   
24
 
           
Item 5.
Other Information
   
24
 
           
Item 6.
Exhibits
   
25
 
         
Signatures
   
26
 

 
2

 
 
PART I— FINANCIAL INFORMATION

DAIS ANALYTIC CORPORATION
BALANCE SHEETS
 
   
March 31,
   
December 31,
 
   
2013
   
2012
 
ASSETS
 
(unaudited)
       
             
CURRENT ASSETS:
           
Cash and cash equivalents
  $ 18,174     $ 294,150  
Accounts receivable, net (including related party receivables of $391,345 and $0
               
at March 31, 2013 and December 31, 2012, respectively)
    451,163       512,842  
Inventory
    353,505       292,443  
Prepaid expenses and other current assets
    46,304       45,945  
Total Current Assets
    869,146       1,145,380  
                 
Property and equipment, net
    92,748       95,557  
                 
OTHER ASSETS:
               
Deposits
    2,280       2,280  
Patents, net of accumulated amortization of $159,803 and
               
$153,796 at March 31, 2013 and December 31, 2012, respectively
    117,507       107,230  
Total Other Assets
    119,787       109,510  
                 
                 
TOTAL ASSETS
  $ 1,081,681     $ 1,350,447  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
               
                 
CURRENT LIABILITIES:
               
Accounts payable, including related party payables of
               
$86,261 and $82,195 at March 31, 2013 and December 31, 2012, respectively
  $ 554,596     $ 559,946  
Accrued compensation and related benefits
    -       10,000  
Accrued expenses, other
    159,091       140,975  
Current portion of deferred revenue
    169,764       189,094  
Total Current Liabilities
    883,451       900,015  
                 
LONG-TERM LIABILITIES:
               
Accrued compensation and related benefits
    1,515,045       1,484,739  
Deferred revenue, net of current portion
    1,863,537       1,894,627  
Total Long-Term Liabilities
    3,378,582       3,379,366  
                 
STOCKHOLDERS' DEFICIT
               
 Preferred stock; $0.01 par value; 10,000,000 shares authorized; 0 shares issued
               
and outstanding
    -       -  
 Common stock, $0.01 par value; 200,000,000 shares authorized; 55,767,097 and 55,274,817
               
 shares issued and 55,509,884 and 55,017,604 shares outstanding, respectively
    557,672       552,749  
 Common stock payable
    -       19,255  
 Capital in excess of par value
    35,792,064       35,723,001  
 Accumulated deficit
    (38,257,976 )     (37,951,827 )
      (1,908,240 )     (1,656,822 )
 Treasury stock at cost, 257,213 shares
    (1,272,112 )     (1,272,112 )
 Total Stockholders' Deficit
    (3,180,352 )     (2,928,934 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
  $ 1,081,681     $ 1,350,447  
 
The accompanying notes are an integral part of these financial statements.
 
 
3

 
 
DAIS ANALYTIC CORPORATION
STATEMENTS OF OPERATIONS (UNAUDITED)
 
   
For the Three Months Ended
March 31,
 
   
2013
   
2012
 
             
REVENUE:
           
Sales
  $ 569,622     $ 1,018,983  
License fees
    50,420       20,500  
      620,042       1,039,483  
                 
COST OF GOODS SOLD
    486,593       683,137  
                 
GROSS MARGIN
    133,449       356,346  
                 
OPERATING EXPENSES
               
Research and development expenses, net of government grant proceeds of
               
$0 and $67,240, respectively
    114,329       91,598  
Selling, general and administrative expenses
    325,371       434,765  
TOTAL OPERATING EXPENSES
    439,700       526,363  
                 
LOSS FROM OPERATIONS
    (306,251 )     (170,017 )
                 
OTHER EXPENSE (INCOME)
               
Change in fair value of warrant liability
    -       (587,930 )
Amortization of discount on convertible note payable
    -       358,555  
Interest expense
    -       77,786  
Interest income
    (102 )     (45 )
TOTAL OTHER EXPENSE (INCOME)
    (102 )     (151,634 )
                 
NET LOSS
  $ (306,149 )   $ (18,383 )
                 
NET LOSS PER COMMON SHARE, BASIC AND DILUTED
  $ (0.01 )   $ (0.00 )
                 
WEIGHTED AVERAGE NUMBER OF
               
COMMON  SHARES OUTSTANDING, BASIC AND DILUTED
    55,422,501       37,774,817  
 
The accompanying notes are an integral part of these financial statements.
 
 
4

 

DAIS ANALYTIC CORPORATION
STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)
 
                     
Capital in
               
Total
 
   
Common Stock
   
Common Stock
   
Excess of
   
Accumulated
   
Treasury
   
Stockholders'
 
   
Shares
   
Amount
   
Payable
   
Par Value
   
Deficit
   
Stock
   
Deficit
 
                                           
Balance, December 31, 2012
    55,274,817     $ 552,749     $ 19,255     $ 35,723,001     $ (37,951,827 )   $ (1,272,112 )   $ (2,928,934 )
                                                         
Stock based compensation
    -       -       -       24,758       -       -       24,758  
                                                         
Issuance of common stock for cash
    492,280       4,923       (19,255 )     44,305       -       -       29,973  
                                                         
Net loss
    -       -       -       -       (306,149 )     -       (306,149 )
                                                         
Balance, March 31, 2013
    55,767,097     $ 557,672     $ -     $ 35,792,064     $ (38,257,976 )   $ (1,272,112 )   $ (3,180,352 )
 
The accompanying notes are an integral part of these financial statements.
 
 
5

 

DAIS ANALYTIC CORPORATION
STATEMENTS OF CASH FLOWS (UNAUDITED)
 
   
For the Three Months Ended
March 31,
 
   
2013
   
2012
 
             
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
  $ (306,149 )   $ (18,383 )
Adjustments to reconcile net loss to net cash and cash equivalents
               
(used) provided by operating activities:
               
Depreciation and amortization
    14,627       13,292  
Stock based compensation expense
    24,758       41,584  
Change in fair value of warrant liability
    -       (587,930 )
Amortization of deferred loan costs
    -       15,224  
Amortization of discount on convertible note payable
    -       358,555  
(Increase) decrease in:
               
Accounts receivable
    61,679       291,289  
Other receivables
    -       73,648  
Inventory
    (61,062 )     (65,123 )
Prepaid expenses and other assets
    (359 )     (27,820 )
Increase (decrease) in:
               
Accounts payable and accrued expenses
    61,787       147,920  
Accrued compensation and related benefits
    (28,715 )     1,667  
Deferred revenue
    (50,420 )     (236,959 )
Net cash (used) provided by operating activities
    (283,854 )     6,964  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Increase in patent costs
    (16,284 )     (12,709 )
Purchase of property and equipment
    (5,811 )     -  
Net cash used by investing activities
    (22,095 )     (12,709 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Payments for loan and offering costs
    -       (4,650 )
Issuance of common stock, net of offering costs
    29,973       -  
Net cash provided by financing activities
    29,973       (4,650 )
                 
Net decrease in cash and cash equivalents
    (275,976 )     (10,395 )
                 
Cash and cash equivalents, beginning of period
    294,150       262,740  
                 
Cash and cash equivalents, end of period
  $ 18,174     $ 252,345  
                 
SUPPLEMENTAL CASH FLOW INFORMATION:
               
Cash paid for interest
  $ -     $ 233  
 
The accompanying notes are an integral part of these financial statements.
 
 
6

 

Dais Analytic Corporation
Notes to Financial Statements
Three Months Ended March 31, 2013
(Unaudited)

1.
Background Information

Dais Analytic Corporation, a New York corporation, (the “Company”) has developed and is commercializing applications using its nano-structure polymer technology. The first commercial product is an energy recovery ventilator (“ERV”) (cores and systems) for use in commercial Heating, Ventilating, and Air Conditioning (HVAC) applications. In addition to direct sales, the Company licenses its nano-structured polymer technology to strategic partners in the aforementioned application and is in various stages of development with regard to other applications employing its base technologies. The Company was incorporated in April 1993 with its corporate headquarters located in Odessa, Florida.

The accompanying financial statements of the “Company” are unaudited, but in the opinion of management, reflect all adjustments necessary to fairly state the Company’s financial position, results of operations, stockholders’ deficit and cash flows as of and for the dates and periods presented. The financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.

The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted although the Company generally believes that the disclosures are adequate to ensure that the information presented is not misleading. The accompanying financial statements and notes should be read in conjunction with the audited financial statements and notes of the Company for the fiscal year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2013. The results of operations for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for any future quarters or for the entire year ending December 31, 2013.

2.
Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses since inception. As of March 31, 2013, the Company has an accumulated deficit of $38,257,976, negative working capital of $63,326 and a stockholders’ deficit of $3,180,352. The Company (used) provided ($283,854) and $6,964 of cash in operations during the three months ended March 31, 2013 and 2012, respectively, which was funded by proceeds from product sales and equity financings. There is no assurance that such equity financing will be available in the future. In view of these matters, there is substantial doubt that the Company will continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:

 
1.
We are currently holding preliminary discussions with parties who are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize certain applications of our technology.
 
2.
We are seeking growth capital from certain strategic and/or government (grant) related sources. In addition to said capital, these sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of our products.
 
 
7

 
 
The Company’s ability to continue as a going concern is highly dependent on our ability to obtain additional sources of cash flow sufficient to fund our working capital requirements. However, there can be no assurance that the Company will be successful in its efforts to secure such cash flow. Any failure by us to timely procure additional financing or investment adequate to pay our outstanding debt and fund our ongoing operations, including planned product development initiatives and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.

The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

3.
Significant Accounting Policies

In the opinion of management, all adjustments necessary for a fair statement of (a) the results of operations for the three month periods ended March 31, 2013 and 2012, (b) the financial position at March 31, 2013 and December 31, 2012, and (c) cash flows for the three month periods ended March 31, 2013 and 2012, have been made.

The significant accounting policies followed are:

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents - Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage reverted to $250,000 per depositor at each financial institution. The Company's non-interest bearing cash balances were fully insured at March 31, 2013..

Accounts receivable - Accounts receivable consist primarily of receivables from the sale of our ERV products. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company’s collection experience, customer credit worthiness, and current economic trends.  Based on management’s review of accounts receivable, we have recorded an allowance for doubtful accounts of $2,576 at March 31, 2013 and December 31, 2012.

Inventory - Inventory consists primarily of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.

Property and equipment - Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 5 to 7 years. Gains and losses upon disposition are reflected in the statement of operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. Property and equipment are evaluated for impairment when events change or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.
 
 
8

 

Intangible assets - Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company’s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 15 years. Patent amortization expense was approximately $6,000 and $4,400 for the three months ended March 31, 2013 and 2012, respectively. Total patent amortization expense for the next five years is estimated to be approximately $24,000 per year.

Long-lived assets - Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company uses market quotes, if available or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether or not the asset values are recoverable. There have been no significant impairments of long-lived assets during the three month period ended March 31, 2013.

Revenue recognition - Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from a related party) and 67% of revenues, respectively.  During the three months ended March 31, 2013 one customer, which is a related party of the Company, accounted for approximately 86.2% of accounts receivable.

In certain instances, our ConsERV product carries a warranty for two years for all parts contained therein with the exception of the energy recovery ventilator core which, in such circumstances, typically carries a 10 year warranty. The warranty includes replacement of defective parts. The Company has recorded an accrual of approximately $94,100 and $92,900 for future warranty expenses at March 31, 2013 and December 31, 2012, respectively.

Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of $50,420 and $20,500 from license agreements for the three months ended March 31, 2013 and 2012, respectively.

The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

Employee stock based compensation - The Company recognizes all share-based awards to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

There were no awards granted during the three months ended March 31, 2013 and 2012.
 
 
9

 

Non-employee stock-based compensation - The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC 505-50, Equity-Based Payments to Non-Employees.  Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The fair value of common stock issued for services is based on the closing stock price on the date the common stock was issued. During the three months ended March 31, 2013 and 2012, the Company did not issue any non-employee stock based compensation.

Research and development expenses and grant proceeds - Expenditures for research, development and engineering of products are expensed as incurred. For the three months ended March 31, 2013 and 2012, the Company incurred research and development costs of approximately $114,300 and $158,800, respectively.  The Company accounts for proceeds received from government grants for research as a reduction in research and development costs. For the three months ended March 31, 2012, the Company recorded approximately $67,200 in grant proceeds against research and development expenses on the statement of operations.  There were no grant proceeds received by the Company during the three months ended March 31, 2013.

Government grants - Grants are recognized when there is reasonable assurance that the grant will be received and that any conditions associated with the grant will be met. When grants are received related to property and equipment, the Company reduces the basis of the assets resulting in lower depreciation expense over the life of the associated asset. Grants received related to expenses are reflected as a reduction of the associated expense in the period in which the expense is incurred.

Financial instruments - Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 
 
Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
 
 
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
 
 
Level 3 - Inputs that are both significant to the fair value measurement and unobservable.
 
 
10

 
 
Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2013. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities, which include cash equivalents of $336 at March 31, 2013. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities.

The respective carrying value of certain on-balance sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued compensation and accrued expenses.

Income taxes - Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are computed on the basis of differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based upon enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2009 through 2012.

Earnings (loss) per share - Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. At March 31, 2013 and 2012, the Company had 38,543,711 and 54,463,590 potentially dilutive common shares that were not included in the computation of income (loss) per share.

Derivative financial instruments - The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 “Derivative and Hedging” (ASC 815) to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.

Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.

Recent accounting pronouncements - Recent accounting pronouncements issued by FASB, the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
 
 
11

 

4.
Accrued Expenses, other

Accrued expenses, other consist of the following:
 
   
March 31,
2013
   
December 31,
2012
 
Accrued expenses, other
 
$
46,838
   
$
29,946
 
Accrued registration rights penalty
   
5,000
     
5,000
 
Accrued warranty costs
   
94,053
     
92,829
 
Contractual obligation
   
13,200
     
13,200
 
   
$
159,091
   
$
140,975
 
 
5.
Related Party Transactions

Timothy N. Tangredi, our Chief Executive Officer and Chairman, is a founder and a member of the board of directors of Aegis BioSciences, LLC (“Aegis”). Mr. Tangredi currently owns 52% of Aegis’ outstanding equity and spends approximately one to two days per month on Aegis business for which he is compensated by Aegis. Aegis has two exclusive, world-wide licenses from us under which it has the right to use and sell products containing our polymer technologies in biomedical and health care applications. As a result of a $150,000 payment made by Aegis, the first license is considered fully paid and as such no additional license revenue will be forthcoming. Pursuant to the second license Aegis made an initial one-time payment of $50,000 and is to make royalty payments of 1.5% of the net sales price it receives with respect to any personal hygiene product, surgical drape or clothing products (the latter when employed in medical and animal related fields) and license revenue it receives should Aegis grant a sublicense to a third party. To date Aegis has sold no such products nor has it received any licensing fees requiring a royalty payment be made to us. All obligations for such payments will end on the earlier of June 2, 2015 or upon the aggregate of all sums paid to us by Aegis under the agreement reaching $1 million. The term of each respective license runs for the duration of the patented technology.

The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Rent expense for this building is currently $4,066 per month. The Company recognized rent expense of approximately $12,200 and $11,400 during the three months ended March 31, 2013 and 2012, respectively. At March 31, 2013 and December 31, 2012, $85,637 and $82,195, respectively, were included in accounts payable for amounts owed for rent.

The Company also has accrued compensation due to the Chief Executive Officer and two other employees for deferred salaries earned and unpaid as of March 31, 2013 and December 31, 2012 of $1,466,024 and $1,494,739, respectively. During 2012, the Company determined that a portion of the accrued payroll, $1,484,739, is a long term liability, as the Company does not believe it will repaid within the next year.

The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.
 
 
12

 

6.
Stock Options and Warrants

Options

In June 2000 and November 2009, our Board of Directors adopted, and our shareholders approved, the 2000 Plan and 2009 Plan, respectively (together the “Plans”). The Plans provide for the granting of options to qualified employees of the Company, independent contractors, consultants, directors and other individuals. The Company’s Board of Directors approved and made available 11,093,886 and 15,000,000 shares of common stock to be issued pursuant to the 2000 Plan and the 2009 Plan. The Plans permit grants of options to purchase common shares authorized and approved by the Company’s Board of Directors.

There were no options awarded or exercised during the three months ended March 31, 2013 and 2012.

The following summarizes the information relating to outstanding stock options activity with employees during 2013 and 2012:
 
   
Common
Shares
   
Weighted Average
Exercise Price
   
Weighted Average
Remaining
Contractual Term
(in years)
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2012
   
18,647,332
   
$
0.29
     
6.06
   
$
26,345
 
Expired/Forfeited
   
(99,999
)
 
$
0.32
                 
         
Outstanding at March 31, 2013
   
18,547,333
   
$
0.29
     
6.03
   
$
356,486
 
                                 
Exercisable at March 31, 2013
   
17,589,137
   
$
0.29
     
5.84
   
$
296,041
 

Stock compensation expense was approximately $24,800 and $41,600 for the three months ended March 31, 2013 and 2012, respectively. The total fair value of shares vested during the three months ended March 31, 2013 and 2012 was approximately $27,400 and $87,300, respectively.

As of March 31, 2013, there was approximately $110,700 of unrecognized employee stock-based compensation expense related to non vested stock options, of which $55,900, $32,300 and $22,500 is expected to be recognized for the remainder of the fiscal year ending December 31, 2013, and for the fiscal years ending 2014 and 2015, respectively.

The following table represents our non vested share-based payment activity with employees for the three months ended March 31, 2013:
 
   
Number of
Options
   
Weighted
Average
Grant Date
Fair Value
 
Nonvested options - December 31, 2012
   
1,235,555
   
$
0.16
 
Granted
   
   
$
 
Vested
   
(138,473
)
 
$
0.20
 
Forfeited
   
(138,886
)
 
$
 
                 
Nonvested options – March 31, 2013
   
958,196
   
$
0.16
 
 
 
13

 
 
Warrants

At March 31, 2013, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:

Warrants
 
Remaining
Number Outstanding
   
Weighted Average
Remaining Life
(Years)
   
Weighted Average
Exercise Price
 
Expiration Year
                           
Warrants-Financing
   
7,000,000
     
3.99
   
$
0.34
 
2016 – 2017
Warrants-Tangredi
   
3,000,000
     
.25
   
$
0.36
 
2013
Warrants-Ehrenberg
   
250,000
     
.59
   
$
0.30
 
2013
Warrants-Consulting Agreement
   
825,000
     
1.77
   
$
0.30
 
2014 – 2015
Warrants-Note Conversions
   
2,302,538
     
1.42
   
$
0.39
 
2014 – 2015
Warrants-Stock Purchases
   
6,218,840
     
4.22
   
$
0.33
 
2014 – 2017
Warrants-Services
   
400,000
     
2.06
   
$
0.50
 
2015
Tota
   
19,996,378
                   
 
7.
Terminated Sales Agreements

On August 21, 2009, we entered into an Exclusive Distribution Agreement with Genertec, under which we are to supply and Genertec is to distribute, on an exclusive basis, three of our nanotechnology-based membrane products and related products in Greater China, including mainland China, Hong Kong, Macau and Taiwan. The agreement provides that during the initial five year term of the agreement, Genertec will order and purchase these products in the aggregate amount of $200 million. A minimum quantity of said products is to be purchased by Genertec during each contract year of the initial term.

In April of 2010, the Company entered into a technical and sales agreement with CAST Systems Control Technology Co., Ltd. (“CAST”) and Genertec with a value of up to approximately $48 million over a twelve month period. Under the terms of the Agreement, the Company will supply to CAST, through Genertec, key system components of its nanotechnology clean water process.

During 2011, Genertec expressed a desire to limit its participation in this endeavor as they find NanoAir and NanoClear to have engineering requirements they are not best suited to undertake. During the three months ended March 31, 2012, we terminated the Genertec and CAST agreements and recognized $150,000 nonrefundable deposit received from Genertec as revenue.

8.
Stock Purchase Agreement

On October 17, 2012, Dais Analytic Corporation (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with an investor, Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Company will offer up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock (such offer being the “Offering”).Pursuant to the terms and conditions of the SPA, Company agreed to issue the Common Stock and Warrants in three tranches. The Warrants are exercisable for 60 months beginning on the date of their issuance. The warrants have an exercise price of $0.30, and are subject to standard anti-dilution adjustments for stock splits and other subdivisions. Pursuant to terms of the Offering, officers of the Company and the Investor have signed lock-up agreements restricting the sale of Common Stock. The Investor does not have any registration rights with respect to the Common Stock or Warrants. No underwriter or placement agent was used in the sale of the Common Stock or Warrants.
 
 
14

 

On December 28, 2012, Dais Analytic Corporation (the “Company”) amended the SPA, dated October 17, 2012, with Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Investor will purchase up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock. Pursuant to the terms of the SPA, the Investor has purchased $1,750,000 of Common Stock and Warrants and the Company as recorded a common stock payable for an additional amount of $19,255. The amendment requires the Purchaser to purchase the remaining Common Stock and Warrants on or before January 31, 2013.

In 2012, the Company sold and issued, in connection with the SPA, 17,500,000 shares of its common stock to the Investor for $1,750,000. In addition, as part of the purchase it issued the Investor a warrant to purchase 4,375,000 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $.30 per share.

During 2013, in connection with the SPA, the Company sold and issued 492,280 shares to the Investor for $49,228 in cash, of which $19,255 was received in 2012.  In addition, under the terms of this agreement, the Investor also received a warrant to purchase 123,070 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $0.30 per share. The SPA expired, per its terms and conditions, on January 31, 2013. The parties are in discussions to permit the Investor to purchase securities on similar terms and conditions

9. 
Deferred Revenue

The Company entered into a licensing agreement during the year ended December 31, 2003 and received an initial fee of $770,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 10 years. In addition, the Company received royalties of $100,000 in each of the first three years of the agreement. The Company recognized revenue of approximately $19,250 for this agreement during each of the three months ended March 31, 2013 and 2012.

The Company entered into a licensing agreement with a biomedical entity during the year ended December 31, 2005 and received an initial license fee of $50,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 7 years. The Company recognized revenue of approximately $1,250 for this agreement during each of the three months ended March 31, 2013 and 2012.

On October 30, 2012, the Company and MG Energy LLC, a Delaware limited liability company (“MG Energy”) , a company in which a shareholder of the Company holds a position, entered into a License and Supply Agreement (the “Agreement”), effective October 26, 2012, pursuant to which the Company licensed certain intellectual property and improvements thereto to MG Energy, for use in the manufacture and sale of energy recovery ventilators (“ERV”) and certain other HVAC systems for installation in commercial, residential or industrial buildings in North America and South America in exchange for the cancellation of $2,034,521 of debt due to MG Energy. MG Energy also agreed to purchase its requirements of certain ConsERV products from the Company for MG Energy’s use, pursuant to the terms and conditions of the Agreement. MG Energy will also pay royalties, as defined, to the Company on the net sales of each product or system sold. The term of the Agreement will expire upon the last to expire of the underlying patent rights for the licensed technology.

The Company has identified all of the deliverables under the Agreement and has determined significant deliverables to be the license for the intellectual property and the supply services. In determining the units of accounting, the Company evaluated whether the license has stand alone value to MG Energy based upon consideration of the relevant facts and circumstances of the Agreement. The Company determined that the license does not have stand alone value to the licensee and, therefore, should be combined with the supply agreement as one unit of accounting. The initial payment for the license agreement will be treated as an advance payment and recognized over the performance period of the supply agreement. Royalties will be recognized as revenue when earned. The Company recognized revenue of $29,920 in license fees and $475,287 in product sales relating to this Agreement during the three months ended March 31, 2013.
 
 
15

 

10. 
Change in Fair Value of Warrant Liability

The Company has accounted for certain warrants in accordance with ASC 815-10, Derivatives and Hedging (ASC 815-10).  ASC 815-10 provides guidance for determining whether an equity-linked financial instrument (or embedded feature) is indexed to an entity’s own stock.  This applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative under ASC 815-10, including any freestanding financial instrument that is potentially settled in an entity’s own stock.

Due to certain adjustments that may be made to the exercise price of the warrants issued in December 2007, January 2008 and August 2008 if the Company issues or sells shares of its common stock at a price which is less than the then current warrant exercise price, these warrants have been classified as a liability as opposed to equity in accordance with the Derivatives and Hedging Topic of the FASB ASC 815-10-15 as it was determined that these warrants were not indexed to the Company’s stock. As a result, the fair market value of these warrants was remeasured on January 1, 2009 and marked to market at each subsequent financial reporting period. The change in fair value of the warrants is recorded in the statement of operations and is estimated using the Black-Scholes option-pricing model with the following assumptions:

   
For the Three Months Ended March 31,
   
2012
         
Exercise price
 
$
0.25
 
Market value of stock at end of period
 
$
0.19
 
Expected dividend rate
   
N/A
 
Expected volatility
   
167% - 174
%
Risk-free interest rate
   
0.19
%
Expected life in years
   
0.70 – 0.84
 
Shares underlying warrants outstanding classified as liabilities
   
13,401,333
 

All warrants issued by the Company other than the above noted warrants are classified as equity.  For the three months ended March 31, 2013 and 2012, the Company recognized a change in the fair value of the warrant liability of $0 and $587,930, respectively.  All of the warrants underlying the warrant liability have expired as of March 31, 2013.
 
11. 
Amortization of Debt Discount on Convertible Note Payable

On March 22, 2011, the Company entered into a 10% note and warrant purchase agreement, secured convertible promissory note and patent security agreement (“financing agreements”) with an investor.In connection with the financing agreements, the Company issued a stock purchase warrant to the investor to purchase 3,000,000 shares of the Company’s common stock at $0.45 per share, exercisable until March 22, 2016. The warrant was fair valued on the date of issuance, which amounted to $1,204,787. The warrant value was recorded as a debt discount based on the relative fair value of the warrant to the total proceeds received, which amounted to $435,240. The warrant was fair valued using the Black-Scholes-Merton valuation model. In addition, the debt contained a beneficial conversion feature, which was valued at the date of issuance at $1,762,163; however, since this amount is in excess of the net value of the debt less the warrant discount, the beneficial conversion feature will be limited to $1,064,760 and recorded as a discount on the loan. The total debt discount of $1,500,000 is being amortized using the effective interest method over the 12-month term of the Secured Note. For the three months ended March 31, 2012 the Company recognized $358,555 as amortization of this debt discount.  The debt discount was fully amortized as of December 31, 2012.
 
 
16

 

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the notes thereto included elsewhere in this quarterly report on Form 10-Q and in our annual report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2013.

THIS FILING, INCLUDING BUT NOT LIMITED TO “MANAGEMENT’S DISCUSSION AND ANALYSIS”, CONTAINS FORWARD-LOOKING STATEMENTS. THE WORDS “ANTICIPATED,” “BELIEVE,” “EXPECT,” “PLAN,” “INTEND,” “SEEK,” “ESTIMATE,” “PROJECT,” “WILL,” “COULD,” “MAY,” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS INCLUDE, AMONG OTHERS, INFORMATION REGARDING FUTURE OPERATIONS, FUTURE CAPITAL EXPENDITURES, AND FUTURE NET CASH FLOW. SUCH STATEMENTS REFLECT THE COMPANY’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, GENERAL ECONOMIC AND BUSINESS CONDITIONS, CHANGES IN FOREIGN, POLITICAL, SOCIAL, AND ECONOMIC CONDITIONS, REGULATORY INITIATIVES AND COMPLIANCE WITH GOVERNMENTAL REGULATIONS, THE ABILITY TO ACHIEVE FURTHER MARKET PENETRATION AND ADDITIONAL CUSTOMERS, AND VARIOUS OTHER MATTERS, MANY OF WHICH ARE BEYOND THE COMPANY’S CONTROL. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD- LOOKING STATEMENTS AS A RESULT OF SEVERAL FACTORS, INCLUDING THE RISKS FACED BY US AS DESCRIBED BELOW AND ELSEWHERE IN THIS FORM 10-Q AS WELL AS IN OUR FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 29, 2013. IN LIGHT OF THESE RISKS AND UNCERTAINTIES THERE CAN BE NO ASSURANCE THAT THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS FORM 10-Q WILL OCCUR. WE HAVE NO OBLIGATION TO PUBLICLY UPDATE OR REVISE THESE FORWARD-LOOKING STATEMENTS TO REFLECT NEW INFORMATION, FUTURE EVENTS, OR OTHERWISE, EXCEPT AS REQUIRED BY FEDERAL SECURITIES LAWS AND WE CAUTION YOU NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS. WE MAY NOT UPDATE THESE FORWARD-LOOKING STATEMENTS, EVEN THOUGH OUR SITUATION MAY CHANGE IN THE FUTURE.

OVERVIEW

We have developed and patented a nano-structure polymer technology, which is being commercialized in products based on the functionality of these materials. We believe the applications of our technology have promise in a number of diverse market segments and products.

The initial product commercialized by the Company is ConsERV, an energy recovery ventilator. Our primary focus is to expand our marketing and sales of our ConsERV products world-wide. We also have new product applications in various stages of development. We believe that three of these product applications, including an advanced air conditioning system which is projected to be more energy efficient and have lower emissions compared to current HVAC equipment, a sea-water desalination product and an electrical energy storage device, may be brought to market in the foreseeable future if we receive adequate capital funding.

We expect ConsERV™ to continue to be our focused commercial product through 2013 with a growing emphasis on moving the development of the NanoClear and NanoAir technologies towards commercialization.

RECENT DEVELOPMENTS
 
In April 2013, the U.S. Department of Defense, Navy and the U.S. Department of Energy Advanced Research Projects Agency-Energy (ARPA-E) approved a grant of up to $800,000 to Company for the funding of a project to produce and trial a chilling system, that is operated by directly manipulating water vapor using Company’s selectively permeable membrane made of a nano-structure solid polymer. The grant requires the Company to contribute $200,000 of the proposed total project cost of $1,000,000. The Company will receive the grant amount in phases upon the meeting of certain milestones. The grant will advance our Nano Air technologies toward commercialization.
 
Joyce Conner-Boyd, was appointed Chief Operating Officer in March of 2013. Prior to accepting this position, she served as Senior Vice President of Vertical Domains for SoftServ Inc. From 1995 to 2010, Ms. Conner-Boyd was employed by HealthPort Technologies, (formerly Smart Document Solutions), in various executive roles specializing in performance improvement and strategic operations.
 
REVENUES

We generate our revenues primarily from the sale of our ConsERV™ products in largely commercial HVAC equipment with a small amount of revenue coming from sales to distributors for residential HVAC equipment. Sales channels for our ConsERV™ products include original equipment manufacturers (“OEM”), our North and South America licensee, distributors and retailers. We also occasionally license our technology to other strategic partners and sell various prototypes of other product applications that use our polymer technology.
 
 
17

 

Our near term revenue growth is dependent on sales from (i) the growth of our licensee’s sales in North and South America, (ii) more seasoned independent sales representatives world-wide, (iii) a greater number of independent sales representatives in certain areas, (iv) fulfilling the ventilation needs of the growing “energy consultant” marketplace which work to lower their client’s energy costs and emissions, and (v) from the Company’s own ‘customer direct’ sales activities, all of which focus on the sale of product primarily into the commercial user marketplace.

As a result of the License and Supply Agreement with MG Energy LLC, however, we anticipate both revenue and cost of goods sold for the second quarter of 2013 may decrease when compared to the same period in 2012.  The Company, MG Energy LLC and its independent sales representatives will work to secure orders for ConsERV™ products, including but not limited to “core only” sales from HVAC equipment manufacturers and from distribution firms servicing the equipment needs of the HVAC installer community. We are also working to create license/supply relationships with HVAC or ERV OEMs preferably having a dominant presence in existing direct related sales channels world-wide.
 
During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from an affiliate) and 67% of revenues, respectively
 
COST OF SALES

Our cost of sales consists primarily of materials (including freight), direct labor, and outsourced manufacturing expenses incurred to produce our ConsERV™ products.

We are dependent on third parties to manufacture the key components needed for our nano-structured based materials and value added products made with these materials. Accordingly, a supplier’s failure to supply components in a timely manner, or to supply components that meet our quality, quantity and cost requirements or our technical specifications, or the inability to obtain alternative sources of these components on a timely basis or on terms acceptable to us, would create delays in production of our products or increase our unit costs of production. Certain of the components contain proprietary products of our suppliers, or the processes used by our suppliers to manufacture these components are proprietary. If we are required to replace any of our suppliers, while we should be able to obtain comparable components from alternative suppliers at comparable costs, it would create a delay in production.

Our cost of sales may fluctuate due to a number of factors, including, but not limited to:

 
 
A change in key suppliers or the prices that they charge for the fundamental components of our ConsERV™ products;

 
 
An increase in the labor resources needed to produce or expand the production of our ConsERV™ products;

 
 
Commercialization of new product applications of our polymer technology;

 
 
Continued technological improvements in key materials or configuration(s) to reduce our ‘per unit’ cost structure; and

 
 
Additional outsourcing of our manufacturing and assembly processes with strategic partners to reduce our ‘per unit’ cost structure.
 
 
18

 
 
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Our selling, general and administrative expenses consist primarily of payroll and related benefits, share-based compensation, professional fees, marketing and channel support costs, and other infrastructure costs such as insurance, information technology and occupancy expenses.

Our selling, general and administrative expenses may fluctuate due to a variety of factors, including, but not limited to:
 
 
 
Additional expenses as a result of being a reporting company including, but not limited to, director and officer insurance, director fees, SEC reporting and compliance expenses, transfer agent fees, additional staffing, professional fees and similar expenses;

 
 
Additional infrastructure needed to support the expanded commercialization of our ConsERV™ products and/or new product applications of our polymer technology for, among other things, administrative personnel, physical space, marketing and channel support and information technology; and

 
 
The fair value of new share-based awards, which is based on various assumptions including, among other things, the volatility of our stock price

Results of Operations

Summary of Three Months Ended March 31, 2013 Results of Operations

The following table sets forth, for the periods indicated, certain data derived from our Statements of Operations and certain of such data expressed as a percentage of revenues:
 
   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
Revenues
 
$
620,042
   
$
1,039,483
 
Percentage of revenues
   
100.0
%
   
100.0
%
Cost of goods sold
 
$
486,593
   
$
683,137
 
Percentage of revenues
   
78.5
%
   
65.7
%
Research and development expenses, net grant revenue
 
$
114,329
   
$
91,598
 
Percentage of revenues
   
18.4
%
   
8.8
%
Selling, general and administrative expenses
 
$
325,371
   
$
434,765
 
Percentage of revenues
   
52.5
%
   
41.8
%
Interest expense
 
$
0
   
$
77,786
 
Percentage of revenues
   
0.0
%
   
7.5
%
Change in fair value of warrant liability (gain)
 
$
0
   
$
(587,930
)
Percentage of revenues
   
0.0
%
   
56.6
%
Amortization of discount on convertible note payable
 
$
0
   
$
358,555
 
Percentage of revenues
   
0.0
%
   
34.5
%
Net loss
 
$
(306,149
)
 
$
(18,383
)
Percentage of revenues
   
49.4
%
   
1.8
%

REVENUES: Total revenues for the three months ended March 31, 2013 and 2012 were $620,042 and $1,039,486, respectively, a decrease of $419,444 or 40.4%. The decrease in revenues in the 2013 period is primarily attributable to transitioning ConsERV™ system sales in North and South America to MG Energy LLC, our licensee.  The decrease in revenues during 2013 is also attributed to the recognition of the $150,000 nonrefundable deposit related to the termination of the Genertec and the CAST agreements during the three months ended March 31, 2012.

COST OF GOODS SOLD: Cost of goods sold decreased $196,544 to $486,593 and represented 79% of revenues, for the three months ended March 31, 2013 compared to $683,137 or 66% of revenues for the three months ended March 31, 2012. Gross profit margin decreased from 34.3% in 2012 to 21.5% in 2013. The decrease in the cost of goods sold and the gross profit margin were due to transitioning ConsERV™ system sales to our licensee in North and South America.
 
 
19

 

RESEARCH AND DEVELOPMEN EXPENSES, NET OF GRANT REVENUE: Research and development expenses, net of grant revenue, of $114,329 for the three months ended March 31, 2013 increased from $91,598 for the same period ended March 31, 2012. The increase was primarily additional monies spent to advance Nanoclear™ towards commercialization without offsetting grant revenues earned during the three months ended March 31, 2013.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses of $325,371 for the three months ended March 31, 2013 decreased $109,394 from $434,765 in the same period of 2012 or 25.2%. The decrease was primarily due to a decrease in stock based compensation.

INTEREST EXPENSE: Interest expense was $0 for the three months ended March 31, 2013 compared to $77,786 for the same period of 2012. The decrease was primarily due to the repayment of debt during 2012.

AMORTIZATION OF DISCOUNT ON NOTE PAYABLE: Amortization of discount on note payable decreased to $0 for the three months ended March 31, 2013 compared to $358,555 for the same period ended March 31, 2012. The decrease was due to the related note payable reaching maturity in the first quarter 2012.

CHANGE IN FAIR VALUE OF WARRANT LIABILITY: The change in the fair value of warrant liability decreased for the three months ended March 31, 2013 to $0 from a gain of $587,930 in the prior period ended March 31, 2012 due to the expiration of the underlying warrants, which expired during the first quarter of 2013.

NET LOSS: Net loss for the three months ended March 31, 2013 increased by $287,766 to $306,149 from $18,383 for the three months ended March 31, 2012. The increase in net loss is primarily due to the decrease in the change in the fair value of the warrant liability and decrease in revenues as discussed above.

Liquidity and Capital Resources

The Company finances its operations primarily through sales of its ConsERV™ products, sales of its common stock, the issuance of convertible promissory notes, unsecured promissory notes and license agreements.

Our historical revenues have not been sufficient to sustain our operations. We have achieved profitability in only one year since inception and we expect to continue to incur net losses and negative cash flow from operations until we can produce sufficient revenues to cover our costs, which are not expected for several years. Furthermore, even if we achieve our goal of selling a greater number of ConsERV™ products, we anticipate that we will continue to incur losses until we can cost-effectively produce and sell our products to a wider market. Our profitability will require the successful commercialization of our ConsERV™ products and any future products we develop. No assurances can be given when this will occur.

Any future financing may result in substantial dilution to existing shareholders, and future debt financing, if available, may include restrictive covenants or may require us to grant a lender a security interest in any of our assets not already subject to an existing security interest. To the extent that we attempt to raise additional funds through third party collaborations and/or licensing arrangements, we may be required to relinquish some rights to our technologies or products currently in various stages of development, or grant licenses or other rights on terms that are not favorable to us. Any failure by us to timely procure additional financing or investment adequate to fund our ongoing operations, including planned product development initiatives and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.

We will be dependent upon our existing cash of $18,174 at March 31, 2013, product sales and any additional debt and equity issuances to finance our operations through the next 12 months, including other contractual obligations of approximately $75,093 as of March 31, 2013. We plan to raise additional capital in the amount of approximately $8.9 million, net of expenses, during the next eighteen months in order to secure new patents for innovative applications of our core technology, purchase equipment, and fund our working capital requirements in accordance with our existing plans through September 2014. This additional capital could be provided by a successful completion of an offering of equity securities or by entering into licensing agreements. If we are unable to raise these funds, we may be required to delay our development plans, and curtail our expenditures.
 
 
20

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses since inception. As of March 31, 2013, the Company has an accumulated deficit of $38,257,976, negative working capital of $63,326 and a stockholders’ deficit of $3,180,352. The Company used $283,854 and provided $6,964 of cash in operations during the three months ended March 31, 2013 and 2012, respectively, which was funded by proceeds from licensing and equity financings. There are no assurances that such financing will be available in the future. In view of these matters, there is substantial doubt that the Company will continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:

 
1.
We are currently holding preliminary discussions with parties who are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize certain applications of our technology.
 
2.
We are seeking growth capital from certain strategic and/or government (grant) related sources. In addition to said capital, these sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of our products.

The Company’s ability to continue as a going concern is highly dependent on our ability to obtain additional sources of cash flow sufficient to fund our working capital requirements. However, there can be no assurance that the Company will be successful in its efforts to secure such cash flow. Any failure by us to timely procure additional financing or investment adequate to fund our ongoing operations, including planned product development initiatives and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.

The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

On October 17, 2012, Dais Analytic Corporation (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with an investor, Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Company will offer up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock (such offer being the “Offering”).Pursuant to the terms and conditions of the SPA, Company agreed to issue the Common Stock and Warrants in three tranches. The Warrants are exercisable for 60 months beginning on the date of their issuance. The warrants have an exercise price of $0.30, and are subject to standard anti-dilution adjustments for stock splits and other subdivisions. Pursuant to terms of the Offering, officers of the Company and the Investor have signed lock-up agreements restricting the sale of Common Stock. The Investor does not have any registration rights with respect to the Common Stock or Warrants. No underwriter or placement agent was used in the sale of the Common Stock or Warrants.

On December 28, 2012, Dais Analytic Corporation (the “Company”) amended the SPA, dated October 17, 2012, with Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Investor will purchase up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock. Pursuant to the terms of the SPA, the Investor has purchased $1,750,000 of Common Stock and Warrants and the Company as recorded a common stock payable for an additional amount of $19,255. The amendment requires the Purchaser to purchase the remaining Common Stock and Warrants on or before January 31, 2013.

In 2012, the Company sold and issued, in connection with the SPA, 17,500,000 shares of its common stock to the Investor for $1,750,000. In addition, as part of the purchase it issued the Investor a warrant to purchase 4,375,000 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $.30 per share.

During 2013, in connection with the SPA, the Company sold and issued 492,280 shares to the Investor for $49,228 in cash, of which $19,255 was received in 2012. In addition, under the terms of this agreement, the Investor also received a warrant to purchase 123,070 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $0.30 per share. The SPA expired, per its terms and conditions, on January 31, 2013. The parties are in discussions to permit the Investor to purchase securities on similar terms and conditions.
 
 
21

 

Statement of Cash Flows

The following table sets forth, for the periods indicated, selected cash flow information:

   
Three Months Ended March 31,
 
   
2013
   
2012
 
Cash flows (used) provided by operating activities
 
$
(283,854
)
 
$
6,964
 
Cash flows used in investing activities
   
(22,095
)
   
(12,709
)
Cash flows provided (used) by financing activities
   
29,973
     
(4,650
)
                 
Net decrease in cash and cash equivalents
 
$
(275,976
)
 
$
(10,395
)

Cash and cash equivalents as of March 31, 2013 was $18,174 compared to $294,150 as of December 31, 2012. Cash is primarily used to fund our working capital requirements.

As of March 31, 2013, the Company had a working capital deficit of $63,326 compared to $245,365 of working capital as of December 31, 2012. During the three months ended March 31, 2013 we used approximately $284,000 of cash from our operations, used approximately $16,300 in support of patent applications and patent issuances and provided approximately $30,000 of proceeds from the issuance of common stock.

Net cash used by operating activities was approximately $284,000 for the three months ended March 31, 2013 compared to approximately $7,000 of cash provided by operations for the same period in 2012.

Net cash used in investing activities was approximately $22,100 for the three months ended March 31, 2013 compared to approximately $12,700 for the same period in 2012. During the three months ended March 31, 2103, we used cash for the patents and the purchase of property and equipment.

Net cash provided by financing activities was approximately $30,000 for the three months ended March 31, 2013 compared to cash used by financing activities of approximately $4,700 for the same period in 2012. During the three months ended March 31, 2013, we received net proceeds of approximately $30,000 from the issuance of common stock.

ECONOMY AND INFLATION

Except as disclosed herein, we have not experienced any significant cancellation of orders due to the downturn in the economy and only a small number of customers requested delays in delivery or production of orders in process. Our management believes that inflation has not had a material effect on our results of operations.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity or capital expenditures.
 
 
22

 

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4T.
CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures
 
Our Chief Executive Officer and Chief Financial Officer (collectively the “Certifying Officers”) maintain a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management timely. The Certifying Officers have concluded that the disclosure controls and procedures are effective at the “reasonable assurance” level. Under the supervision and with the participation of management, as of the end of the period covered by this report, the Certifying Officers evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act). Furthermore, the Certifying Officers concluded that our disclosure controls and procedures in place are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported on a timely basis in accordance with applicable Commission rules and regulations; and (ii) accumulated and communicated to our management, including our Certifying Officers and other persons that perform similar functions, if any, to allow us to make timely decisions regarding required disclosure in our periodic filings.

Changes in Internal Control Over Financial Reporting
 
During the three months ended March 31, 2013, the Company has not made any changes to our internal control processes.
 
 
23

 

PART II—OTHER INFORMATION
 
Item 1.
LEGAL PROCEEDINGS

We are not currently a party to any pending legal proceedings. In the ordinary course of business, we may become a party to various legal proceedings generally involving contractual matters, infringement actions, product liability claims and other matters.

From time to time, claims are made against us in the ordinary course of our business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
During the three months ended March 31, 2013, the Company issued the following equity securities.

On February 22, 2013, in connection with a private offering, the Company sold and issued 492,280 shares to one purchaser for $49,228 in cash. In addition, under the terms of the private placement offering, the Equity Investor also received a warrant to purchase 123,070 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $.30 per share.

The issuance was not a public offering based upon the following factors: (i) the issuance of the securities was an isolated private transaction; (ii) there was no public solicitation; (iii) the investment intent of the offerees; and (iv) the restriction on transferability of the securities issued. There was no underwriter used in the transaction. The proceeds from the private offering will be used for the repayment of an unsecured note, working capital and general corporate expenses. All of the foregoing securities were issued in reliance upon the exemption from registration pursuant to Rule 903 of Regulation S.

Item 3.
Default Upon Senior Securities

None.

Item 4.
Mine Safety Disclosures

Not applicable.

Item 5.
Other Information

None.
 
 
24

 
 
Item 6.
Exhibits
 
31.1
 
Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
31.2
 
Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
32.1
 
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2
 
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS **
 
XBRL Instance Document
     
101.SCH **
 
XBRL Taxonomy Extension Schema Document
     
101.CAL **
 
XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF **
 
XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB **
 
XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE **
 
XBRL Taxonomy Extension Presentation Linkbase Document
__________
** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
 
 
25

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  DAIS ANALYTIC CORPORATION  
  (Registrant)  
       
Date: May 15, 2013
By:
/s/ TIMOTHY N. TANGREDI  
    Timothy N. Tangredi  
    President and Chief Executive Officer  
    (Principal Executive Officer)  
       
       
Date: May 15, 2013 By: /s/ JUDITH C. NORSTRUD  
   
Judith C. Norstrud
 
    Chief Financial Officer and Treasurer  
    (Principal Financial and Accounting Officer)  
 
 
26


 
EX-31.1 2 dais_ex311.htm CERTIFICATION dais_ex311.htm
Exhibit 31.1
 
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934
 
CERTIFICATION
 
I, Timothy N. Tangredi, certify that:
 
1. 
I have reviewed this quarterly report on Form 10-Q of Dais Analytic Corporation;
 
2. 
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. 
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. 
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. 
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
       
Date: May 15, 2013
 
/s/ Timothy N. Tangredi
 
   
Timothy N. Tangredi
 
   
President, Chief Executive Officer and Principal Executive Officer
 
EX-31.2 3 dais_ex312.htm CERTIFICATION dais_ex312.htm
Exhibit 31.2
 
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934
 
CERTIFICATION
 
I, Judith C. Norstrud, certify that:
 
1. 
I have reviewed this quarterly report on Form 10-Q of Dais Analytic Corporation;
 
2. 
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. 
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. 
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. 
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
       
Date: May 15, 2013
 
/s/ Judith C. Norstrud
 
   
Judith C. Norstrud
 
   
Chief Financial Officer, Treasurer and Principal Financial Officer
 
EX-32.1 4 dais_ex321.htm CERTIFICATION dais_ex321.htm
Exhibit 32.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S. C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dais Analytic Corporation, (the “Company”) on Form 10-Q for the three months ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy N. Tangredi, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
       
Date: May 15, 2013
 
/s/ Timothy N. Tangredi
 
   
Timothy N. Tangredi
 
   
President, Chief Executive Officer and Principal Executive Officer
 
EX-32.2 5 dais_ex322.htm CERTIFICATION dais_ex322.htm
Exhibit 32.2
 
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S. C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dais Analytic Corporation, (the “Company”) on Form 10-Q for the three months ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Judith C. Norstrud, Principal Financial Officer of the Company, certify, pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
       
Date: May 15, 2013
 
/s/ Judith C. Norstrud
 
   
Judith C. Norstrud
 
   
Chief Financial Officer, Treasurer and Principal Financial Officer
 
EX-101.INS 6 dlyt-20130331.xml XBRL INSTANCE DOCUMENT 0001125699 2013-01-01 2013-03-31 0001125699 2013-05-14 0001125699 2012-12-31 0001125699 2011-12-31 0001125699 2012-01-01 2012-03-31 0001125699 2013-03-31 0001125699 2012-03-31 0001125699 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0001125699 us-gaap:CommonStockMember 2012-12-31 0001125699 us-gaap:CommonStockMember 2013-03-31 0001125699 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-03-31 0001125699 us-gaap:ConvertibleNotesPayableMember 2012-12-31 0001125699 us-gaap:ConvertibleNotesPayableMember 2013-03-31 0001125699 DLYT:CapitalnExcessOfParValueMember 2013-01-01 2013-03-31 0001125699 DLYT:CapitalnExcessOfParValueMember 2012-12-31 0001125699 DLYT:CapitalnExcessOfParValueMember 2013-03-31 0001125699 us-gaap:RetainedEarningsMember 2013-01-01 2013-03-31 0001125699 us-gaap:RetainedEarningsMember 2012-12-31 0001125699 us-gaap:RetainedEarningsMember 2013-03-31 0001125699 us-gaap:TreasuryStockMember 2013-01-01 2013-03-31 0001125699 us-gaap:TreasuryStockMember 2012-12-31 0001125699 us-gaap:TreasuryStockMember 2013-03-31 0001125699 2012-01-01 2012-12-31 0001125699 DLYT:BiomedicalEntityMember 2013-01-01 2013-03-31 0001125699 DLYT:BiomedicalEntityMember 2012-01-01 2012-03-31 0001125699 DLYT:LicenseFeesMember 2013-01-01 2013-03-31 0001125699 DLYT:ProductSalesMember 2013-01-01 2013-03-31 0001125699 us-gaap:InvestorMember 2012-01-01 2012-12-31 0001125699 us-gaap:WarrantMember 2012-01-01 2012-12-31 0001125699 us-gaap:InvestorMember 2013-01-01 2013-03-31 0001125699 us-gaap:WarrantMember 2013-01-01 2013-03-31 0001125699 us-gaap:InvestorMember 2012-01-01 2012-03-31 0001125699 DLYT:WarrantsFinancingMember 2013-03-31 0001125699 DLYT:WarrantsTangrediMember 2013-03-31 0001125699 DLYT:WarrantsEhrenbergMember 2013-03-31 0001125699 DLYT:WarrantsConsultingAgreementMember 2013-03-31 0001125699 DLYT:WarrantsNoteConversionsMember 2013-03-31 0001125699 DLYT:WarrantsStockPurchasesMember 2013-03-31 0001125699 DLYT:WarrantsServicesMember 2013-03-31 0001125699 us-gaap:MinimumMember 2013-01-01 2013-03-31 0001125699 us-gaap:MaximumMember 2013-01-01 2013-03-31 0001125699 DLYT:WarrantsFinancingMember us-gaap:MinimumMember 2013-03-31 0001125699 DLYT:WarrantsFinancingMember us-gaap:MaximumMember 2013-03-31 0001125699 DLYT:WarrantsConsultingAgreementMember us-gaap:MinimumMember 2013-03-31 0001125699 DLYT:WarrantsConsultingAgreementMember us-gaap:MaximumMember 2013-03-31 0001125699 DLYT:WarrantsNoteConversionsMember us-gaap:MinimumMember 2013-03-31 0001125699 DLYT:WarrantsNoteConversionsMember us-gaap:MaximumMember 2013-03-31 0001125699 DLYT:WarrantsStockPurchasesMember us-gaap:MinimumMember 2013-03-31 0001125699 DLYT:WarrantsStockPurchasesMember us-gaap:MaximumMember 2013-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DAIS ANALYTIC CORP 0001125699 10-Q 2013-03-31 false --12-31 No No Yes Smaller Reporting Company 2013 55509884 Q1 153796 159803 82195 86261 0.01 0.01 10000000 10000000 0 0 0 0 0.01 0.01 200000000 200000000 55274817 55767097 55017604 55509884 257213 257213 -2928934 -3180352 552749 557672 19255 35723001 35792064 -37951827 -38257976 -1272112 -1272112 0 391345 620042 1039483 50420 20500 569622 1018983 325371 434765 114329 91598 133449 356346 486593 683137 439700 526363 -306251 -170017 -102 -151634 -102 -45 -77786 358555 -587930 -306149 -18383 -306149 0 67240 55274817 55767097 24758 24758 29973 4923 -19255 44305 492280 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dais Analytic Corporation, a New York corporation, (the &#147;Company&#148;) has developed and is commercializing applications using its nano-structure polymer technology. The first commercial product is an energy recovery ventilator (&#147;ERV&#148;) (cores and systems) for use in commercial Heating, Ventilating, and Air Conditioning (HVAC) applications. In addition to direct sales, the Company licenses its nano-structured polymer technology to strategic partners in the aforementioned application and is in various stages of development with regard to other applications employing its base technologies. The Company was incorporated in April 1993 with its corporate headquarters located in Odessa, Florida.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements of the &#147;Company&#148; are unaudited, but in the opinion of management, reflect all adjustments necessary to fairly state the Company&#146;s financial position, results of operations, stockholders&#146; deficit and cash flows as of and for the dates and periods presented. The financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted although the Company generally believes that the disclosures are adequate to ensure that the information presented is not misleading. The accompanying financial statements and notes should be read in conjunction with the audited financial statements and notes of the Company for the fiscal year ended December 31, 2012 included in the Company&#146;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2013. The results of operations for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for any future quarters or for the entire year ending December 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses since inception. As of March 31, 2013, the Company has an accumulated deficit of $38,257,976, negative working capital of $63,326 and a stockholders&#146; deficit of $3,180,352. The Company (used) provided ($283,854) and $6,964 of cash in operations during the three months ended March 31, 2013 and 2012, respectively, which was funded by proceeds from product sales and equity financings. There is no assurance that such equity financing will be available in the future. In view of these matters, there is substantial doubt that the Company will continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 3%">&#160;</td> <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">1.</font></td> <td style="vertical-align: top; width: 94%; text-align: justify"><font style="font-size: 10pt">We are currently holding preliminary discussions with parties who are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize certain applications of our technology.</font></td></tr> <tr> <td>&#160;</td> <td style="vertical-align: top"><font style="font-size: 10pt">2.</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">We are seeking growth capital from certain strategic and/or government (grant) related sources. In addition to said capital, these sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of our products.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s ability to continue as a going concern is highly dependent on our ability to obtain additional sources of cash flow sufficient to fund our working capital requirements. However, there can be no assurance that the Company will be successful in its efforts to secure such cash flow. Any failure by us to timely procure additional financing or investment adequate to pay our outstanding debt and fund our ongoing operations, including planned product development initiatives and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, all adjustments necessary for a fair statement of (a) the results of operations for the three month periods ended March 31, 2013 and 2012, (b) the financial position at March 31, 2013 and December 31, 2012, and (c) cash flows for the three month periods ended March 31, 2013 and 2012, have been made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The significant accounting policies followed are:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Use of estimates</u></b> - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Cash and cash equivalents</u> -</b> Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage reverted to $250,000 per depositor at each financial institution. The Company's non-interest bearing cash balances were fully insured at March 31, 2013..</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Accounts receivable</u></b> - Accounts receivable consist primarily of receivables from the sale of our ERV products. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company&#146;s collection experience, customer credit worthiness, and current economic trends.&#160;&#160;Based on management&#146;s review of accounts receivable, we have recorded an allowance for doubtful accounts of $2,576 at March 31, 2013 and December 31, 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Inventory</u></b> - Inventory consists primarily of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Property and equipment</u> -</b> Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 5 to 7 years. Gains and losses upon disposition are reflected in the statement of operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. Property and equipment are evaluated for impairment when events change or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Intangible assets</u></b><u> -</u> Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company&#146;s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 15 years. Patent amortization expense was approximately $6,000 and $4,400 for the three months ended March 31, 2013 and 2012, respectively. Total patent amortization expense for the next five years is estimated to be approximately $24,000 per year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Long-lived assets</u> -</b> Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company uses market quotes, if available or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether or not the asset values are recoverable. There have been no significant impairments of long-lived assets during the three month period ended March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Revenue recognition</u></b> - Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from a related party) and 67% of revenues, respectively.&#160;&#160;During the three months ended March 31, 2013 one customer, which is a related party of the Company, accounted for approximately 86.2% of accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In certain instances, our ConsERV product carries a warranty for two years for all parts contained therein with the exception of the energy recovery ventilator core which, in such circumstances, typically carries a 10 year warranty. The warranty includes replacement of defective parts. The Company has recorded an accrual of approximately $94,100 and $92,900 for future warranty expenses at March 31, 2013 and December 31, 2012, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of $50,420 and $20,500 from license agreements for the three months ended March 31, 2013 and 2012, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, &#34;Revenue Recognition&#151;Multiple-Element Arrangements,&#34; In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Employee stock based compensation</u></b> - The Company recognizes all share-based awards to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no awards granted during the three months ended March 31, 2013 and 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Non-employee stock-based compensation</u> - </b>The Company&#146;s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC 505-50, <i>Equity-Based Payments to Non-Employees</i>.&#160;&#160;Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor&#146;s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The fair value of common stock issued for services is based on the closing stock price on the date the common stock was issued. During the three months ended March 31, 2013 and 2012, the Company did not issue any non-employee stock based compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Research and development expenses and grant proceeds</u></b> - Expenditures for research, development and engineering of products are expensed as incurred. For the three months ended March 31, 2013 and 2012, the Company incurred research and development costs of approximately $114,300 and $158,800, respectively.&#160;&#160;The Company accounts for proceeds received from government grants for research as a reduction in research and development costs. For the three months ended March 31, 2012, the Company recorded approximately $67,200 in grant proceeds against research and development expenses on the statement of operations.&#160;&#160;There were no grant proceeds received by the Company during the three months ended March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Government grants</u></b> - Grants are recognized when there is reasonable assurance that the grant will be received and that any conditions associated with the grant will be met. When grants are received related to property and equipment, the Company reduces the basis of the assets resulting in lower depreciation expense over the life of the associated asset. Grants received related to expenses are reflected as a reduction of the associated expense in the period in which the expense is incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Financial instruments</u></b> - Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity&#146;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 5%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 2%; text-align: justify"><font style="font-size: 10pt">&#149;</font></td> <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 92%; text-align: justify"><font style="font-size: 10pt">Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">&#149;</font></td> <td style="vertical-align: top; text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">&#149;</font></td> <td style="vertical-align: top; text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2013. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities, which include cash equivalents of $336 at March 31, 2013. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The respective carrying value of certain on-balance sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued compensation and accrued expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Income taxes </u></b>- Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are computed on the basis of differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based upon enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2009 through 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Earnings (loss) per share </u></b>- Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. At March 31, 2013 and 2012, the Company had 38,543,711 and 54,463,590 potentially dilutive common shares that were not included in the computation of income (loss) per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Derivative financial instruments</u></b> - The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 &#147;<i>Derivative and Hedging&#148; </i>(ASC 815) to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Recent accounting pronouncements</u></b> - Recent accounting pronouncements issued by FASB, the AICPA and the SEC did not or are not believed by management to have a material impact on the Company&#146;s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Accrued expenses, other consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2013</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2012</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%"><font style="font-size: 10pt">Accrued expenses, other</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">46,838</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">29,946</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accrued registration rights penalty</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued warranty costs</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">94,053</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">92,829</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Contractual obligation</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,200</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,200</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">159,091</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">140,975</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Timothy N. Tangredi, our Chief Executive Officer and Chairman, is a founder and a member of the board of directors of Aegis BioSciences, LLC (&#147;Aegis&#148;). Mr. Tangredi currently owns 52% of Aegis&#146; outstanding equity and spends approximately one to two days per month on Aegis business for which he is compensated by Aegis. Aegis has two exclusive, world-wide licenses from us under which it has the right to use and sell products containing our polymer technologies in biomedical and health care applications. As a result of a $150,000 payment made by Aegis, the first license is considered fully paid and as such no additional license revenue will be forthcoming. Pursuant to the second license Aegis made an initial one-time payment of $50,000 and is to make royalty payments of 1.5% of the net sales price it receives with respect to any personal hygiene product, surgical drape or clothing products (the latter when employed in medical and animal related fields) and license revenue it receives should Aegis grant a sublicense to a third party. To date Aegis has sold no such products nor has it received any licensing fees requiring a royalty payment be made to us. All obligations for such payments will end on the earlier of June 2, 2015 or upon the aggregate of all sums paid to us by Aegis under the agreement reaching $1 million. The term of each respective license runs for the duration of the patented technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Rent expense for this building is currently $4,066 per month. The Company recognized rent expense of approximately $12,200 and $11,400 during the three months ended March 31, 2013 and 2012, respectively. At March 31, 2013 and December 31, 2012, $85,637 and $82,195, respectively, were included in accounts payable for amounts owed for rent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also has accrued compensation due to the Chief Executive Officer and two other employees for deferred salaries earned and unpaid as of March 31, 2013 and December 31, 2012 of $1,466,024 and $1,494,739, respectively. During 2012, the Company determined that a portion of the accrued payroll, $1,484,739, is a long term liability, as the Company does not believe it will repaid within the next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Options</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2000 and November 2009, our Board of Directors adopted, and our shareholders approved, the 2000 Plan and 2009 Plan, respectively (together the &#147;Plans&#148;). The Plans provide for the granting of options to qualified employees of the Company, independent contractors, consultants, directors and other individuals. The Company&#146;s Board of Directors approved and made available 11,093,886 and 15,000,000 shares of common stock to be issued pursuant to the 2000 Plan and the 2009 Plan. The Plans permit grants of options to purchase common shares authorized and approved by the Company&#146;s Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no options awarded or exercised during the three months ended March 31, 2013 and 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the information relating to outstanding stock options activity with employees during 2013 and 2012:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Common</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in years)</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%"><font style="font-size: 10pt">Outstanding at December 31, 2012</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">18,647,332</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">0.29</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">6.06</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">26,345</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expired/Forfeited</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(99,999</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.32</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td colspan="4">&#160;</td> <td colspan="4">&#160;</td> <td colspan="4">&#160;</td> <td colspan="4">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Outstanding at March 31, 2013</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">18,547,333</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0.29</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.03</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">356,486</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercisable at March 31, 2013</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">17,589,137</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.29</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5.84</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">296,041</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense was approximately $24,800 and $41,600 for the three months ended March 31, 2013 and 2012, respectively. The total fair value of shares vested during the three months ended March 31, 2013 and 2012 was approximately $27,400 and $87,300, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2013, there was approximately $110,700 of unrecognized employee stock-based compensation expense related to non vested stock options, of which $55,900, $32,300 and $22,500 is expected to be recognized for the remainder of the fiscal year ending December 31, 2013, and for the fiscal years ending 2014 and 2015, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents our non vested share-based payment activity with employees for the three months ended March 31, 2013:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%"><font style="font-size: 10pt">Nonvested options - December 31, 2012</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">1,235,555</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">0.16</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Vested</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(138,473</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.20</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Forfeited</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(138,886</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Nonvested options &#150; March 31, 2013</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">958,196</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.16</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2013, the Company had outstanding warrants to purchase the Company&#146;s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt"><b>Warrants</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining Life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Years)</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Expiration Year</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 55%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 10pt">Warrants-Financing</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,000,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.99</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.34</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2016 &#150; 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 10pt">Warrants-Tangredi</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,000,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">.25</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.36</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2013</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 10pt">Warrants-Ehrenberg</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">.59</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.30</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2013</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 10pt">Warrants-Consulting Agreement</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">825,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.77</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.30</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2014 &#150; 2015</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 10pt">Warrants-Note Conversions</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,302,538</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.39</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2014 &#150; 2015</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 10pt">Warrants-Stock Purchases</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,218,840</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4.22</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.33</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2014 &#150; 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 10pt">Warrants-Services</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">400,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.06</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.50</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2015</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0in"><font style="font-size: 10pt">Tota</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">19,996,378</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 21, 2009, we entered into an Exclusive Distribution Agreement with Genertec, under which we are to supply and Genertec is to distribute, on an exclusive basis, three of our nanotechnology-based membrane products and related products in Greater China, including mainland China, Hong Kong, Macau and Taiwan. The agreement provides that during the initial five year term of the agreement, Genertec will order and purchase these products in the aggregate amount of $200 million. A minimum quantity of said products is to be purchased by Genertec during each contract year of the initial term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April of 2010, the Company entered into a technical and sales agreement with CAST Systems Control Technology Co., Ltd. (&#147;CAST&#148;) and Genertec with a value of up to approximately $48 million over a twelve month period. Under the terms of the Agreement, the Company will supply to CAST, through Genertec, key system components of its nanotechnology clean water process.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2011, Genertec expressed a desire to limit its participation in this endeavor as they find NanoAir and NanoClear to have engineering requirements they are not best suited to undertake. During the three months ended March 31, 2012, we terminated the Genertec and CAST agreements and recognized $150,000 nonrefundable deposit received from Genertec as revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">On October 17, 2012, Dais Analytic Corporation (the &#147;Company&#148;) entered into a Securities Purchase Agreement (the &#147;SPA&#148;) with an investor, Green Valley International Investment Management Company Limited (the &#147;Investor&#148;) pursuant to which the Company will offer up to $7.0 million of the Company&#146;s common stock, $0.01 par value per share (the &#147;Common Stock&#148;), and warrants (the &#147;Warrants&#148;) to purchase up to 17,500,000 shares of Common Stock (such offer being the &#147;Offering&#148;).Pursuant to the terms and conditions of the SPA, Company agreed to issue the Common Stock and Warrants in three tranches. The Warrants are exercisable for 60 months beginning on the date of their issuance. The warrants have an exercise price of $0.30, and are subject to standard anti-dilution adjustments for stock splits and other subdivisions. Pursuant to terms of the Offering, officers of the Company and the Investor have signed lock-up agreements restricting the sale of Common Stock. The Investor does not have any registration rights with respect to the Common Stock or Warrants. No underwriter or placement agent was used in the sale of the Common Stock or Warrants.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">On December 28, 2012, Dais Analytic Corporation (the &#147;Company&#148;) amended the SPA, dated October 17, 2012, with Green Valley International Investment Management Company Limited (the &#147;Investor&#148;) pursuant to which the Investor will purchase up to $7.0 million of the Company&#146;s common stock, $0.01 par value per share (the &#147;Common Stock&#148;), and warrants (the &#147;Warrants&#148;) to purchase up to 17,500,000 shares of Common Stock. Pursuant to the terms of the SPA, the Investor has purchased $1,750,000 of Common Stock and Warrants and the Company as recorded a common stock payable for an additional amount of $19,255. The amendment requires the Purchaser to purchase the remaining Common Stock and Warrants on or before January 31, 2013.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In 2012, the Company sold and issued, in connection with the SPA, 17,500,000 shares of its common stock to the Investor for $1,750,000. In addition, as part of the purchase it issued the Investor a warrant to purchase 4,375,000 shares of the Company&#146;s common stock with an exercise period of five years from the date of issue at an exercise price of $.30 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013, in connection with the SPA, the Company sold and issued 492,280 shares to the Investor for $49,228 in cash, of which $19,255 was received in 2012.&#160;&#160;In addition, under the terms of this agreement, the Investor also received a warrant to purchase 123,070 shares of the Company&#146;s common stock with an exercise period of five years from the date of issue at an exercise price of $0.30 per share.<font style="background-color: white"> The SPA expired, per its terms and conditions, on January 31, 2013. The parties are in discussions to permit the Investor to purchase securities on similar terms and conditions</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a licensing agreement during the year ended December 31, 2003 and received an initial fee of $770,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 10 years. In addition, the Company received royalties of $100,000 in each of the first three years of the agreement. The Company recognized revenue of approximately $19,250 for this agreement during each of the three months ended March 31, 2013 and 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a licensing agreement with a biomedical entity during the year ended December 31, 2005 and received an initial license fee of $50,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 7 years. The Company recognized revenue of approximately $1,250 for this agreement during each of the three months ended March 31, 2013 and 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2012, the Company and MG Energy LLC, a Delaware limited liability company (&#147;MG Energy&#148;) , a company in which a shareholder of the Company holds a position, entered into a License and Supply Agreement (the &#147;Agreement&#148;), effective October 26, 2012, pursuant to which the Company licensed certain intellectual property and improvements thereto to MG Energy, for use in the manufacture and sale of energy recovery ventilators (&#147;ERV&#148;) and certain other HVAC systems for installation in commercial, residential or industrial buildings in North America and South America in exchange for the cancellation of $2,034,521 of debt due to MG Energy. MG Energy also agreed to purchase its requirements of certain ConsERV products from the Company for MG Energy&#146;s use, pursuant to the terms and conditions of the Agreement. MG Energy will also pay royalties, as defined, to the Company on the net sales of each product or system sold. The term of the Agreement will expire upon the last to expire of the underlying patent rights for the licensed technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has identified all of the deliverables under the Agreement and has determined significant deliverables to be the license for the intellectual property and the supply services. In determining the units of accounting, the Company evaluated whether the license has stand alone value to MG Energy based upon consideration of the relevant facts and circumstances of the Agreement. The Company determined that the license does not have stand alone value to the licensee and, therefore, should be combined with the supply agreement as one unit of accounting. The initial payment for the license agreement will be treated as an advance payment and recognized over the performance period of the supply agreement. Royalties will be recognized as revenue when earned. The Company recognized revenue of $29,920 in license fees and $475,287 in product sales relating to this Agreement during the three months ended March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has accounted for certain warrants in accordance with ASC 815-10, Derivatives and Hedging (ASC 815-10).&#160;&#160;ASC 815-10 provides guidance for determining whether an equity-linked financial instrument (or embedded feature) is indexed to an entity&#146;s own stock.&#160;&#160;This applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative under ASC 815-10, including any freestanding financial instrument that is potentially settled in an entity&#146;s own stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to certain adjustments that may be made to the exercise price of the warrants issued in December 2007, January 2008 and August 2008 if the Company issues or sells shares of its common stock at a price which is less than the then current warrant exercise price, these warrants have been classified as a liability as opposed to equity in accordance with the Derivatives and Hedging Topic of the FASB ASC 815-10-15 as it was determined that these warrants were not indexed to the Company&#146;s stock<i>. </i>As a result, the fair market value of these warrants was remeasured on January 1, 2009 and marked to market at each subsequent financial reporting period. The change in fair value of the warrants is recorded in the statement of operations and is estimated using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Three Months Ended March 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 87%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%">&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Exercise price</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.25</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Market value of stock at end of period</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.19</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Expected dividend rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">N/A</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">167% - 174</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk-free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.19</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected life in years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.70 &#150; 0.84</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Shares underlying warrants outstanding classified as liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">13,401,333</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All warrants issued by the Company other than the above noted warrants are classified as equity.&#160;&#160;For the three months ended March 31, 2013 and 2012, the Company recognized a change in the fair value of the warrant liability of $0 and $587,930, respectively. All of the warrants underlying the warrant liability have expired as of March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 22, 2011, the Company entered into a 10% note and warrant purchase agreement, secured convertible promissory note and patent security agreement (&#147;financing agreements&#148;) with an investor.In connection with the financing agreements, the Company issued a stock purchase warrant to the investor to purchase 3,000,000 shares of the Company&#146;s common stock at $0.45 per share, exercisable until March 22, 2016. The warrant was fair valued on the date of issuance, which amounted to $1,204,787. The warrant value was recorded as a debt discount based on the relative fair value of the warrant to the total proceeds received, which amounted to $435,240. The warrant was fair valued using the Black-Scholes-Merton valuation model. In addition, the debt contained a beneficial conversion feature, which was valued at the date of issuance at $1,762,163; however, since this amount is in excess of the net value of the debt less the warrant discount, the beneficial conversion feature will be limited to $1,064,760 and recorded as a discount on the loan. The total debt discount of $1,500,000 is being amortized using the effective interest method over the 12-month term of the Secured Note. For the three months ended March 31, 2012 the Company recognized $358,555 as amortization of this debt discount.&#160;&#160;The debt discount was fully amortized as of December 31, 2012.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage reverted to $250,000 per depositor at each financial institution. The Company's non-interest bearing cash balances were fully insured at March 31, 2013.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable consist primarily of receivables from the sale of our ERV products. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company&#146;s collection experience, customer credit worthiness, and current economic trends.&#160;&#160;Based on management&#146;s review of accounts receivable, we have recorded an allowance for doubtful accounts of $2,576 at March 31, 2013 and December 31, 2012.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consists primarily of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 5 to 7 years. Gains and losses upon disposition are reflected in the statement of operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. Property and equipment are evaluated for impairment when events change or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company&#146;s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 15 years. Patent amortization expense was approximately $6,000 and $4,400 for the three months ended March 31, 2013 and 2012, respectively. Total patent amortization expense for the next five years is estimated to be approximately $24,000 per year.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company uses market quotes, if available or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether or not the asset values are recoverable. There have been no significant impairments of long-lived assets during the three month period ended March 31, 2013.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from a related party) and 67% of revenues, respectively.&#160;&#160;During the three months ended March 31, 2013 one customer, which is a related party of the Company, accounted for approximately 86.2% of accounts receivable.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In certain instances, our ConsERV product carries a warranty for two years for all parts contained therein with the exception of the energy recovery ventilator core which, in such circumstances, typically carries a 10 year warranty. The warranty includes replacement of defective parts. The Company has recorded an accrual of approximately $94,100 and $92,900 for future warranty expenses at March 31, 2013 and December 31, 2012, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of $50,420 and $20,500 from license agreements for the three months ended March 31, 2013 and 2012, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, &#34;Revenue Recognition&#151;Multiple-Element Arrangements,&#34; In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes all share-based awards to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no awards granted during the three months ended March 31, 2013 and 2012.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC 505-50, <i>Equity-Based Payments to Non-Employees</i>.&#160;&#160;Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor&#146;s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The fair value of common stock issued for services is based on the closing stock price on the date the common stock was issued. During the three months ended March 31, 2013 and 2012, the Company did not issue any non-employee stock based compensation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Expenditures for research, development and engineering of products are expensed as incurred. For the three months ended March 31, 2013 and 2012, the Company incurred research and development costs of approximately $114,300 and $158,800, respectively.&#160;&#160;The Company accounts for proceeds received from government grants for research as a reduction in research and development costs. For the three months ended March 31, 2012, the Company recorded approximately $67,200 in grant proceeds against research and development expenses on the statement of operations.&#160;&#160;There were no grant proceeds received by the Company during the three months ended March 31, 2013.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Grants are recognized when there is reasonable assurance that the grant will be received and that any conditions associated with the grant will be met. When grants are received related to property and equipment, the Company reduces the basis of the assets resulting in lower depreciation expense over the life of the associated asset. Grants received related to expenses are reflected as a reduction of the associated expense in the period in which the expense is incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity&#146;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="width: 5%; text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; width: 1%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#149;</font></td> <td style="vertical-align: top; width: 1%; text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; width: 93%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</font></td></tr> <tr> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#149;</font></td> <td style="vertical-align: top; text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</font></td></tr> <tr> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#149;</font></td> <td style="vertical-align: top; text-align: justify; line-height: 115%">&#160;</td> <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2013. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities, which include cash equivalents of $336 at March 31, 2013. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The respective carrying value of certain on-balance sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued compensation and accrued expenses.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are computed on the basis of differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based upon enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2009 through 2012.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. At March 31, 2013 and 2012, the Company had 38,543,711 and 54,463,590 potentially dilutive common shares that were not included in the computation of income (loss) per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 &#147;<i>Derivative and Hedging&#148; </i>(ASC 815) to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Recent accounting pronouncements issued by FASB, the AICPA and the SEC did not or are not believed by management to have a material impact on the Company&#146;s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Accrued expenses, other consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2013</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2012</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%"><font style="font-size: 10pt">Accrued expenses, other</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">46,838</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">29,946</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accrued registration rights penalty</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued warranty costs</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">94,053</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">92,829</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Contractual obligation</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,200</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,200</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">159,091</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">140,975</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the information relating to outstanding stock options activity with employees during 2013 and 2012:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Common</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in years)</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value</b></p></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2012</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,647,332</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.06</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,345</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired/Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(99,999</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.32</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td colspan="4" style="line-height: 115%">&#160;</td> <td colspan="4" style="line-height: 115%">&#160;</td> <td colspan="4" style="line-height: 115%">&#160;</td> <td colspan="4" style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2013</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,547,333</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.03</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">356,486</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2013</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,589,137</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.84</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">296,041</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents our non vested share-based payment activity with employees for the three months ended March 31, 2013:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Nonvested options - December 31, 2012</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 8%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,235,555</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.16</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(138,473</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(138,886</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td> <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Nonvested options &#150; March 31, 2013</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">958,196</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.16</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2013, the Company had outstanding warrants to purchase the Company&#146;s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining Life</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Years)</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Expiration Year</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 59%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 8%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 8%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 8%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 8%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Financing</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,000,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.99</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.34</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016 &#150; 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Tangredi</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,000,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">.25</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.36</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Ehrenberg</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">.59</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Consulting Agreement</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">825,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.77</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2014 &#150; 2015</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Note Conversions</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,302,538</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.42</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.39</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2014 &#150; 2015</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Stock Purchases</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,218,840</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.33</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2014 &#150; 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants-Services</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">400,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.06</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tota</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19,996,378</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The change in fair value of the warrants is recorded in the statement of operations and is estimated using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Three Months Ended March 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 87%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 10%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.25</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Market value of stock at end of period</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.19</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">167% - 174</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.19</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life in years</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.70 &#150; 0.84</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares underlying warrants outstanding classified as liabilities</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">13,401,333</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> 63326 -283854 6964 2576 2576 6000 4400 114300 158800 336 54463590 38543711 12200 11400 82195 85637 1494739 1466024 1484739 24800 41600 27400 87300 110700 150000 19250 19250 1250 1250 29920 475287 358555 0 587930 17500000 4375000 492280 123070 17500000 49228 19255 P5Y P5Y 0.30 0.30 29946 46838 5000 5000 92829 94053 13200 13200 18647332 18547333 -99999 17589137 0.29 0.29 0.32 0.29 P6Y21D P6Y10D P5Y10M2D 26345 356486 296041 1235555 958196 -138886 -138473 0.16 0.16 0.20 19996378 7000000 3000000 250000 825000 2302538 6218840 400000 P3Y11M26D P3M P7M2D P1Y9M7D P1Y5M1D P4Y4M19D P2Y21D 0.34 0.36 0.30 0.30 0.39 0.33 0.50 2013 2013 2015 2016 2017 2014 2015 2014 2015 2014 2017 0.25 0.19 0.0000 1.67 1.74 0.0019 P8M12D P10M2D 13401333 14627 13292 24758 41584 -587930 15224 358555 61679 291289 73648 -61062 -65123 -359 -27820 61787 147920 -28715 1667 -50420 -236959 -283854 6964 16284 12709 5811 -22095 -12709 4650 29973 29973 -4650 -275976 -10395 294150 262740 18174 252345 233 512842 451163 292443 353505 45945 46304 1145380 869146 95557 92748 2280 2280 107230 117507 109510 119787 1350447 1081681 559946 554596 10000 140975 159091 189094 169764 900015 883451 1484739 1515045 1894627 1863537 3379366 3378582 552749 557672 19255 35723001 35792064 -37951827 -38257976 -1656822 -1908240 1272112 1272112 1350447 1081681 5 to 7 years P15Y 24000 24000 24000 24000 24000 0.94 0.67 0.862 92900 94100 50420 20500 67200 55900 -0.01 -0.00 55422501 37774817 EX-101.SCH 7 dlyt-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0006 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0007 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - Accrued Expenses, Other link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - Stock Options and Warrants link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - Terminated Sales Agreements link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - Stock Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - Deferred Revenue link:presentationLink link:calculationLink link:definitionLink 0017 - Disclosure - Change in Fair Value of Warrant Liability link:presentationLink link:calculationLink link:definitionLink 0018 - Disclosure - Amortization of Debt Discount on Convertible Note Payable link:presentationLink link:calculationLink link:definitionLink 0019 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0020 - Disclosure - Accrued Expenses, Other (Tables) link:presentationLink link:calculationLink link:definitionLink 0021 - Disclosure - Stock Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 0022 - Disclosure - Change in Fair Value of Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 0023 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0024 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0025 - Disclosure - Accrued Expenses, Other (Details) link:presentationLink link:calculationLink link:definitionLink 0026 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0027 - Disclosure - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0028 - Disclosure - Stock Options and Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 0029 - Disclosure - Stock Options and Warrants (Details 2) link:presentationLink link:calculationLink link:definitionLink 0030 - Disclosure - Stock Options and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0031 - Disclosure - Terminated Sales Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0032 - Disclosure - Stock Purchase Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0033 - Disclosure - Deferred Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0034 - Disclosure - Change in Fair Value of Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0035 - Disclosure - Change in Fair Value of Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0036 - Disclosure - Amortization of Debt Discount on Convertible Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 dlyt-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 dlyt-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 dlyt-20130331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Total carrying Value [Member] FairValueByBalanceSheetGroupingDisclosureItemAmounts [Axis] Fair Value Inputs Level 1 [Member] FairValueByFairValueHierarchyLevel [Axis] Fair Value Inputs Level 2 [Member] Fair Value Inputs Level 3 [Member] Warrants Tangredi [Member] Statement .Equity Components [Axis] Warrants Additional Financing [Member] Warrants Robb Trust Note [Member] Warrants Financing [Member] Warrants Placement Agent Warrants [Member] Warrants Ehrenberg [Member] Warrants Consulting Agreement [Member] Warrants Note Conversions [Member] Warrants Stock Purchases [Member] Warrants Services [Member] Minimum [Member] Range [Axis] Maximum [Member] U.S. Department of Energy [Member] Geographical [Axis] Pasco County Florida [Member] Biomedical entity [Member] Related Party [Axis] Intellectual property [Member] Secured Debt [Member] Credit Facility [Axis] Common Stock Common Stock Payable Capital in Excess of Par Value Accumulated Deficit Treasury Stock License fees Product sales Investor [Member] Warrant [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Balance Sheets ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable, net (including related party receivables of $391,345 and $0 at March 31, 2013 and December 31, 2012, respectively) Inventory Prepaid expenses and other current assets Total current assets Property and equipment, net OTHER ASSETS: Deposits Patents, net of accumulated amortization of $159,803 and $153,796 at March 31, 2013 and December 31, 2012, respectively Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable, including related party payables of $86,261 and $82,195 at March 31, 2013 and December 31, 2012, respectively Accrued compensation and related benefits Accrued expenses, other Current portion of deferred revenue Total Current Liabilities LONG-TERM LIABILITIES: Accrued compensation and related benefits Deferred revenue, net of current portion Total Long-Term Liabilities STOCKHOLDERS' DEFICIT Preferred stock; $0.01 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.01 par value; 200,000,000 shares authorized; 55,767,097 and 55,274,817 shares issued and 55,509,884 and 55,017,604 shares outstanding, respectively Common stock payable Capital in excess of par value Accumulated deficit Total Treasury stock at cost, 257,213 shares Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Balance Sheets Parenthetical Other assets: Accounts receivable, net Patents, net of accumulated amortization Current liabilities: Accounts payable, including related party payables Stockholders' deficit: Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Treasury stock shares Statements Of Operations REVENUE: Sales License fees TOTAL COST OF GOODS SOLD GROSS MARGIN OPERATING EXPENSES Research and development expenses, net of government grant proceeds of $0 and $67,240, respectively Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Change in fair value of warrant liability Amortization of discount on convertible note payable Interest expense Interest income TOTAL OTHER EXPENSE (INCOME) NET LOSS NET LOSS PER COMMON SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED Statements Of Operations Parenthetical Research and development expenses, net of government grant Statement [Table] Statement [Line Items] Equity Components [Axis] Beginning Balance, Amount Beginning Balance, Shares Stock based compensation Issuance of common stock for cash, Amount Issuance of common stock for cash, Shares Net loss Ending Balance, Amount Ending Balance, Shares Statements Of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash and cash equivalents (used) provided by operating activities: Depreciation and amortization Stock based compensation expense Change in fair value of warrant liability Amortization of deferred loan costs Amortization of discount on convertible note payable (Increase) decrease in: Accounts receivable Other receivables Inventory Prepaid expenses and other assets Increase (decrease) in: Accounts payable and accrued expenses Accrued compensation and related benefits Deferred revenue Net cash (used) provided by operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Increase in patent costs Purchase of property and equipment Net cash used by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Payments for loan and offering costs Issuance of common stock, net of offering costs Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Notes to Financial Statements Note 1 - Background Information Note 2 - Going Concern Note 3 - Significant Accounting Policies Note 4 - Accrued Expenses, Other Note 5 - Related Party Transactions Note 6 - Stock Options and Warrants Note 7 - Terminated Sales Agreements Note 8. Stock Purchase Agreement Note 9 - Deferred Revenue Note 10 - Change in Fair Value of Warrant Liability Note 11 - Amortization of Debt Discount on Convertible Note Payable Significant Accounting Policies Policies Use of estimates Cash and cash equivalents Accounts receivable Inventory Property and equipment Intangible assets Long-lived assets Revenue recognition Employee stock based compensation Non-employee stock-based compensation Research and development expenses and grant proceeds Government grants Financial instruments Income taxes Earnings (loss) per share Derivative financial instruments Recent accounting pronouncements Accrued Expenses Other Tables Accrued expenses and other expenses Stock Options And Warrants Tables Outstanding stock options activity Non vested share-based payment activity Warrants Change In Fair Value Of Warrant Liability Tables Change in fair value of the warrants Going Concern Details Narrative Accumulated deficit Working capital Stockholders' deficit Cash in operations Significant Accounting Policies Details Narrative Allowance for doubtful accounts Property and equipment estimated useful life Patents estimated useful life Patent amortization expense Future amortization expense year one Future amortization expense year two Future amortization expense year three Future amortization expense year four Future amortization expense year five Percentage representation in revenue Percentage representation in receivables Warranty accrual Revenue recognition Research and development costs Grant proceeds against research and development expenses Cash equivalents Dilutive common shares Accrued Expenses Other Details Accrued expenses, other Accrued registration rights penalty Accrued warranty costs Contractual obligation Accrued Expenses Related Party Transactions Details Narrative Rent expense recognized Accounts payable for rent Deferred salaries earned and unpaid Accrued payroll Stock Options And Warrants Details Information relating to outstanding stock options activity with employees Common shares outstanding Common shares forfeited/expired Outstanding at March 31, 2013 Exercisable at March 31, 2013 Weighted average exercise price of shares outstanding Weighted average exercise price of shares expired/forfeited Weighted average exercise price of shares outstanding at March 31, 2013 Weighted average exercise price of shares exercisable March 31, 2013 Weighted average remaining contractual term (in years) of shares outstanding, Beggining Balance Weighted average remaining contractual term (in years) of shares outstanding, Ending Balance Weighted average remaining contractual term (in years) of shares exercisable Aggregate intrinsic value of shares outstanding, Beggining Balance Aggregate intrinsic value of shares outstanding, Ending Balance Aggregate intrinsic value of shares exerciseable Stock Options And Warrants Details 1 Non vested share-based payment activity with employees Nonvested options, Number of Options Granted, Number of Options Forfeited, Number of Options Vested, Number of Options Nonvested options, Number of Options Nonvested options beginning, Weighted Average Grant Date Fair Value Granted, Weighted Average Grant Date Fair Value Forfeited, Weighted Average Grant Date Fair Value Vested, Weighted Average Grant Date Fair Value Nonvested options ending, Weighted Average Grant Date Fair Value Remaining Number Outstanding Weighted Average Remaining Life Weighted Average Exercise Price Expiration Year Stock Options And Warrants Details Narrative Stock compensation expense Total fair value of shares vested Unrecognized employee stock-based compensation expense related to non vested stock options Expected to be recognized expense related to non vested stock options Terminated Sales Agreements Details Narrative Nonrefundable deposit received recognized as revenue Common stock shares Common stock shares, value Exercise period Exercise price Recognized revenue Exercise price Market value of stock at end of period Expected dividend rate Expected volatility rate Risk-free interest rate Expected life in years Shares underlying warrants outstanding classified as liabilities Change In Fair Value Of Warrant Liability Details Narrative Fair value of warrant liability Amortization Of Debt Discount On Convertible Note Payable Details Narrative Amortization of debt discount Amortization of deferred loan costs Amortization of discount and beneficial conversion feature on notes payable Amortization of discount on convertible note payable Change in fair value of warrant liability Custom Element. IncreseDecreseInFairValueOfWarrantLiability Custom Element. Custom Element. PaymentsForDebtIssueCostsAndDeferredOfferingCosts Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom element. Custom element. StockholdersEquityIncludingTreasuryStock Note 6 - Stock Options and Warrants Custom element. TotalOtherAssets Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Assets, Current Background Information Assets Liabilities, Current AccruedCompensationAndRelatedBenefits Liabilities, Noncurrent Change in fair value of warrant liability [Default Label] Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Licenses Revenue Revenue, Net Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Shares, Issued Issuance of note payable with a beneficial conversion feature [Default Label] Net loss per common share, basic and diluted Increase (Decrease) in Inventories Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PaymentsForDebtIssueCostsAndDeferredOfferingCosts Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Policy [Policy Text Block] Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] RevenueRecognized AccruedExpensesOther Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average remaining contractual term (in years) of shares outstanding Weighted average remaining contractual term (in years) of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value NonvestedOptionsNumberOfOptions Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Exercise price [Default Label] EX-101.PRE 11 dlyt-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Deferred Revenue (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Recognized revenue $ 19,250 $ 19,250
Biomedical entity [Member]
   
Recognized revenue 1,250 1,250
License fees
   
Recognized revenue 29,920  
Product sales
   
Recognized revenue $ 475,287  
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses, Other (Details) (USD $)
Mar. 31, 2013
Dec. 31, 2012
Accrued Expenses Other Details    
Accrued expenses, other $ 46,838 $ 29,946
Accrued registration rights penalty 5,000 5,000
Accrued warranty costs 94,053 92,829
Contractual obligation 13,200 13,200
Accrued Expenses $ 159,091 $ 140,975
XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Going Concern
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 2 - Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses since inception. As of March 31, 2013, the Company has an accumulated deficit of $38,257,976, negative working capital of $63,326 and a stockholders’ deficit of $3,180,352. The Company (used) provided ($283,854) and $6,964 of cash in operations during the three months ended March 31, 2013 and 2012, respectively, which was funded by proceeds from product sales and equity financings. There is no assurance that such equity financing will be available in the future. In view of these matters, there is substantial doubt that the Company will continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:

 

  1. We are currently holding preliminary discussions with parties who are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize certain applications of our technology.
  2. We are seeking growth capital from certain strategic and/or government (grant) related sources. In addition to said capital, these sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of our products.

 

The Company’s ability to continue as a going concern is highly dependent on our ability to obtain additional sources of cash flow sufficient to fund our working capital requirements. However, there can be no assurance that the Company will be successful in its efforts to secure such cash flow. Any failure by us to timely procure additional financing or investment adequate to pay our outstanding debt and fund our ongoing operations, including planned product development initiatives and commercialization efforts, will have material adverse consequences on our financial condition, results of operations and cash flows.

 

The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V M,&(T-CAA9C0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-4051%345.5%-?3T9?4U1/0TM(3TQ$ M15)37T1%1CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-4051%345.5%-?3T9?0T%32%]&3$]74U]53D%51#PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D)A8VMG#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O'!E;G-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E M;&%T961?4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7V]F7T1E8G1?1&ES M8V]U;G1?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D%C8W)U961?17AP96YS97-?3W1H M97)?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=O:6YG7T-O;F-E#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7T%C M8V]U;G1I;F=?4&]L:6-I93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-T M;V-K7T]P=&EO;G-?86YD7U=A#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%M;W)T:7IA=&EO;E]O9E]$96)T7T1I#I7;W)K#I3='EL97-H965T($A2968] M,T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V M,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T M9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!);F9O2`Q-"P@,C`Q,SQB2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^665S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL M(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^43$\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q M7V)F.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2D\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4L(&EN8VQU9&EN9R!R96QA=&5D('!A6%B;&5S(&]F("0X-BPR-C$@86YD("0X,BPQ.34@870@36%R8V@@,S$L(#(P M,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R+"!R97-P96-T:79E;'D\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)FYBF5D.R`P('-H87)E6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA&-E'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO2!S=&]C:R!S:&%R97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U M7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T M+U=O'0O M:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)FYB6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W M8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X M868T+U=O'0O:'1M;#L@8VAA6%B;&4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V%P:71A M;"!I;B!%>&-E'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E M931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)? M,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA2!O M<&5R871I;F<@86-T:79I=&EE'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)FYB2!I;G9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U M7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`@2!W:6QL(&-O;G1I;G5E(&%S(&$@9V]I M;F<@8V]N8V5R;BX@5&AE($-O;7!A;GD@:&%S(&EN8W5R2`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`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU2!D;R!N;W0@:6YC;'5D92!A;GD@861J=7-T;65N=',-"G)E M;&%T:6YG('1O('1H92!R96-O=F5R86)I;&ET>2!A;F0@8VQA2!S:&]U;&0@=&AE($-O;7!A;GD@8F4@=6YA8FQE('1O(&-O;G1I M;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X M,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IU6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE('-I9VYI9FEC M86YT(&%C8V]U;G1I;F<@<&]L:6-I97,@9F]L;&]W960@87)E.CPO<#X-"@T* M/'`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`P+C5I;CL@=&5X="UA;&EG M;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!N;W0@8F4@28C,30V.W,@97AIF5D(&]V97(@=&AE:7(@97-T:6UA=&5D('5S969U;"!O<@T*96-O M;F]M:6,@;&EV97,@;V8@,34@>65A2`D-BPP,#`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`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IUF5D#0IA2X\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M86QI9VXZ(&IU65E('-T;V-K(&]P M=&EO;G,L(&%S(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&EN('1H92!F:6YA;F-I M86P@&-H86YG92!F;W(@=&AE(&%W87)D+"!K;F]W M;B!A'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^/'4^3F]N+65M<&QO>65E('-T;V-K M+6)A2!F;W(@97%U:71Y(&EN&-H86YG M92!F;W(@9V]O9',@86YD('-E2U"87-E9"!087EM96YT2!D:60@;F]T(&ES2!N;VXM96UP;&]Y964-"G-T;V-K M(&)A6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'!E;F1I='5R97,@9F]R(')E2!A8V-O=6YT&EM871E;'D@)#8W+#(P,"!I M;B!G6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^/'4^1V]V M97)N;65N="!G2!C;VYD:71I M;VYS(&%S2!A M;F0@97%U:7!M96YT+"!T:&4@0V]M<&%N>2!R961U8V5S('1H92!B87-I'!E M;G-E#0II;B!T:&4@<&5R:6]D(&EN('=H:6-H('1H92!E>'!E;G-E(&ES(&EN M8W5R6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^/'4^1FEN86YC:6%L(&EN2!I;B!A;B!O2!D:7-T:6YG=6ES:&5S(&)E='=E96X@*#$I(&UA2!A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)W=I9'1H.B`U)3L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G/B8C,30Y.SPO9F]N=#X\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,24[('1E M>'0M86QI9VXZ(&IU6QE M/3-$)W9E'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0M2<^/&9O;G0@2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@2<^/&9O;G0@2P@:6YC;'5D:6YG('%U;W1E9"!P2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@2<^/&9O M;G0@2<^ M/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2<^1F%I M2!M87)K970@=')A M;G-A8W1I;VYS(&EN=F]L=FEN9R!I9&5N=&EC86P@;W(@8V]M<&%R86)L92!A M6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU&EM871E9"!T:&5I M'0M86QI M9VXZ(&IU"!A'!E8W1E9"!T;R!B92!R M96%L:7IE9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@ M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Y M)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$ M)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(Y+#DT M-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C M,38P.SPO=&0^/"]T6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0G/D%C8W)U M960@=V%R6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/CDR+#@R.3PO9F]N=#X\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@F4Z(#$P<'0G/D-O;G1R86-T M=6%L(&]B;&EG871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)W9EF4Z M(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0MF4Z(#$P M<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0M86QI9VXZ(&IU M&5C=71I M=F4@3V9F:6-E2!!96=I&-L=7-I=F4L('=O6UE6UE;G0@;6%D92!B>2!!96=I2!P87EM96YT65D(&EN(&UE9&EC86P@86YD(&%N:6UA;"!R96QA=&5D#0IF:65L M9',I(&%N9"!L:6-E;G-E(')E=F5N=64@:70@6%L='D@<&%Y;65N="!B92!M861E('1O('5S+B!!;&P@;V)L:6=A=&EO;G,@ M9F]R('-U8V@@<&%Y;65N=',@=VEL;"!E;F0@;VX-"G1H92!E87)L:65R(&]F M($IU;F4@,BP@,C`Q-2!O2!!96=I'0M86QI9VXZ(&IU2!R96YT M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU2X@1'5R:6YG(#(P,3(L('1H92!#;VUP86YY M(&1E=&5R;6EN960@=&AA="!A('!O2P@ M87,@=&AE($-O;7!A;GD@9&]E'0@>65A6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@'0M86QI9VXZ(&IU2`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`U,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE M/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE M/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G/D5X<&ER M960O1F]R9F5I=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/B@Y.2PY.3D\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/C$X+#4T-RPS,S,\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C8N M,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z M(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V)O2`D,C0L.#`P(&%N9"`D M-#$L-C`P#0IF;W(@=&AE('1H2`D,C'0M86QI9VXZ(&IU&EM871E;'D@)#$Q,"PW,#`@;V8@=6YR96-O9VYI>F5D#0IE;7!L;WEE92!S M=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O(&YO M;B!V97-T960@'!E8W1E9`T*=&\@8F4@65A'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&-E;G1E6QE/3-$)W9EF4Z(#$P<'0G/DYO;G9E6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA M;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`N,38\+V9O;G0^ M/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G/D=R86YT960\+V9O;G0^/"]T9#X-"B`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0G/E9EF4Z M(#$P<'0G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`N,C`\+V9O;G0^/"]T M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)V)OF4Z(#$P<'0G M/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M28C,30V.W,@8V]M;6]N('-T;V-K('=H:6-H('=EF5D(&%S(&9O;&QO M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W9EF4Z(#$P M<'0G/CQB/E=A6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&-E;G1E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`U-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Y)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE M/3-$)W=I9'1H.B`Y)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W9EF4Z(#$P<'0G/E=A6QE/3-$)V9O;G0MF4Z(#$P M<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/BXR M-3PO9F]N=#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/C`N,S`\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$ M)V9O;G0MF4Z(#$P<'0G/E=A6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C@R-2PP,#`\+V9O;G0^/"]T M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0G/C(L,S`R+#4S.#PO9F]N=#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(P M,30@)B,Q-3`[(#(P,34\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W9E6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C0N,C(\+V9O;G0^ M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`\=&0^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`N,S,\+V9O M;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(N,#8\+V9O;G0^ M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`\=&0^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`N-3`\+V9O M;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0G/E1O=&$\+V9O;G0^/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M86QI9VXZ(&IU M&-L=7-I=F4@8F%S:7,L('1H M2UB87-E9`T*;65M8G)A;F4@<')O M9'5C=',@86YD(')E;&%T960@<')O9'5C=',@:6X@1W)E871E65A2!O9B!S86ED('!R;V1U8W1S(&ES('1O(&)E M('!U2!'96YE'0M86QI9VXZ(&IU2!E;G1E0T* M'0M86QI9VXZ(&IUF5D("0Q-3`L,#`P(&YO;G)E9G5N9&%B;&4@9&5P;W-I M=`T*'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M/&9O;G0@28C,30X.RD@96YT97)E9"!I;G1O(&$@4V5C=7)I M=&EE2!,:6UI=&5D("AT:&4@ M)B,Q-#<[26YV97-T;W(F(S$T.#LI('!U28C,30V.W,@8V]M;6]N('-T;V-K+"`D,"XP,2!P87(@=F%L=64@ M<&5R('-H87)E("AT:&4@)B,Q-#<[0V]M;6]N(%-T;V-K)B,Q-#@[*2P@86YD M('=A&5R8VES86)L92!F;W(@-C`@;6]N=&AS(&)E9VEN;FEN9R!O;B!T M:&4@9&%T92!O9B!T:&5I'0M86QI9VXZ(&IU28C,30X.RD@86UE;F1E9"!T:&4@ M4U!!+"!D871E9"!/8W1O8F5R(#$W+"`R,#$R+"!W:71H($=R965N(%9A;&QE M>2!);G1E2!,:6UI=&5D("AT:&4@)B,Q-#<[26YV97-T;W(F(S$T.#LI('!U6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@&5R M8VES90T*<&5R:6]D(&]F(&9I=F4@>65A'0M86QI9VXZ M(&IU28C,30V.W,@8V]M;6]N('-T;V-K('=I=&@@86X-"F5X97)C:7-E('!E M6QE/3-$)V)A8VMG2`S,2P@,C`Q,RX@5&AE('!A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F M85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B M-#8X868T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IUF5D(&]N(&$@65A M2!R96-E:79E9"!R;WEA;'1I M97,@;V8@)#$P,"PP,#`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@ M2!H87,@86-C;W5N=&5D(&9O2!F'0M86QI9VXZ(&IU2!B92!M861E('1O('1H92!E>&5R8VES92!P2!A6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0G/C`N,C4\+V9O;G0^/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V9O;G0M6QE/3-$)W9E'!E M8W1E9"!V;VQA=&EL:71Y/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0G/C$V-R4@+2`Q-S0\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@6QE/3-$)V9O;G0MF4Z(#$P<'0G/D5X<&5C=&5D(&QI9F4@:6X@ M>65A6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M2!O9B`D M,"!A;F0@)#4X-RPY,S`L(')E2X@06QL(&]F('1H92!W87)R M86YT2!H879E(&5X M<&ER960@87,@;V8@36%R8V@@,S$L(#(P,3,N/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6%B;&4\8G(^/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N(&]F($1E8G0@1&ES8V]U M;G0@;VX@0V]N=F5R=&EB;&4@3F]T92!087EA8FQE/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU2!E M;G1E&5R8VES86)L92!U;G1I;"!-87)C:"`R,BP@,C`Q-BX@5&AE('=A MF5D#0IUF5D("0S-3@L-34U(&%S(&%M M;W)T:7IA=&EO;B!O9B!T:&ES(&1E8G0@9&ES8V]U;G0N)B,Q-C`[)B,Q-C`[ M5&AE(&1E8G0@9&ES8V]U;G0@=V%S(&9U;&QY(&%M;W)T:7IE9"!A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^ M/'`@2<^5&AE('!R97!A2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'!E'0^/'`@2<^06-C;W5N=',@ M0T*;V8@2!R96=U;&%R;'D@7-I28C,30V.W,@8V]L;&5C=&EO;B!E>'!E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@ M2<^ M26YV96YT;W)Y(&-O;G-I2!O9B!R87<-"FUA=&5R:6%L M'0^/'`@ M2<^ M4')O<&5R='D@86YD(&5Q=6EP;65N="!A'!E M;F1I='5R97,@87)E(&-H87)G960@=&\@97AP96YS92!A2!N;W0@8F4@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU28C,30V M.W,-"F5X:7-T:6YG(&EN=&%N9VEB;&4@87-S971S(&-O;G-IF%T:6]N(&5X<&5N&EM M871E;'D@)#8L,#`P(&%N9"`D-"PT,#`@9F]R('1H92!T:')E92!M;VYT:',@ M96YD960@36%R8V@@,S$L(#(P,3,@86YD(#(P,3(L(')E2X- M"E1O=&%L('!A=&5N="!A;6]R=&EZ871I;VX@97AP96YS92!F;W(@=&AE(&YE M>'0@9FEV92!Y96%R2`D,C0L,#`P('!E2`Y-"4@*#2P@86-C;W5N=&5D(&9O2<^26X@8V5R M=&%I;B!I;G-T86YC97,L(&]U2!F;W(@='=O('EE87)S(&9O7!I8V%L;'D@8V%R2<^4F5V96YU M92!D97)I=F5D(&9R;VT@=&AE('-A;&4@;V8@;&EC96YS97,-"FES(&1E9F5R MF5D(&%S(')E=F5N=64@;VX@82!S=')A:6=H="UL M:6YE(&)A2!R96-O9VYI>F5D(')E=F5N=64@;V8@)#4P+#0R,"!A;F0@ M)#(P+#4P,"!F2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!A8V-O=6YT65E M('-T;V-K(&)A'0^/'`@2<^5&AE($-O;7!A;GD@65E(&ES(')E<75I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO28C,30V.W,@ M86-C;W5N=&EN9R!P;VQI8WD-"F9O6UE;G1S('1O($YO M;BU%;7!L;WEE97,\+VD^+B8C,38P.R8C,38P.U-T;V-K+6)A2!I;G-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU&EM871E;'D@)#8W M+#(P,"!I;B!G6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU2!C;VYD:71I;VYS(&%S2!A;F0@97%U:7!M96YT+"!T:&4@0V]M<&%N>2!R961U M8V5S('1H92!B87-I'!E;G-E#0II;B!T:&4@<&5R:6]D(&EN('=H:6-H('1H M92!E>'!E;G-E(&ES(&EN8W5R'0^/'`@2<^1F%I28C,30V.W,@;W=N(&%S6QE/3-$)W9E3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W9E'0M86QI M9VXZ(&IU3L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`H92YG+BP@:6YT97)E2!C;W)R96QA=&EO;B!O3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3L@ M=&5X="UI;F1E;G0Z(#,V<'0G/B8C,38P.SPO<#X-"@T*/'`@2<^1F%I2!M87)K970@=')A;G-A8W1I M;VYS(&EN=F]L=FEN9R!I9&5N=&EC86P-"F]R(&-O;7!A6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#`[('1E>'0M M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE&EM871E9"!T:&5I'0^/'`@2<^26YC;VUE('1A>&5S(&%R92!A8V-O=6YT960@9F]R M('5N9&5R#0IT:&4@87-S970@86YD(&QI86)I;&ET>2!M971H;V0N($1E9F5R M&%B;&4@ M;W(@9&5D=6-T:6)L92!A;6]U;G1S(&EN('1H92!F=71U2!T;R!R961U M8V4@9&5F97)R960@=&%X(&%SF5D+CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU"!P;W-I=&EO;G,L(&EF(&%N>2P@ M86YD(')E8V]G;FEZ97,@=&AE(&EM<&%C="!O9B!U;F-E2!T:&4@2X@4W5C:"!P;W-I=&EO;G,@87)E(&1E96UE9"!T;R!B M92!U;G)E8V]G;FEZ960-"G1A>"!B96YE9FET2!IF5D(&$@;&EA8FEL M:71Y(&9O<@T*=6YC97)T86EN('1A>"!P;W-I=&EO;G,N($EF('1H97)E('=E MF5D('1A>"!B96YE9FET+"!T:&4@0V]M<&%N>2!W M;W5L9"!R96-O9VYI>F4@:6YT97)E65A&%M:6YA=&EO;@T*8GD@=&AE($EN=&5R;F%L(%)E=F5N=64@4V5R=FEC M92!I;F-L=61E('1H92!Y96%R'0^/'`@2<^0F%S:6,@:6YC;VUE M("AL;W-S*2!P97(@2!C;VYS:7-T(&]F M(&EN8W)E;65N=&%L('-H87)E&5R8VES M92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT2!D:6QU=&EV92!C;VUM;VX@&-L=61E M9"!F2!D;V5S(&YO="!U2!F2P@:7,@ M2<^1G)E97-T86YD:6YG('=A2!T:&4-"D-O;7!A M;GD@:6X@8V]N;F5C=&EO;B!W:71H('1H92!I2!I;G-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9EF4Z(#$P<'0G/D%C8W)U960@97AP96YS M97,L(&]T:&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0G/B0\+V9O;G0^/"]T M9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M2!C;W-T M6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0G/C$S+#(P,#PO9F]N=#X\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9"<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$S+#(P,#PO9F]N=#X\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)V9O;G0M3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X M,E\P-64V,&(T-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M964T8C(T9F%?-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q+C5P="!S;VQI9"<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9"<^#0H@("`@("`@(#QP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE M/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W9E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$ M-"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O M6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q,SPO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6UE;G0@86-T:79I M='D\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M:6YD96YT.B`S-G!T)SXF M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A M+"!386YS+5-E6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E M6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P M="!S;VQI9"<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`W."4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W=I9'1H.B`Q)3L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)A8VMG6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U M<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\ M+W1A8FQE/CQS<&%N/CPO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M2!H860@;W5T M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9"<^#0H@ M("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&-E;G1E6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@8V]L6QE/3-$)V)O&5R8VES92!06QE/3-$)V)O'!I6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`X)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`X)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M/"]T6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE M/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)V)O6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X\+W1R/@T*/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!486)L97,\+W-T6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS M<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W=I9'1H.B`X-R4[(&QI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3`E.R!L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE65A6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q M7V)F.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA65A'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XV+#`P,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&5X<&5N M65A'!E;G-E('EE87(@='=O/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PP,#`\'!E;G-E('EE87(@ M9FEV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A8V-R=6%L/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"PQ,#`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T-CAA9C0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%?-V)C-5\T.&8Q7V)F M.#)?,#5E-C!B-#8X868T+U=O'0O:'1M;#L@8VAA'!E M;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4 M'!E;G-E(')E8V]G M;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4@9F]R(')E;G0\+W1D/@T*("`@ M("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!I7,\7,\65A&5R8VES96%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^,C`Q-SQS<&%N M/CPO&5R8VES M92!0'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7,\'!I65A7,\'0^,2!Y96%R(#4@;6]N=&AS(#$@9&%Y/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS<&%N/CPO7,\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!I&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A&5R8VES92!0'0^,C`Q-3QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'1087)T7V5E-&(R-&9A7S=B8S5?-#AF,5]B9C@R7S`U938P8C0V.&%F-`T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E931B,C1F85\W8F,U7S0X M9C%?8F8X,E\P-64V,&(T-CAA9C0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H M1&5T86EL&5R8VES92!P'!E8W1E9"!D:79I9&5N9"!R871E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO6EN9R!W87)R86YT'0^."!M;VYT:',@,3(@9&%Y'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y M(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA65A7,\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2!$971A:6QS($YA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E931B,C1F85\W8F,U7S0X9C%?8F8X,E\P-64V,&(T M-CAA9C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO964T8C(T9F%? M-V)C-5\T.&8Q7V)F.#)?,#5E-C!B-#8X868T+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'1087)T7V5E-&(R-&9A7S=B8S5?-#AF,5]B9C@R7S`U938P8C0V.&%F %-"TM#0H` ` end XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants (Details 2) (USD $)
Mar. 31, 2013
Remaining Number Outstanding $ 19,996,378
Warrants Financing [Member]
 
Remaining Number Outstanding 7,000,000
Weighted Average Remaining Life 3 years 11 months 26 days
Weighted Average Exercise Price $ 0.34
Warrants Financing [Member] | Minimum [Member]
 
Expiration Year 2016
Warrants Financing [Member] | Maximum [Member]
 
Expiration Year 2017
Warrants Tangredi [Member]
 
Remaining Number Outstanding 3,000,000
Weighted Average Remaining Life 3 months
Weighted Average Exercise Price $ 0.36
Expiration Year 2013
Warrants Ehrenberg [Member]
 
Remaining Number Outstanding 250,000
Weighted Average Remaining Life 7 months 2 days
Weighted Average Exercise Price $ 0.30
Expiration Year 2013
Warrants Consulting Agreement [Member]
 
Remaining Number Outstanding 825,000
Weighted Average Remaining Life 1 year 9 months 7 days
Weighted Average Exercise Price $ 0.30
Warrants Consulting Agreement [Member] | Minimum [Member]
 
Expiration Year 2014
Warrants Consulting Agreement [Member] | Maximum [Member]
 
Expiration Year 2015
Warrants Note Conversions [Member]
 
Remaining Number Outstanding 2,302,538
Weighted Average Remaining Life 1 year 5 months 1 day
Weighted Average Exercise Price $ 0.39
Warrants Note Conversions [Member] | Minimum [Member]
 
Expiration Year 2014
Warrants Note Conversions [Member] | Maximum [Member]
 
Expiration Year 2015
Warrants Stock Purchases [Member]
 
Remaining Number Outstanding 6,218,840
Weighted Average Remaining Life 4 years 4 months 19 days
Weighted Average Exercise Price $ 0.33
Warrants Stock Purchases [Member] | Minimum [Member]
 
Expiration Year 2014
Warrants Stock Purchases [Member] | Maximum [Member]
 
Expiration Year 2017
Warrants Services [Member]
 
Remaining Number Outstanding $ 400,000
Weighted Average Remaining Life 2 years 21 days
Weighted Average Exercise Price $ 0.50
Expiration Year 2015
XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants (Details 1) (USD $)
3 Months Ended
Mar. 31, 2013
Stock Options And Warrants Details 1  
Nonvested options, Number of Options 1,235,555
Granted, Number of Options   
Forfeited, Number of Options (138,886)
Vested, Number of Options (138,473)
Nonvested options, Number of Options 958,196
Nonvested options beginning, Weighted Average Grant Date Fair Value $ 0.16
Granted, Weighted Average Grant Date Fair Value   
Forfeited, Weighted Average Grant Date Fair Value   
Vested, Weighted Average Grant Date Fair Value $ 0.20
Nonvested options ending, Weighted Average Grant Date Fair Value $ 0.16
XML 19 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Stock Options And Warrants Details Narrative    
Stock compensation expense $ 24,800 $ 41,600
Total fair value of shares vested 27,400 87,300
Unrecognized employee stock-based compensation expense related to non vested stock options 110,700  
Expected to be recognized expense related to non vested stock options $ 55,900  
XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Terminated Sales Agreements (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Terminated Sales Agreements Details Narrative  
Nonrefundable deposit received recognized as revenue $ 150,000
XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Background Information
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 1 - Background Information

Dais Analytic Corporation, a New York corporation, (the “Company”) has developed and is commercializing applications using its nano-structure polymer technology. The first commercial product is an energy recovery ventilator (“ERV”) (cores and systems) for use in commercial Heating, Ventilating, and Air Conditioning (HVAC) applications. In addition to direct sales, the Company licenses its nano-structured polymer technology to strategic partners in the aforementioned application and is in various stages of development with regard to other applications employing its base technologies. The Company was incorporated in April 1993 with its corporate headquarters located in Odessa, Florida.

 

The accompanying financial statements of the “Company” are unaudited, but in the opinion of management, reflect all adjustments necessary to fairly state the Company’s financial position, results of operations, stockholders’ deficit and cash flows as of and for the dates and periods presented. The financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.

 

The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted although the Company generally believes that the disclosures are adequate to ensure that the information presented is not misleading. The accompanying financial statements and notes should be read in conjunction with the audited financial statements and notes of the Company for the fiscal year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2013. The results of operations for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for any future quarters or for the entire year ending December 31, 2013.

ZIP 22 0001477932-13-002502-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-13-002502-xbrl.zip M4$L#!!0````(`+:%KT*#YCW73'```.>Z`P`1`!P`9&QY="TR,#$S,#,S,2YX M;6Q55`D``_?SDU'W\Y-1=7@+``$$)0X```0Y`0``[%UM<]LVMOY^9^Y_P'K; MWF1&LD11KW:2'<>.6T_3V&NGZ?;3#DQ"$EJ*5`'2MOKK[SD`09$2)5,2%3N6 M.IW6(@&<@X/GO`(DW_SK8>21.R8D#_RW!]9A_8`PWPE<[@_>'OQZ4SVY.;VX M."#_>O>__T/@GS?_J%;).6>>>T3.`J=ZX?>#8_*)CM@1^9'Y3-`P$,?D"_4B MO!+\Y_WU1_BIQS\B]F'3(=5J@<&^,-\-Q*_7%\E@PS`<']5J]_?WAWYP1^\# M\:<\=()BP]T$D7!8,M;9Q]\__]>J_V4=/O2!W3,:PL5&W;)K]5;-:GZVVD?U MWE&S67#PD(:13`:O/]3C?W3W-P^WPN-'^%\"TO;ET8/D;P]2\[FW#P,QJ#7J M=:OVGU\^WCA#-J)5[LN0^@X[,+T\[O^9U\_J]7HU==9\WZ1,'Q:*@6R85N5=/A\$&Z M!_%M)/WV0/+1V`-LU3Z]S%.WW.!%%`>::UF-5KO7>U.;[3PE5\NE%U,; M@_@#=YX+T",1HKEY-YV.&6EZ;ZX;&,-4)YSWE+R;Z6*N9Q@P%V.1+I;SB;SL M:QJMJM7\QF2KK53X;CJ!A$1\IU0A-:KP[S<'P)20X@EL54C6MRXD:YM"BLU: M(V76&M^^66NL8]8:7\>L?8.RS9HU>]L:^VT",&/6MBBDQ8'(?T^#T2CP;\+` M^?,7-KIEXLE$.%5+-ABQU-R36RXP\S#VN,-#S2MQ.;3426`_ M(N`;YC<.?/@I3QZX/'AGFLW-^TTMET2:O5H^?R\YIHJ][1XF3P63KQSY[,W" M\UGOK?K-I2[!OV,BY+<>^Q2$3%[1"86_=PP'2V2P=Q7+7<4>/L\*/D_F0O8X M>*XX>#+70L<\I)[_X<%A$N!R187:?M@)4&!I^FBY!/:>9:EGV:/G6:'GJ1S+ M'@;/%09/Y5>N64BYS]P/5/C<'\B=@()IEC_YO2M9YDKV@'ERP#R1]]BO_'-: M^:=R&)\%HS(2D]VK<.;,?.\JEKF*/52>1SG\:SJ)_9H_CS7_&NXA>X[E6SSX M4\8YEHQNE6M/E[CA]SP8,9<[U/N@9OPR5.V:>2`]%[+R5S^>+8>^6"QX[V\/HV<+H^9VJ6V*-/G('UH"=,_9"LL*5$30G@;T-*@J> M*Q&XD1/>4&]GT3,O@CU\"D:<_[WP[Y@,`[%[T#%]LA+X%KW6]F/H/.3\1@5( M.'P9P"F8I6;FO(=*41^U-S+/R,@\6_>4AYR]D=E#I6`ROCZ;2 M'BN9/.<^]1WN#UX&;(J`?B6SW8/`0B'L&!CPH0C]C`3*\H7435UAL4:)Z&59CJT6C+YE$_;$D$I8- MP%VU@D\$P!VV@'E5XMTU@.O5S/?VKV3X[:KY>QKXO53K%_E<8^_7F[,Y%(W4 M\\CL7?RUDR-H8P8SM[(D<+0%X]\,J6!R(8E87JK1VC2`OZL%=%Q^!_"=ERWV M_83?/L'/$,WC9049S/*8-VJ*Z!GS@Q'W'R/[N%QFZ>8-;.YGI%!`H%=,.(#5 M1U9M#'\67S.7\:,/"O_7;,!EB$J-7T4B,3ZO\0,PRS[?7UU=O:HL&G2=Z"O,1U+OP7?;P,YL4IIHVAPM'2Y,["YP(E?_S9%Q\;E:] M^F\]?KI[WK!72L4_Z.)_X?'3)F3A:&ER)W#7Q1;G'AT4)M.GGF2:0F:`],BG MD1!XF4N'>K\S*E:=2]4\R;%LM'D`_,8\[V<_N/=O`*K@9=P+*2-P!$7)?@K2 M`%@PVCS9+X$7^2$5DW/N0>2^)KF947+@K>5PS<:!P$+)C?K26&%JOZ.5>6RT M>:J*FU,0]R`0Q57J9D0]Z$>2X0DZ?NI/TBQDALY3A.F2G\.5XE/%O[-*,#-2 MCG"G;RC7;N8R"M$!X[?O,G1GOHI$T/ZI&[%W(BYS.,Q>OCVH'[QKM5KU7K?; MS$A^":G%4M!JO)H<_FWE22$UDB%G8J%S",5#]I'?`=@!B_X`7[%[(B6#<,V! M,2)U-O]DA&OZ-\43^WFR,:_[F,H&(Y"L8*R6W>FUW]36I[P=WHWLEO/>Z];M M,GF'9@$HOWF1<>H9",YDK*GK2KK;L'JM*;-%2)7%7A%A=MN-MK49>U>"]1G< M<77^0,6E4%F'J][>"7!7:E98?E?SFGSQZ1S"A,-ZBM%B1,MC-5>67X]53>@D M"H>!X'\SMY@T%[!GQ9_$7,3B++'-69N7WE=D3<4-FTGL$7XTA82CHJ9 MB7(MUS1I68>MS*L.=>O-=*W5:5BI:#MG_#59**Y8J[.@;@T#SX547E>^UXW? MJXU>H]NS4ZLQ/_9ZU(N$YW`?FS7TS%%Z7+9 MB+E>H][>@IX_\G;^Y>K?Z;6L;J.S/9&MQ5473'*OT]Z>K/)>5;R4):L!/L+: M@BU8]O+DLCDRU9<3WU5J?Z8'\WQL*0.NXR?-@3MS?0:94FLP4'>!\27>HJZW6MV[<(LQ"^S M-"W*$$(+1)!"R0R%-1A850:->JM>G(&T@'X,`E>6A(56N]=N+,""H;,N+ZNC MPNKV%J%B(3/,\\"$_\A\)J@'*G7BCKBO]FQ#?L<^/(Q1K&6(RFZT[$[:CQ>B M7!Z_JXJS:3<[[=:F_%XSR:APAM#^#%;""\;J8$UY8K6LIMU(1==+"6[,W:I" M[.'&RYK,_2@"*:]$T.>EJ*IEV\UT&I(:?D7*JPK!;K7M9KL0Y=-`AI=]I:P@ M(_-(]`T$`&6(H-EMMWIVND:PB-IF?*TJH';7MNS..GQ=CO%4#ZAEC*'"&ZW+ M-;_72?N6.2)K<;&J4%J-MMVVU^'BPG>"$?L(("M#&E6[WFZTK!Q&IG369&55 MD50M6)=T:;(`*Y\"/\BV*M'X5JUZRODO)+413ZL+J66UT[6GPFSIM_6A1=;- M+H`7`5?*E]0B2IMPM+*%SYPC^G7)>1 M+OOQ4>F/G-YR;[9B4)+`UB2[,HI:W4[/KL=B*D!TSO*QL'SO9*7#N@R%E(W*L=F- M7J]CQVOR.,7M,+CB[GZSUW@&'*][`J`:'P%X8O[7U^)FTZX_.?\E:'=YS&Q3 MTW..2:VI2`N\.&A3HULOL)[Y!ZHNQ8#Z<1J-+XL)/.ZJ'Q`[74%[")#B%#M^ MI1;UDD>/)6;=7H!/+WZ&R;WW@%CAAVA^\,+C,9'AQ&-O#_K0Z8A8]7%(/O,1 MR.L3NR?7P8CZ%7VA0FZ8X/UC,J)BP/TC4C\F2*9*/3Z`GW]$,N3]R<$/@_#X MC'))3GSJ34+ND--`C`.AYE`A5`W\>R"0S]3U5^&0D1_H:'S\3ZO9.8X?JC(7 MNL>O?_BG91\/J03IJW@2@C'JNX3CRHY&3*!<^-]X0I".\0EG-:XDD<1+/)0$ M9!=4):#'"4%<9!QX$^@&)6\FD[AP_67%/OD%4P7Q(H\RXF$Y9.O21]Z1)(1 M[J<)_L14$;)"OL3CJA_8\80+D*;O#`%":E ML,GQR<(T6V:]H.$=%3R()`Q%!T`[Z)M5Q8[DGH=#D.Z`"A?I!3"LR*XJ&XV] M8&)6]A8"#,5"PB=G4J^FF>8]1;H&<<`7,'$R%MPC5J]G:XHX5-*"#!EU_XI@ M@OC@(^B5Z77I@KFG%7+N!0(4]1"UJ#9&U"L6]'^VIEDQHMKUXZ]+%V5)'4=+ M$^7>-[8(US`V1KB.CZBQ5B%0O\BG$>"3N15R&X4D!D\PYCXB!08"/@$;.&X% ML-#W$+_4\P#6R)>FYS/TO50H6/8I%]Y$LY.&N"'>/I93KA4?XT!R;7U`,R-/ M3R#>!`"456"LZ;FBZ3"`U3Z^04'AV0&[3OI><`^JK?KC1=1KY`#L>*SR^N4& M$HR),NC,5?!47"R3I($O2@RZ@KYI$.)2"!?]C(8NU8=]<&$`U##:&!2=#/0F M/`@%[K-Q#&`<]U=\KL\ERH]H[06")Z#JH&&*>XZ%;SY*+3/WX?I(26:',)_` M-!_PN+1^H!99KY!>7(0"K/B(A_!#<7D[(1`$C`@^*W](3M3RP6IYDPIQ(`J& M2"PMX&1<,-S&OP/:\3:N)BRP%[EZ-7/9RH>*8F1SN)`45(;TCI%;QD!C]61! M1<-A$`V&&?@F(VM9,(^#M9?0A(9:3U*S1$%2EX'I134.P-GB]6G;M)BF`N):GH$M4R]WL:T*P?I69ID7V+,3WX^`NGX8G0"+!F0_ M`Q4/NB8LWS`G$AR?-54,0M:BMB44%QBIXL+6*)V2KI<55,F:;*RR[RJO?,6.&PA0]M>HC.L$580]C M\`%,6U&AD+:,S(1::*K2?3%P7'C[#@>:P3C2,D@B!_F`?/G9V.UH8[5 M\)%HB)6!1P[N%FO4("^,5"&B=]`.H(U";T1.%#`3L"D>4%[92!>'IF@?7 M$T<.O;^SNY5&JU/I==H5`.A`09+<0YZB^-3)OFK8MBMVHZVTB#X2(1A(?V=7 MK&Z]8K<:V9F^@N#??8T9!K[BQB6OOFMT[4JWU7RMAO^N7>FUFTA411E@!E+* MYX(Z`VZ^><>SCK9!XY0=5F@0*CI!*&AS&P&1V6X:&*#;](Y"HH.; MU+&MT[JM\I@[#H#6=@%2);#\J.QJ:34]&=VJ%THA2-T@N@U)+OX4%X4QB&FE M?B8?;-0X$C(RPNX''D1[^$L&D7"TF0>_(70\Z`7^H`H7),4?!8AE*_QY@EQK]79N.>N^$0F]:_/Y@217HB^8G63UURS?AQ+_O[ M/.9#=TE/52\$UVDL5QB,$R;,<-`!)Y">3%7ROYF>D6IC:GVFM\O MB5P+!PH)<"BL/0;I6"AA/67C"EK,1#!/:RO<3C*_AK!3PLO M8&EJL'Z#9`N5O!K@)NIKL.W:M<7&::X2)"EWS>B5V*8:0P:!5D4;._2VT%BE MGN:MU=EH;%J%RPN2E;5'=Z)+5X!3XQIN@C_1YDNZX#%T].">PK]4@"G7% M"Z-4GWD05OHLU*[/0"X>1ZX$N)HRA9E+)412$,0R[%L_;''_>2:R.TXS`,95H MO2CY.6*V1K9#E:,B93TW4/EPG.AKFT,]3@/11T7;"NYY?,3"XY\:_Z(\(]?P4F!$H"7 MY2.UE8'\1$GPIQJ3JLKL=:DJ,9%YYMEL8X+QP!HSVM=RR^5Q2"-3I@#MY8C^ MR5)ST+O,<4UMK'5;F6/:[^,NF+8`6/'%U8]-.NX\*6.OJQ`I2ZZ"Z\2PJE!, MV>>!BDMR^QBE-WM8QF\MK'*IF&6(BN.^HI*">*0*HI55C#"``@O?T'?(11$M15\':H9W!+/>K'"22L,E8.29^YL79PM8&#^`*- MDO.E7A_C>@4.P3'2=&,%F)AZKTEI=00$ZV[H`5C`C?J!7S7E#_`65.@D`N:7 M\'6/Z0*$_BEN@/OY'1/\>"Z8<4*6/4(U9UH5%1AGQZFC MKU-[8',4#L$VN$R8/!A'2U4R(9-10C*QGE8D4T16G*LD!UTJ`WC@V3ECG$`8 M[QD`"(^%$%W\GG;0(>.`*7T4L2R_:[3JE7J]CIH'N8-R^!A[A(11S-[SEOY0 M,9-:P?^3Z\L_Z_V8>?NPJSJ`3Y;Z8'XF"Y"?W#=XQT,. M:;#3^Z1\,8V@N-2!BC(W"$",F(4.@21D82[#G1KE[&XG^N0?F+)*_%<000;, M(-1P50(-Q/YDX2&N)?P?QTYW-ZA'*CX+X]Q=E5M05^[P:'`E#B?'H'7`??S= M`,G=.(4C`PZSU)4T&8#>.EH9F#IBC/N1'I9X9,PXCP]/*BCI0W)]ZOQ_>]_> MW+B1Y/E5$'-VG#H"TA`@P<=XSQ%R2^WINWXHNMOC\%\;(`E)6$,`!R#5UGSZ MRU<5"B!(`21(D9(V-L8MB:S*RLK*RLK\928PZ>7:0UB[!10$,Q<_BHI>!(,MX%RRS-P`Z&8^4A\WW]$FS"(2=GAM/B2"MED0P^@ MANU,;F'/V+@06]\R0OEG:QAN!7A`?(7N".]P`L:"WLKS'U\2"-`DV`J>1_X7 MT3\)T\GB#IVI$_H%04H,9_#$3U.",[!%56(W6JWHAAL;WK5HIZZ&YO&"@SEA M>1\`85^5PM:?EO/&_WZO6G&A2)9'4>\/OHFKY8`?"BP'VPG`JBTO6;>FB1#\ M!;<.(8[+M*LKR4*=S=?1#&8GF_R*_\&H-LZ7#W)U$*;+"B%AOY\V;+2"<#RE M`'A0-9ZOC2<\<(CCH`OF+QH6R/FA3U8^`4IZ=@_^6>&2:XP;`8,QP2C-;`TM M:IX8I`ONU'L&9&6H.O-E@[)``$B19+>'-+--"ZS"K[W8.^T#(DI0"J9+)ZYP MG2U]SC+/$U\F;9ZI<9+\R79-09^N.EL:[ZP>&7SA8"P==ESI?T0T!&3*"$UD M[!\IJ\-E!*]?+00:_<8`Q(Q[,VU,("^&*O6Y=YP_F0>V5&;12/2/V[2 M9#'+#88T0(\,ZITHO"9X%'U_<0O2H.16CY."JSGG M$X>$EH2J&G>V#O?Y8D^NJN.(>W##4(<5SYM?E2^Y*(?RQ?\$*A;(X]$QIA<0 M/][9`,QNQ9["")P\GV$!&EQ8VNAD#$L0$Y"%3`+%^CT>T@QC%IT+VG85?5][ M=93#.-?H;-`4J1>R`O(6%/^H]Z-U,AC\:/B.D0PR@GWE".1KP0=#DF&2_<+G ML](]565$7=3#3O)"DCC0U"NT9)A5D5-R<]AKESKLG[D_KO`XO)`3\SXVDA]$ MO=ODFD+HM>&>(ON-8AE@WU#I'(J3LC1^3\2L(!Y'$6'C.-^3_=CD7PT-^#Z^ MIVF%R!1?]SW M6>1/]--L&ERS\/)"EAWF!2_49)(N))D`9:EH1HUZMJ-,OY%KC\3VDWM*4Z(# M,[7CO,43]B*$52GS*7P#K\,EEVJ>29G1'I)YPL]ET>(2VLEA,/;) M7ZJN?[KT14IE`G)&83@R,G]KT69*3!%&8,^4KS+-EJ^4:>%*06^EU[%[KDB+ MV[$]E!94&4KX$7*#,FX[6:1]XIMAN;)L#>NT4TQ_BR%41&4'IA M1HWNPTPA=O`W.A'%R@$Q&'N.IWXZS:Q?$DRC/7EW_O67-]6?>`M6N$8/G9Q_ M??L&WG:@SJQ^QSMU/5OR.;L]=0:(I"^&4-!V]#1`^S3E0(?.F4)FJHQD-1S[G>2E M(3=YX=MI(!EE5L9@@8"2_S/CFD;6:6$\:032:U3EA`D"*T-_A9)6%`.7]LOY<\QFPS4`(<*Y=(I2K#BUQY)->L MQ=;A>T%UX^LF7;9;K<+:Z+/BZ,-8H4BBFDA$-IR_7$?T)26H!P$G"(G$3(P: M.&N0*BNL?S1MJ*?V*8_F?Z?3BWL@DQ40HH0'I]T.BK0D,T&3^EF!(NVV42DX MJQ`R9JPC3`FJ)B].E%",'RM?E&!O\SLGO]CDO3A5+UD\B_BD5K2&F4++D)C) M*P9$C*L<*ZA.('F,^D8BKMC6G]C>&%?(;V@8*`/Y55]7LY\LL@49;?@IQ.KF M0)0W+T1TV25``7H$4K-,D>P$TSHY9D3>TFW_ZCROU`J?DOBT>!I/UVD&T`>Y M4C=8/5Q;EH MB9P\`1YF)6M$O4#`?+`\L!O`F"3B0]*&1,HI!>*M*_]!TDD2"QFB5"7[->GS ME8_VKROX9>*#8H/!9(CK%[CV?Q8BM;GN4G>8SI]A79DJ=:D@U,O?4(P1WP`Y M5&'FNR3E+'*,4*M(<3'*P)X\M@`(9G>]GM@KB`(*!=QRBC\O]2!)TGGQ9#[N\>>:A77]]%&=&Y M^.FJA2,\@A\61?^3X_3LKG)`.=[0'G8Z-=RSY4A1X>FL4]/UTX><%$8JI%B^ M)BLY$P76L!#7=OS(8HASM;W=[K+;GAUTI4#LP':!&S!Y43A`KR"D8[Z2)HX( M*^E*UN(Y5G'4L/)*LVM&BL[7NJ%:O3`QKW&>7"'\6I:]55$>%DP5EI,G$49A MV4?-CQJZ7+.$LZG\YY\<0.<[9?,^W7(X.(1?I[7I5)]I>2=C&'+L[CYS-,;4>?&:!*6.)TQ/<^?L3GG1\'\^]8RT;B_51981+.\I/`QZYLK"^9@+=@<*,^I&H- M*-V+,+L%%JOQ3YPW%7,4LGSRI'IM*/(WV-'ISWW)L5:W'KZ%53ZVRK4^2<9H M"C."\@F]I3D5/AC0KZN)54\KTODTI$/*-G?J&96 MKNY2!'2<+.)EDM>P5R&`U9.3+Z=QFOA3#9#E\WD3WHL:P@QV)&N&J%E)5U_$ MG($)E!/(8\HV>,95TR@"QTQ@6X(=SQ-,CV8U!K\KYTR=?,#Y+>>-=JNB>EN: M=VFYEGRQ*^OF)?%B-+JDBA>HTZ9!-DG#L:HT!UOR_>`2`@^Q`HVWKG)+2V5I MW"VKPZAS.F(ZVJE9X^QAX:-M5RXG"6Z*W^J?4S:`4LJ*"@0*MD)_%\^T#:<2 M$YA@8&U5E$_X]I5MU'IWQOS#$;6#7"++E$OY)*1V$XG)P;U8%JUB'%%)HQ8P M0X7KT(,R1+3585M!2#-P_67$!J<$5N2?S'!-<7KR&X5W<&NFU;*X+/L_50R1 M7UEUQELZ1.@8XDE^4O?42H8U8XQU$IS=G-FZ;)6%8DR5AJ.L/[U9A=#!BRFL8/]$FJI8'&?BH+`:40OY[K9W*NN_FY MUK(S3K`:E0%[E)BZ84R9%P.*GVF>O=:6>LST,YYQ.AU?E:N#(RG0.]H*>B,0 M5%6A_HS'3>$!P@6SX0W%I8RJ7A)4-D$74?"+%4"-RK4%2#?9`:P6R#6'V`4< MB"6`0T3Y>A3,5NG^/"#N5U9-T.!0*>=3SK'G,J/=?D7N,Y%J.>BBK]/HGMRNYCW`E5[37TCGP4F(BJ6;)\#>E#L M#K"5NZ?SM*$\R".2F\2GDMUNP2,_F)>*2YM1*L,)/%V&3*B:`^31Q2JB7#PT M]N=2K(,A4<:`)"Q94$K0US$Q%C[&(X$`VM49S?J7,VZ[8S.2M!Q:I3(D\@?E M1WLAHK#LW>(FA-;<_PN&KO)JX?5C?$3>(08"G&!\.JK`9I&I1!XD7Q13305` M&NH15]9W22E$"/>>X8)17E;Z4NR?DN#0Y)JIZ M5,$-:RY4A<,FX@%6=7.$/F;IF?4O`@+J&E[ASF*^Q M/87:'04RN*H\EE)]*1YB\P(.5?9G5H!A9G`HE%)%+JK,8\JXXHVA3`H31\T7 M.68J32CXM6($.G):0KC$BF]%L(O\@$&$QFD4_AE$#Z?XBU-\[W#&"Q]&(UE+ MIU:/`[P/%K/;(!+!T!FK$C[3ES,00Z"!!1QI]/V=65\Q>R"GCQ\W*`/ M0L>%Z!C"G7X=SHV:4/R.R68)UXTT'-Q906:U(C`NJ8K:.\G<#$69#G/65P9C M"WS`PK+7PE8**P(_5U%?#`ZQ+U]_,G\"JGO&"-V41Q0')_.$ZGBJ+^M\69(OQ_Y`"P6"23[!ZI35DSZE/>$R= M&!@Z^U6`ALH6Q`_Q8)7='CHC2]4,>M%E0%0S.NL$2QN\H=)$A'E=<=_^`M?4 M1-V1^7<8MT+?$TC10NSB:7@?TL'!O,SB]_SY/`W'BWE>Q3*'W4B%?W7$OP>8 ML($'1NHJJ<]RJSFCL*N&G>47%USN8;28YW?[TEI-FF]"LMBEWA1>9ICAE M=4B>D"D.1L:J2<.9=95_AH,UE9^C;%V5OTY%IB;\%/8C]0F$!A%/Z*;FD">6 MDF585@%33,=/THKRPG`3ZO28J2,#7^+V*&)ZEGE-R*^E.]ZG'4-.D>*B[A,J MWFK79(HN[:$P]!0VGX>G^N-,\D*9$.(#U*D^JN`'=YVH3)9:1H/<^E.K.[2] M7M<>.(Y^7'D]N]?OVMZH4X=RMK<"<<7R#+;A8BV,K&3Q;;J0I0K5JVI/17O-J*]@D*`!8V&L*YNI>CS:?I&*F"_D M%+]+@T!71]=7BL!J2T`U+MD:!\4N78*FXG:L%`"11$U=:[T"4LR/:7T[\&:O M.!]DCQ=J%XF[))=A!1XJ]^M;SN23DP#WMM%_07YI$V[C7CU7Z=J%9R6YM*FF M8EY8QP!^(0;=%T]0I4XHGH$RCY=E7E4,9YB.,(_J5L#M7'&$7DJ69Q5">!*4 MRC:G29S@^7K[5N&[<'C$:I.V> MN(?-^L-4$,3/R_^KEW7N*JIX+:E,R3R?O"IAK++>>[T:[H4&S^?\.+R4-]QG M%.#]5WNG[3XO^4-M<VIC`@*=,!!`3^2!)SIDWHT)>X;1XX/%D!FG]H*O2"<4G M@@'^KQ>+?3Z,6*HBT2(O*N/TZZ7N)[`1)W]BL:5X>@I,2=)_6/_K[=O+RW?O MJ@2R!!T;].NW&UNA+QH&XS5TJW&TO?3-&A3_L!EMHQ+BBWJ-U9ZTU[>'W>%3 M<>7Y\=,=V:->?P?\;.FP?;\-Y\%*W=_@7*7!39BIWF#2WXY=P`]/I60KX$#- M-L^C\H=/0_VQK7+WRK^I1.K"2I1*=K1"..K9':_[[*5PY-I#=W0H8KBU6GPK MSC%LHI+7^&MY%^N:CHTOUV:V:+.-=KJ8?OG$Q_$ENJN=]49V9^0S1P-O%R#0BLZ+!]!#$;X`;^4'Z].9]6Y_ZH@M^%+_9_*K2! M%:L#8<`L^^)-?4?,HKM/LPS6-L18$8IQS]=*LA!03L M5(F"#_R-,_DBAM5Q8`I[8[<1&[ON1-/3[UAX2U>WI%#<(N-8H$(\ELQ:6&*`YBJ?5*@1AL\2(HYXE*X#8B/]RMBE** MN1\+VK/LG]`LZ\'Y60(W8"PU^")<<-DU1J M+CM)5`CP637^!MG*:)6W#[`EL6[<;0,GX.3BODQ3?\:].*)D?BMQ#M[H$TI^ M]>=S$I)`5W:;<@GS?%_]&(0[*A13O@Z#:"I9RV46FY1+'UKF'MQ9P[E\N\6`C<6EL@N8)]1)E3^D3^8Q3X@N/CHN]#@(5)".@ M7WD;J+@";BH=!^Y69Y;=IB`WS:NVC00H0)Q_K&'"1BVG_[N`;7#)?>I1%5B% MR/%O0.O<2"EZ*A2XN,MT0OPBT\)OY95$\[*85,P)5_"#8]T!!01O44585"DD MB7)K;+S>F(71>G:ZR#ML4HR3ND-@!%$=[I<2%#3!(RF'BT$UA]&42ZKX5'X* MK@:)9H/>+0#-DFN]_[J:."I_#-2J"N3TQ^J+\,SZ8A0DDNVART$H0&6G;Z@? MX*'?[^>721$AR:I!PS!3<^"*DC\NU;CABC\.M1NI447P\7K!I";KEJ?^8>C9 M_>Z`J1BZMC/RBN/9C*4R<53EC`@N)ZY:F9H=-)`#+U"*_2A+2"%69HH8:2PE MF20230,-A9U#IGFI/NJAI]#T<%/Y5$,=5%\LL(I%S'=Q1:)7M130;0D"V._; M';>G`=3XJU'/'G1'Y7XV4DVMHD9:7EZ/(5$607V,HC'"$)"<-(DBFR89RB0, M.D]4[P34ID9^L%A-)LS,#-;CY2-9%K1\HZHQ-=5Y08UQ4!3]<7+/Q?D$?:/Z MV0O$0>5HA-1HE#J\H%(TLR4+54X)J%$2#IU@!"D%U,#\SX/8\GOXNN)U#>K?AR#JR&ZI_$.!%"">& MY`@8_1DC(/SL)?I]+`:=,N@_@723#L.$`'[H_J)>IQ?Z=>I/$VPV;FN5AI\C M@*\R'NA*OD=<-"H*&OXJ\F.Y6SLC^JFH_L!>3V[R"N7Y,Q<_6GSFXD&DWZJB MS`6,.YGA4I]0H<+A9/Q[`0P@Z%BN\\O=4LR#HR">";:P*53WS)_I>3XLGG6@ M!.;(UO9PJ^*F\(I&XQ>8SC$&^Z4SZMK#89_^ZE"\BIY?"NA?JOK).#E&:#%V MJ_3V*^Z%_(;WH\!8O&_F1@EO@Y,PY.06:Z*6H.V<9?0?A4*49:F7_KPN0U[. M;6(41-3I"UC^FJO:JAR'E46PB<"U)NS+864.=L.')W;EU4EZ1H(ZE]]`5B9+ M*3*E-!+42N@(HPLUUQA3;:+E7'Z%UQTGO*Y(EQJK/1$MX=3&'!M%E;G2SM@? M(5]):5<2LK\@S)%LVN\JV>Z8]QB#2"X?PJASO@:]?KV[UA MW3?),5R1KY][_=Q1FH\.1[70'AWB= M/(?DLD,U;0Y9*KVS8>](>'9T\NB.^G:GMWTN:86:;[FERI/BI`BW6P3-JS0* M;.I=RJ-P>]@LF3,8>H[=[W2(/`6SW#B1@ML+)EC?MUC_3W"$]P$U6ML8]%:Y ME@'E@7`VQ@`[0I>S._:Z$4\E`.<5N0NVJJ&^S#7'Z=@#8!L5N"\UJE>0.,:= MGBXW9]>B9513C^'7LKT%N)V=9Q7]X'GV"+?GAZZ;=^YV7=O#OM69;F=`1*A* MJ#HU2`DG%U*?YCFVUV&&Z7X()D!A1WWCAM@U:26YB9Q7-^>J(E[$IX#X(EN]?\ M=1?U+]+Q1RNF)TYW:/<&C4("-89]"6`L]V"J#6ZM;'>%*3Q*>`$=B6&S./@3 M'(EG#478UU6QT6-@G1>EP<8]JV&.D^JG'N90]/_R6U4=0'C7OV('JE@V\H:V M,]H>+/4:J-WV==OH>+4SA(5>TL#Z$UX=`T,D?KP4DCEF@]E'I M9C/?QZ9]""GEERT"E,T:-]$&#\H:84_/.[*T_&.B]G6=A[C.M7-N<,JJW#;I MS?C$[?1LMSNT7<][LXW9JJS5TW?J\?'$GHG-G_X#5;KTB5:POY5VSYI507C6 MT>'.6;?MM(?MB7([3M_TA<+/JW.%6E(+OV_KS=6Z0'7X.5I5T'TQJN#,W;X# MUS/2!&W[U5O1!*MC'X=L$%S>ID$\#M+C-0A<[X7H`._5&C!T0-L;?APZH+W; M_VT>:SA7L8:CU0%#]V7T&7?.!D^5C/ZJ!.HJ@5[I2;#:=#MDP^!3,L?(9PQD M9#K/Z!AU`Z9_NK;7';X`[=![T@J`AZ8=VK:7CE,[M&1SY.D,C`+Y&@2K(+`UJ/^6S/U]ZI-#1I0[6!6];W<'A_Z. M>?WYPUT+.._2S,;"E(A*U0L<"1 M'R?P[=L85.G-`Y8M4U7!15PJ)>X*J%N!K$SGE#C;]).]*+>ZP(V\\QPI06/L->XOG`V;2R%;-.+7&#SE9 MLJ;`A\U5;7IY0;(6M5)#L0L#2-D`9S>3C%MHGBD+))<-!)H6S/4 M$$1>+DATG-Z>?_UF?7W(YL%=9E%[N`1;PRFIAU^=V=:'^?3,.E$Y%H.?\$OJ MI^%/;XJ'C8;U\Y)_BQEN=*'L'!'R0V^H),9*[E'\K/GW(+J7@F#8GCA,8-[? MZ)A3N3!JJR[[?Y[+LLD%$F?1`3`M4DK'.EGB+[W2882'8`/Z%"-V%[H;K&%HC^`MKP>&A]2W012'KWBC$AM+( M/FI)/PEG!($E"DF!A%SFS;]/4DR`@8U[P)R;J?4)V'T>L@K"?[^-2'@2N&6R12B%".EZF/M_!F<6KT$4YN-E MYURZHN;Z>B4!TTLGK8VG)D\#$OVO2Q3^X'#<&VODI<$U4$)I-M-@EF0AZTSX M=!!B1_!KN):-P3,8YSZ(%\'9DG'P^'U?,`_(EE`.0?WA0[(-RJ;UNO18L",^ M3^8)II`X`[5+%W[(2NT\]J,'$#A0`^DL$>#U2;''?"E3#/56265^#28@*/,0 MEJ7XEJN9\G!?K\[-H5CKQ3`4IN,F*5>.A/L_B+%R5@1R^AYGBXDVT,KOZ8,T M\D<_]CG53*NQ#WB2@++2I.]E='-FL_L[&T-E?2B7]#7PCI7Q#X.S3JY[KU?U M;3<3Z6SKA\Y9Q\&#+:H=]#,7?JQ@-'Z-Y,\@E$MOJFPXHJGT19VW9:S.[$7/ MQ&/I;_;AJ&JRL`)S3NLD6P`7>,'C0)E&^3R?\2^H$/)YSJZ$BZPD$N.^D>2_ M:J5;(L99EO@ MUW[`<"WO#^YGMAC_3S#1K*!\+3^%OX$I=SH-([;-_2F>9=9_2![G6V:S*!2% MF¡QL&MZ'%*<\LZX,82U:)W-=U4?Y2Q56AU%73ZZ*DE,KO#-J]DL[)C$?K#XX] M$&LON5:L6:'YE?K2ZBPCJS&=DAU=R%N?^0]:\?NH;/G^P><#)SN?B;1:A1G$8%;6"%'";WX< M0CNP,GXAF58.&UG^?(4Q`[9,KFU>HH#F3_;N>KDJ"Z65"R21V!NYMCO4.ULI M8#W00>Z0IO&S6[/*/VLG,FOT:S?D\W!692,4Y'-1]/KD02``QD_#`:B_K_AT<'?PG^FPK2RXPJ?=1:^ M=?"%B'^XH6A+=&`<)G?!%,,3K%,Y2%0I]^72ZQUOIE3T!TKRFXLB2B*1L:DTKNJ6]$(DT7`1HS=KV>Y&?GS\U;J,@_0& MWLT?WH(9#-(5^=_QUHOX'2T:SA^'$8KD1+YK1+_T$.;3VN8'''T6E!>;0#[? MZK=@6N5MBG29,_@M;+%%,0'2C\7C0X1\4#(&I'_EJ-9*CW0>+#=?T<'U-?W#4&F@@Y3(I8`W"$\-G+L'ZQ[50^2#T2%NXWS-EU_^ M50Y$*DK9_?C/?YV_M3*);^+\89S-_2AB1PX9QW=W:)7Y$;4+"]'%A;J$/CI= MH/\0?AHOP@@#]^2]_92D\UOV#L%708GQ]B0+4&WJ-R&A"VZQAIQN=S1!IZR: MFH+F=J?;LSW7P9^FP1C/>5#@V9DAL&3>YJ[F@O$5DK/3B(S!@(H1F$T&?,I# M[]I&53N-!"Y)-1K!L%E%*5GC%M?AM?/\/LZ))]\2K6#F/^27/CU$026#J@7; M-7>B$EGBW(Z#.<>O2390`\I*<(\D@(NO%]*Y3(6!>3@WKAX@@>UD:S&3P2,_ MHX7)[^5+]/J('E#ESD`]PY?%YZNV4IT-*X\1OQ`M:]YKZ`GC`W,=XHT:18J! MTR`*L;S4&+T_QQKQ4YB,!\,-D%Q*XS!6!'SVE5;L5HCD1.= ME68F"&BR2-5\9DQX$8=\:OS)!/UK%(HHP"O0C4E.W.^W`:D6DQA6#MJ!;EC(7I9'&'8T^"9?!#TC&7+BLXN"@`!JJAZ)GE%[Y$M>HSR:T99;2`25*&3 M/JM?[554TDH&O49PK<\?\#GRIQAC M4J863@]:,^F"K4$8`=])4]SW:S@FL(5O\,6#8;N_V&;`T>BI95[RR7=Q*I$(6MALA=`SG05SY4$5=##:HGV`)?7=@MXW1 M:)\&RE`K^C/-B\PH>JR*+N=1UDYG8&LW)/PTI'.D8,+X>3-XT.6]:_GP5N@5HF.5+OF6S,*)NJ/>G7_]Q3@!IXZ' M\X0,&*BX\@VB&38="$#.4`0KG-[,PTB*DI\1BI[+D9_C0H'IBTB\[M37&<3J M3[#.-=:SQ#)V_=\%/EXG4\/Y3'0)'IP63@,193(D+(5,_6PQSH"'9"'HDYT& M,WB"D74N(-%OK$KPM06L+O:<+LFC#KGFL$2RA^;:AX,FI,_/&@Z(6*!BR$\# M]ENF;MM?,(?D].L$WO$HBP3:/T71(7QW`M9KOL]Y*UV0G,4=`_Q?ZWX_52/; M;NT"O>U4@WTG3Y5O9*!]9`/MLFB@$=UC'1%I*2?L>?-5]^%LG6^->K6HH43Z MAX.CJM'J='8S:4M<;Z'1WV713-E!BEX-(O;:WV[[BH2[/C-U%_.Q9&%P/!ZM M@Y@>\6P`O(`]=;:OF')()Q)!LW#](31XBEN9JD[7QUBTY-/?SP]E<[8^<'IK M[A/T.>&SYFCWQ>D/?K1.+6?0J#QQC8%_W+6MT<(9^Q)F?YZB>X0\Y(B$/^Y# MUE0%'L(VMG<:"7@`CU5&OQSO'@XZ9D6=SMEP^\KAAW/DOK)?RH@>:K^#V="L MZ#]2WJ/PB*MV.5V[UW'L;@M%G"IVL^7"#$_J93V/HB7GZ/BA&/:6Z*+X*OUQ M@E:(HL;.QTHVO7!#U44-+>#T=`#,\;0H2N-+C9CA'">[*P2YO M.+!'"-*1]*GP/H@>SJSS/("L>60%_5J',,J!+_.[]#O M^!]R#GZ^O@C&9YC!"MRS[G30$%,. M;]@?.F<]+T=_VY:9\HG!\JBX8?U"1B>YU_'@$1ET^*;EA%"5"FHK1-J=1#\Q MM!@-%`URS5<@DVEY>$A]BJ;XUCB( M@^N0`@X376M713(5L4B*4"&`BS+K::,=>]!W;:'4IA)*K;/*E3"+_G.Y3A%_5RY"^:WB0'C<-Q3 M+@UBXKN^BN9!G7MFU;WFW,(114K,\@U=;VA['H79?$/C6RH!I;#0%5'SH,0. MDMD%!IXU!^2V,O'-1$H)LRN7UA9W3SEGXK<,;KQ+B6EEV]Y,?X\16Q.U!-:8 MI<',3S6_\Z"?#M%E*G`'=".L!^\1AI5KB!%Z>N%;,XS,W2"R_SHD+,)D";^KLR;L\W99"DW\&.A28:0B;$=+C&*Q/HBR*$2.5N-5T MNAG?D&6!@+L,VY]^GFKP#0$X$UH,@ZFJOJ.BW:;:,2Z]`M,T(JZ*)`$I\8?` MED)L4F9"BY8CKN<,N..0,%,R(738-*3""P(R33*#997XHZ(PED7UK9_=GL=3 M_,\E;`IH05S,51*%D_9P1NU),-+)L#W\1Y!33(E5F&S+UXO:N2):)9PO=-C9 MION$YQ_[$968@%4!321]&?1YLXA\>*NB%(3! M=PTV+,S,"?T(!YZ2A9!I2UH]:7PL.4%91VL>$H1XQCLR/]>V-8%5)W"'61/L M'0`YBFW^?LR*\0;\@O\HJ8N?$\J&ODNQ:0EJ6 M;$QNA==O^G"P%XRF4(EPELLPW>3^=^(67J:8N:(A3&0)Z$<*[`)G)$V2#-X+ M!HIL_,#9EJ!R;/E7LE"VN(T8/$9HG5D2F@T+(+2",*NW2QK`2OY#XD_/&"E[ M0@EP0#U:+@5(O'4#[X`8=6@RSO`E-V'YYE<1OA$BT+-1)H2'JBY+7G4(\?-) M6FUPK-KDLC!<22[!%2C9.4@2*L@9GH&#%8XK,_LA4.22Z5$`O?ESVOY6,4$O8Q)D8(1O(;A>;X(99W=X028(:GX0EHT-+U^?T@C25'WV^ M_I#$-Q_0+6I^]0#O'*3S-.),_.4C5%)^[';H!B_\@VC`6/@LO]7SPF`*>,`H?C,U";Z/#,^W@'8ET^:& MN05I8.1/P#/:3+>D1+0E6=YJ;N^-K);INE_EQ5#_*KC&Y[BFJ)395U3DH]Z/ULE@\*/AZT0RR!SU\\K] M/AA";[11V"]\/BO?/15OYHL&N9B4'*NHM_-$I1(Y9E*5;)^]=JG#_IG[XXHW M>9-,ME:$L%$/C/V0I,KRY04M1,/;Y-XI%4M@OS98;>2A5Y$VKI@P_YZHHE]4 M?"RB'2@K6E+J`85+)7[-5P(/J&A>N)3C7#S.^T*R< M3*F_I,DM1$\?)(.2#G]>@Y8J4*@0'"VD:(92V+(0$Z:4MA2#`,O%;$8]VU'& MWLBU1V+MR56E*=&AAB5O9;6GQQ9_M7D.7T6:X9ZBUBAW5M65-YV7DG(NT;/5 M-<",_/:-ZB&1CXC!"X5EV\2M92"KV^5)##:G.,K96,4]1W=]C!?`:R%T2R*PLS-",EP762 MJXZ&G.=1W*]2>3RS?DFP`/D)IL*^J?[$6S#LT031)34P'_^-9-+V.]ZIZ]D" M/>WV]&DQC#@%2W5^^BB4GUXRY=:YL4!;CX$0$FZ<@R$MIDE)7D$<;>T,56R\ MPTQGJ9SR((@.H]B)*&BNKJ$[[^C"&NAKDH>+V`V%;Z?HU,L89D6A=*ENHDP) M(TRN03QA7BYH0@7*0Y\CEL'"\",IIJ0B*H0<">;3?EEV^ M>8E0*@Z03'R)42LO9&$MY4HM*KA-A0HF]%A2TIGF6ZS7IO&37-B`'7Q&;;7B M9)4OB4=?`>5G`X&#*:J"4@"\8"0'F0/D.\`L2.``>N(.SF=6J9ZYB@-!UXSN M6%A-;4JE(H*[690\!/2,U2)T(WCH:_UGP<-Q!C57A)H8'-)N'#D(E>`&$XTF M@+@<($:6#(9=E6]JN:B+62H&'Y13]=0E0%JL?*I?-NDF3*G]"GC.LI9!6V!-;)\."V!V-1BR$5 ML+CD*CJT!=85%XPB+?4IB4\OE::BW>?B%U4/?*I-S+JNJ*,,"`W"-;3FH]NL M\%H?FW'UN2JD47!HJL$RU45$5*,ENF3Y&XHQXD<@[RK,?)>0*\Z?8G!8!6FU M3X[CQ%R<@TM)X8UWO7*2U9M9#`&+HQ8>H'"U4I#Y)'R38]3\N:Z.B7CH,&]N M@5.;I;HD+R*7$V0`2PGK8;BQ47>G,$'E#*N^;0JO.6&H<&RP?0'"2=_'$K;) MN#!E37&VZW)0E2,IW4+Z=:2^*&,78.S\9BI.4@"8"VG4FT=?3\6KTD*T(8XJ MV'Q)BH$7/59">#X6$=BXDJ(KM^,8]SCA-)G*JBQ;F_K11- M'=@N%THG$O-T"O\&T13SU31IIUM2@E&H!V(.I5C%4#(0943!6$5@_2^@N)_PYPU!UD)0WQ7CG MJ%+I$KG$'3&*]\((":*``J.>9W&(NT!%-&^*"8AY'?_<`II5HF+*8@W'1_H3 MB4^QB!@*U(6'U3()K38UP4HBQ"RR5=Y(8TTTY)DEK*VB./=#%W!&I8.^/+)) M11%UI&N`L]M?7K"&-JV&$M05V+*H&YF,VI/V/C=3#NVJ>I=;+:&N_ZR>Q6R% MH)RR,U'5G-4;AST)`RPG'>>1[!DVET97$VQR=DW=A/,442[Q2+XZ?%3C1WS> MTG$P_XXA:8FZZ[:U=`;GV@XJ6\E+MM)Q.DC':>J07PGBVF&=< M%/W$?;.ZRJ5)A3\FM.=:4MDT7":7SC*"U$/*RQ%,ID8OR`$IPBI.%O$RR6O8 MJU"O>5P4+Y-QFOA3#0KE@W=#H"6<\3:\N0T8[)U0UBEU!^8"ET`Y02VF+'92 M`9:"8,P$J1I/OEKJILWZ"7Y73L0Y^8#S6\X;[8U$O;4T[])R+?EB5];-2^+% M:(Q'%2]064V#;)*&8S&JQK`EWYO4%7QJ#]&F=0C?`@7C-+2M?V+'<-P9H!6. M]>GCA0C7%$"0;WD_KE@F1L!.;P.,AL'8CM>\<%JY',4\F>7$-IRVHBY#G51Q MD^;>:'75O-TOH"6^C;I[9)R<<>O4^JV^!F&;*Z54J3\+RR?NI8HC\ M*J\SWM(11D\53_*3NK]7,JP98ZR3X.SFS"Z6Z\K>_,09/#R5'E'!/"31F:)% M9!4RNQ1N01=/*&R+%,!\[50R#0RBF1.]'@B M*@,'8Y$PI43!E=4UE`,#_,IJ"1IDR]?8-O<)]$]N;S4%:4SPY!+J6_F*177=I2H@`UZ;3?2 M0=\HEJKB`WGR51XN4ZWBXE-)I>=HTVT0E$LSJ'B?X86?2NJ4`311!0[(K7Z; MI/-3BN+%W/Q$-T@P!B2QR@Q4B_@2C0BC(:YV=::U_J5TC;<9F5L.4E.Q$OF# M\GBNZH^=.R5KN1:7$ZEAYN";_]?!.MJ90FON_R5NWV*8GK"*6B&QL6:>N0=) MA,4<6L'1AGK$E25>4HJDPGUH.,R4\YOKI@3D%5-N0^5_K,`\L9,)YM(#K)B4 M+E[RX[-/G?QP_E\JH6C*[FU2+5(01@&M&*R=`Q;H7@ABG]ZB.'7D?^?YR%(U MP7=R!M@9GA6]X>9"5;!Q(HYX53I'Z&.6GEG_4M6[6#>K(@+R_0QO>?2W2J`D M#O"5C<5%YHD$&G*TL[$]Q2H@)AGD;<:<]8*C_G@TZZXA@+KI7U9`H_(-OHB5 M7D5>J\1KR66C]!43<,XN6LP!FU`2PHIOTZ'4,L3E7'RCJP]"74ZC\,\@>CC% M7YS".TW5E!D;%2A)*E56.5FT)W83JL5)1-3JG/[Z]LEG!=6"-@D16D6JL*NJ,LNI\J MZOPD\V*9SGP\U5QO!7//K/?7PE8*ZP(_3>HM@_)B%(]C,_J3^=-573-&C&T] M/Z2U+'U9I]J3G1E+*SZ\ISDPC8V0U?6U(E7:2&"$+_%R.5D7V_#W2`;-:"B3^5="9ZB;&#_%@U0VJ1Y:J3[024;CJ?BS?HY=^BHO( MKH*48"T'>YW^`K?01%V!)UC&X4U>V))*2\B]ISA-E?]Q?S!5M?@]?SY/P_%B MKFX2$WS$O90S=3Z_TZ,5I5T*,*G/2BE.H^JRQ':C5449)* M@ZKNM;IEF>Z,D1AO-%U#5\6CC#J0\`4LRJI-1E63P^0UX=^6KG"?=@PY15J' M,GI55-NNR12QA!C_3\"$>7BJ/JH12O/;A;(0Q/&HDYI4H1*JZ'%>F3RV#*6Y M]:=6=VA[O:X]S>_VN[8TZE50K.*!!.9M3>4LUH4P%-TE:=/7"%7)5 MJ1(>.>IES6"TCONBBO-A64CUVW-\]'`'\P-1$>9]I;O18COPO-WCTN,')!(N MP!LR$KDN(LJH2FRWU3L:4PO!`(`II<;5Y,%*PPPD^!LUJ^9BBBLK$Q<>>%(< M55L",*$&MU;DOC^H?,^\V:71OK*P%N4!TPD$A>:61B=W#5J^*'+&:!&8UT,V MFO2I%J1O5#6+PI-&);4H3S&%QI.,B]XBV"2WS`AP5F5U8-BJ6'*X"H9J,*#@ M?U$&8"F)@JSMO(@N)>+D!20IAW>535@+0)(94K M7^U[Y2DT.JFN*%%?J%815A?(D]90JX2HP6`E`7;H)6!Q6G"`80KLJ M\_I*XM8P)'U%M\WE3`$X*W`_&_WMY9(I6>J1NG0JJJK[<]D.RQ<0SM)!>UC1Y+G>;5&^94"@\FS+JS2) M$WQ"&(Z?@S5(L=1?/"_6!#;)%ZXK6$I,P MAV(1!9^OS_G-]B'7V-^>IH.!JMI9<%3:XELW3&1R4JG.JCOIIOH$R*;GT6'5 MW7,GT*+]3Q2N[PGZ7!FQ5#*C15Y41OY;;;14`N(-^JLCT64.K-`7#>/SK?5A MK4%QT^Z1"NY60KLUZ]34Z]O#[O"IN/+\^.F.[%&OOP-^MG38MNY`=ZX]N3/M#^EA=<D.Z3:=67S+$]:>A] M[99[YB)WL4=$%.S,"'Q\ZJUVUAO9G9%SB(?A6;"WU[%'`V\7)R='#AN%)6J[ MRE8[V:J+4U!=&:Y0D2E7;+O.MW;#>-KK9F6+.VP^HG$\.>!5HF@11UNPEX<1 MC"\%JU6LDESU>?$<*1I0".GN(;MQ`PSW$^0Q-G?WJ6]LGUJPQ0@;>,:*:U%C MM2[D)9?;F,T\@FE$!1_:[.GHX0[CE?3LVK;_KF!%YPPK.AP!N%2(GRM, M.G@5A!<=89VOS>PN]UGQ\,U@VW#L#;#C#LAL'-6V\_^'/;RD`]7_ZRS<6SX4+GW M4H^5V[>[O;J^QBTWH*5[>V64ZQ%;8ALV7?XU0P3KW]\EZ7408L)/,XX]J:F] M*LJY$X$Z&8WLT:BIJMX!(6\.98OVJ3_V=1&/Z/W MM]?1GJD54'JO5\"S]ZD0'P=O[&..O;WG/7K/[Y_-3[A1^[0<#F6G-WCG'_4> M'^%AA/?_ZS%\YL>PZ_7MWK"IF^?9676O([R.\#K"ZPC/X?4B(!M?ZK0?XNNE MA*'=SRQ[>L$,;&\XLIWNX+F83O4VZ\F-IR?9[>?TBGG&A]([&_9>UC:]S./H MCOIVIUVTC++OP)L]G(> M3R^E4NRW!']E&`O'D;+!N0II((5GL$HB5C/CA(U[6J39U!TK!'+!X159&M>/ M-+?4EM-KZD8M*_A@'^C'!43]M""$8')-*QIKW?.$J$]1))4$'?9U>EQ;KU#[ MA[/S!Y<^0,U0K8N#PFE3KY+GBHP>#'>#F_N$=4WISE;9E*?/'QX]W!\\VG:[ MGNUY>P+^'<1@^WSY['U#.V?.GB"Y1^P`I=OA%;KY6/\WS_GI"%ET`*?^&>W2 M_@R)'7"(71I'*,-[0F@[W:'=&[04\MF&DE>(]BX#$'5K+[VP,.C3I7"\)(P8 M*9EA6P"BXU(RKT"SHS)G-C);5NFX[:7G=>1V3^,QKOJP1S[BRW_9KZCT3^>G M5T34?H/R(V]H.Z-=0HP/<*>>_(I_(CA48_?D+L`7>X9*K*F7:31]O*0&2)^2 M>?"[M$[ZG'[!96<'B+E8:DJXW(O0*(A)NZ$;0LT3:[:`[P)W5W4-,OLT2F/& M[]P6EWM)+3?GNEM$\W`6!:JU$&;FY1N:-]?"!COX4?S[31I(ZR'KO='*WJSJ MR1W-C5Y6>4E0ZEK%N)-LC]B/?73I.23PQU9OBDB%S&4#B5%YY'4OM\UQ@0L. ML/">0%V,I-M*V@[;8C@N*3B"PI#6A_#Z@.@Z^>.U`./+ELS#J%V[21^VW?CS MDQA6\@5^A!D3)&QTC6F4S]-!A4G:X@[WR[#GQK"EE+?DQTYOQ MB=OIV6YW:+N>]V;/CQWUQCE]IU[`1^A1VX\;:H`]XQKTC3LD#AT+C[MG;17_ M.P3V;L.)0P6&=/>?\KBG++^.TS?C.?#SZF3KEI3_[T\0Q-(:_YL?WZ3!-#S" M\[8G9?2J\'?.XS.W:1;!(?#F)>G[_8=8]Z;O5T?IGYEQ?WF;!O$X2%^-^Y72 MX+UJ^AUK>N_5LC]L3;]_Z7\^FOY)+?FW.3SA7,$3CO"L[4<:AJ[WJNEWFQ]\ M-CC&,F6OJO[X10]4?:_DQ%G]OGQF1CZ"`*VW"%%.,UU2Y;B.X)Z$Q.YV7-OK M#H^00\?"8^>L]XR:O#S+.V#_S['G>P<\J?E/>'#K2M#1KWI_9>],_=5[Q^VWM]_;MJ3Z?V=!W`/Q?:'7]V'DR?0_2^I*D'O-1J\ZR/< MO#?P(3#G!=T>WC/V'#W+5\*W9.X?QJWPC)/1'>Q:W+>[@Y?I4GH=X3A'J%!K MC[0=:)9YKE+8+S[\\>T?;V\QK_I]C!6-J:#QYVOUQ4/N$3`ALC%Y_!I+,=\C MY59R33GH*L.;N!=F5AI,4"51JCG^/9O[26<`)3916CDGA`27^+;]3?XF-"_2TNB_TM:(UCK6A:LJM>]VV;?=.%SUO? MEXUJ-*G4J\'!9H6U.UCG*4EK:5.?IBJOSI.>Z3SI`["RG^,+?Z>`_'TIEAUP M!NZU/X-Y;@!RF2%_CFV=\&M5 M$E=*XJ!C8C$ZNVV5?-1:CJK&9A;0$:31`[IS=>50HQJJ-8G\+`NO0RXA&H7^ M&._G\!7OM_J&[MJ]CF-W=XIXJA`],X;2+/11")C\GJ1_PL:_]6?AW(\*49'S M[/.U$0D!V0GY#[]]O?B;-0TFX9T?9>A2_[G?[;I]H:,X8C$ZXV>W[^//>8RB M9A!FW=2G[K`[]'J*":49&D_O&M.[=58^ZC\VMXIPG6,@Q8\GP;LDO4@6X_GU M(CJ?3$`WS+,OP20([SE\L;P%[BG\_R.$N-Z@GT?3ZLW5'H5U=FH;"HG!5V"6 MQ?/SNP14[7^(QWAAQEG0AASU.YV.;.3*>3:GIJE8]7H-J?D29`'&1,[CZ45P M'T3)#$.";Y-LWLHI5U.T9JYM:&K*(\<;#IO0I"0/SRG&E>_]""MLG\_? M@IK$*Y&TYJ;2W>T:PKU^B@*3+L)H,0_O@[=45URNZ5HZ@#]KDO'^T[N__>SU M>OVN-U*,J1I_(P*6F;""`%3'W8'CU"!`\4N49GSS(<#D@B_`-!'R3\&\%?EU M71256O-M35QC079Z&Q.G5.:5_X#Z\O/\-DC?+M(4\0`;WB1#UQEYAJ)>/<.6 MQ-39N*'7[PX:$<-"%UP'\-OI5S_R4S!?+_TTIKX(O\4S/YQNRAJG-^H-NB,E MV>LGV9:@6G+=Z_<[;F\#@H"3Z8)Z2*1)%'W!Q@+X4XK&_N-"78=50X-5ZV9; MZD&!,0_N9W$5^6W>\6YO:!ZTZHDV)Z?Q)0]F?G-R6ND0\CZ^HDB2?BRTPMY! M08_MB-(G9$C3#1X.ND_`D,N[690\!(&D:U3/JKM,T009`G@C\^]H.7U*YG\$ ML+9)XD5Q$R?Q`HN_OCQB3!X`;X^#\"J.?X`S#Q?;NR#(:M#LCD;N`1!]E2;3 MQ60.EE4MJGL#SQT.FI/-QI+QUO]\?1&,YQ=A1G9O&ZJAZPT]SU-VVMVC#5;RA5QO1__V>[KDD79*J M%<]K9T`7CZ)O:=YVJ)*UUB4*'OQ>JS15G<&FG.J-7'>X8YH:\LEQNV`+;492 M3;/T$:FJN!4>$:AEGU5]TAIM8X4:Q1WZP^[PX83?PENPFS.D31.^+H* M8C\J7?`-5F]<3X]-L34]=9BR`3VYH\B'AV8Z%9M4I.B!AJF.X=9AT,@=NB/3 M&[5NDNU)JL.C4:_C=378&Q-0ZT&_ M`0';^IN,MI;2Z'*;N)0S[/<&W:[;GC]LB;XG84#MN)@S])`!W2-BP+LDO0[" M^0*6PSVEI5U>IIR0S5]_*YAS.L+_:X\UCU)>CU5,[?EB?IM08^7?$#]5K75Y;8H M4S6I/B!F5=XLSYI9CY[[VBRLZ\M:8_&W>-=MM:ZVF6PHB".2R)I4%ZQ_&G"\ MB7Y=5J_&B1"*2F3H!M*&=?L[..?GX`LHP M#\:)R*CJ$;/FO57?9>%VO3Q6^LA,VU)5^Q4X\H;.J-^,J+;V[%?R5RN;\]H.N>='O@_[6A)BKR;V/,Q`X_"6' M'[[=^K$Z/>HTE2[X^U<]K>T`5=N>XUEYJNP.5P='"?] M;&8P;QA?&XU&_>Y@F"]_W2PM4:300]F[,/9C+%A9`WLRZ`A:YRD(5>W<:]#9 M?4HZ=2_B.@A3[^GHS)MJZIZ:-2@>NMZ348RU>(W^;W7XV^VX7O>)3A99Z[IK M40UJ^ZXS'/:>B+FJPT8=:-P&IVN-?VY9K8\;!W96.>.ZFZC`GZ^Z?SC.1[>_ MWJ^X4[J/@6\EC0QL^_C*L"97P\]7@\>9ZNOJ9^OG#]&'P>O_-O@TD3> M>1\?"=Z]>-Y5WN`_7_7^Z'UT1J^\:V)/_'SE/AHLWC//VD&8\$/R?3Q)L63" M1<#_71?E=[9^EJW!??1:\I!NM\(C8_:ZI^4:7O=?>=V#_R(SEHT!]MRGB6'P:XF*EOK\!%O%_.4S-K__@BV^MWBSIBVOY=I M_;]*TPYV,>W*Z[=BW;T]$[#$@9WL=^5-N*_5KYA\/RNONI#VM?#JN3>3^=WE M*+@YWU=AX+DGC=3`H%6=SR_CZ>?K35/`UL,UE.7UR+3ET(N.%I_G;0H5L.A" M&I9\\><;\`_FPZYI%;06(S!U*6A"^;]TBXP&M)Y#>`T?0D52NY!)22M> M#3\Z.BI2,6QKTQ85XI692?#8M*Q#?M,E[97F-:S2M[J>_7GV(:]FWQHBTNGV MX-/%M\M&%"W7K9JE,!7;X_'4K-/42GVX7M\ME*=:.=N6A#6N"M=U1^Y&A%6_ M9=HI&SKPAH_AHC8GIWG94&_8JTN.5!R!UY@\RK+*%@';EO-:BPO<,]W5U8(?F6X=:5(C#D[D+T$<7(=P M0J/QX^T9-BT`8+3 M'QCV1YUIVR*U*,.6Z>54*KY%]H^XMM-W)1%@VZ_-US'H?*DCY.)=:OB M>9)N9#]5J.F^T^F[ZT@T)MR:NL:72-]SW&YKU%VE`59@5TI6RE^!6J!M`!,_ M:*=/QVG76WLNZM"QN]4TW@1W,#01Z;M:3ZFK`!J:7))KJR=#E8H=F$5A-R-D M=\MI;$ST!J/UV]/.>E2]<&D;T/*FG+K#@>.M6\7J^=NFO?$.]/MKY6D;RDLE MBUMAM=?IK1>8TJ2M4-EWK^T[:F6P&3V+3F?_'L1IN@?\^.;$#5.:S>KTW?- M5_>C<[9"9&-]X`XZHS:)A-T`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`-%VQI&'KGH5Y`933H-Z:A/:$8P8$PX[Z/[T%[8C`>7'@DO(V(6Z%7&UO/<+A*:.G5\RP%2GU_$)] M>(1N0HHA<=MSI-L=C+K]?J4\MT!"K;=X=S#TAFY#$N`YRORBL$)3-^=C]UC- MT3>\)8UXR%;^6<^#AYD1EBN/N\F\]0RD07_@/CYONFM;MU:`M\V MF'13(V6).=@B;SG*&IW1^?K!WRZL$[ MAR[PSXQ9U2>/,Y20G[=)-`W23-7IG40+S$SZAK&A1?JPE?"=.GVO/W1=E1!5 M<[K6:*S%16?4&;J]SH8T*LX7_KB5"G;<@>LXABY<'GJSR6O9$,TG-^Y6L+^6 M^=>:1^*QB=H@;",O1E/"5GH[+[,Y3`.'];9.@&GD4STT;B"9^`J&_?@^@^^`@4WF[\ MZG![Q<3NK8C8;DF8]?KM>_(D*Y&Y6UC`;1ILWG9HZR7@[-LOXEVRV+@#^M9K MP,E;6`)\]NF6`)]=\BK&W`6II,K[-ZVFV9M^ MK[KSMTGW>HC!:KI-I']3NCF=WOB23OO:`\.'?64--J&@:!$&403FV*]!'*1^ MA&DDTSL0P&R.T/#[0*2LLF)6+5>@.^IH:[#>5&V15RMRVG.V(D]D!'B>W,38 M?+$5\#:GI-SWU$P&;:!($T^S\!AY+&0R:@4::W!):]CZ( M$K:/F'GMY#8,7$U??GM^13$G-;%:.I9BNH5,_+#\<6 MI%2D\L"!_Y!D&=+U%N@,XP6U2@VDLS'H@HLP6N`X6.*@U3I#IYTSTT'2F)B= MK.91&5NWFDX+JZ$]+I7L4PT%V1V3$0%&.1,9IAU!Z[FNA]NR.1V[64GCB@"# MP:`WU*6]-EW)?_W]KW$:A?_`_X4?_S]02P,$%`````@`MH6O0K9Z,3RP#``` MNI4``!4`'`!D;'ET+3(P,3,P,S,Q7V-A;"YX;6Q55`D``_?SDU'W\Y-1=7@+ M``$$)0X```0Y`0``U5U;<^(X%G[?JOT/6N9A>ZJ6<$FZ>Y+I[!0!TDTM$U*! MGIE]ZE)LD;C:2+1EDK"_?H^,[1C;LF7`2,E#+D3G^#OGDXZ.;M:GWUX6+GHB M'G<8O6QT3MH-1*C%;(<^7#:^3IN]:7\T:B#N8VICEU%RV:"L\=N___XW!%^? M_M%LHFN'N/8%&C"K.:)S]BNZP0MR@3X32CSL,^]7]`=V5^(3]M?5W1C^W#SN M`IV>G%FHV510]@>A-O.^WHUB98^^O[QHM9Z?GT\H>\+/S/O.3RRFIF[*5IY% M8EV#\7]GWSKM'YV3ESG`'6`?/NRV.Z>M]OM6YVS6^7#1/K\X.U-4[F-_Q6/E M[9=V^+41_^0Z]/N%^':/.4'@?\HO7KASV4B8]'QZPKR'5K?=[K3^^GT\M1[) M`C<=*GBP2".2$EKRY#KGY^>MX+]1T4S)EWO/C9YQVHK@Q)KAOTY!^002[ESP M`-Z86=@/JE'I8Y"TA/BK&15KBH^:G6[S%)CA=B-R?N!!C[GDCLR1^`D5(WZJ MC1V.*7;7OF-!A5BT1($6D+1:$.KWJ#VDON.O!6/>(@`,1@0:'STROVS8(-D4 MY+=/-X_]24767R^A:7!GL73!*:T]D%YA5WAV^DB(S\N@Y1:N"*:2\L@=DT'F@#M0.#*'6LL!P'YYVRURH+Z2<217APV&%9W@K8@]?EH1R MPB?0#KTRB$4RAT-V1URHTS9$!W\]\S#EV%**AV5RAVRI$`XFRT`[]*E_8@\> M5][7E8@=#M^,>`N'"F=,L4MX[\$CFQA1AK!4\,`^O(4L]A'RI/A!2BZ42AT. M'01YXGG$OB-/A*Y(:8*57_QP>/J/F#Z0$;W&CA>DY9-Y6'W&#KYW7,CIRC!6 M4''`*+-@GN_\+XC\D_F`W/L#AP?!;4(A#,.XS7?N77+#?'*+U_C>+77U[AJ/ M%.[(\I];Y5DNQQU!25'S:VJ^G\/E3K'157-/-P3BJRVL&NMW.`A M8_A[2P)2)T)M8D=ZA.$'6.2`CX6>=KO=04T4221_Q=1&&W&T)5\K]/R%C!AK M%P#&<[7P^U5OW+OI#]'TRW`XFT8+0Q$VEUE;>%RQ,L52\W,AG&#Y:8[Y?;`& MM>+-!XR7+:@+W19Q?1Y](FI'M]GNA$M1/X4??^MQ#H#[*\]+3*2X^)ZXP6._ MB:7%5)F6/K1BBALJA_@Q_+&"B.2*\-/S^U!IUY"^!PU:8H6B;-JZ1#WI>19B MGDV\RT:GW8X>@SUKJWYDUP3#$BV^6FSJ8M.!BA#)SSVVD/HZ]"NK;$:2$'A^ M`ST3Y^'1!^1:"0Q'6OR.6`2PBPA$_)+:5RBB1E=7&UTJ!AO'T@CZ!PJZUX!5 MPLIV$3463K6QD&>0<5Z_]<@2.]&X'MIX,+)7"=!*DFHT1]&(*([#M$+PVR94*:.S\5HM3L-HZNPE8O:^M:4L7Q2C(_D#:)8Q(A<,+]K*[=4C1XMB56>2=*V;UHMBV9U M'%*21.45-&"D%,[.J(V1TH4U1RBY[_.&2/F6&E>AAHNER]:$A"M:RO5+04YS M`%.C2]E^XY@+%TZ5&2LHKSDN*S>L8GN-8RBU.%),CZRPYH&N&C?%EAI'3,*H MTH&EI*PYU4IA:"PM;TZ/FC/HE=>O6D?(DCF4,/STV4+,Z&Q<1.VPV[@BE,P= M^1!+3=:<#K.8C4JNJ)^9Y'D&,181"VV6NQ*'YF8>P7SEK8,B$G+4Q?7.IFY: M0`"E:&$HMZ3F=EZ5H=1$JLQRX_H5:!$+1DLIRA;3W/+WX4=F<_WM/O'DU.9H MN;_C@II3W@-Y/'=3N$$-HF?;CO`$=F^Q8X]H'R\='[L)"V0]IH*@YLQX'PK5 M_6(/Q0KN2 MO.T['Z=OD+N+B;O./.B;456VLJ!4H8F?6FD+Q_#WT7:GYK]W(=ZJ>EJX516] MVQ+_N>9MM24ON8A!GZ5`3V>]V?#WX0T`GERCR>WPKC<;36X`_M>;WM?!:#8< M_*QQUVUPY"*:FI.N=F=*ZW'IM+AV];)317_QRTLJIOHFDHA+-8:`26[LYR+BP,*(^\0@OZ7TS MI31/'E5B2F*B>=F<.#3'?9$4;&R*@$M)D177O.Q8D9UBHTV;V:OR:M5XMNS] M#K-E&B?^BEZ_&MOTH="FZ6S2_\^7R7@PO)O^$PV&UZ/^:+8U&7@\<[+O:8V- M^%AH1+\W_8*NQY,_39G&%$>9P1@8Q#XYX(^K]5;DBRC.].KS$PR".;::URN,"!+CUA.M)LRF0%)."J4T)WM M[<68@B^,XV_Z"!W*%>;;^V)E0W=)8=V9WUZL%7N@_E$5-'+(;`_/&M6MT"KSS!L@-7K7E'S46R*C M1N7Y6Z$RQQ]O@,7P;511^I#[5BIE>M64*4\9O!'BJ[CP#=2(U&LJQ"@[<[Z^ MNE!UC'*42NS?K?GNL6>0JT'G^':^#]:89ZUD_5HY'TJ_?DYBG(&?FVD8! M@UNGXU7]8MZ"?`:Z]+URJMP6*#!S.617DDL]91[;$@^$]R_L'JAR%1QRWC-R M_C7SQ+T#(\Y7))AZ#7::;GJ)R1Q^!A='R:>I=]!C9F0JH"ROTE;VVR'KKFRE M","($V23>>+$/9@[F:LPJ2QM9M!1Y*^BCTS;251\76^\1>47<=6&PRV7\95' MQ/G`6.Z(UVWD7N0;8SQ/8PR*H[A\O5M]E"[RC;!VVFFL"7GTJ@"]:J@5?>$= MOS'H3AIT*(8BN7^A4+)6L*57_L:`NVG`H2@*9-&V<,T[P8IO`8XAGV8JAI!$ MH6APR\VK<*V0RZ\%CD&?I4&_RJ)`&"6EZW>T_*[@&/+[?#]'DB@A6N_E1Y(! M=`ST0QIH)($RDPJU`*QR("`&_3$->J,%.10)/2A0A-@\JLLH9[](/8%N]XN$ M8^,R?6%2J3!*J$617@2?)30CH1IE%N2/WR?)^Z9,/UK2-Z%WT6]U[Z=5N(PX MLJ*;Z6$EG15ZM]%0_UY@E?N)8_B9OE;>#QS+@NHW%G]Y!JNCVJE=DQQ;DTD+BH+:D;A1O3LY-B+3_2L8@3IZS>AFSHVDQHLK=S;$IF5R@0J9VI(B]SUW.L9V9'*&ZG4?,?@YWK7/L M@$QFL?,H5NZ0<#I;?+N'1@V?_!]02P,$%`````@`MH6O0D_26QDT#0``]:H` M`!4`'`!D;'ET+3(P,3,P,S,Q7V1E9BYX;6Q55`D``_?SDU'W\Y-1=7@+``$$ M)0X```0Y`0``[5U9<]LX$G[?JOT/6,W#9JM6T>$CB6>\4[(E3U1K6RY)26:> M5#`)R2A3@(>@?,RO7X`B84HD0%#FY5KE(7'D[N;7W6`#:'1#O_SZO'3`(W(9 MIN2TT?G8;@!$+&ICLCAM?)LT>Y/SX;`!F`>)#1U*T&F#T,:O__G[WP#_\\L_ MFDUP@9%CGX`^M9I#,J<_@VNX1"?@-T20"SWJ_@R^0VBW"NN_0!`3B9@B9SYH13O)A(.8J/YZ$'$)^Z85-/IN8I&E\F8&404 M@WOB4>O^CCHV#_)]-,<6]K)@UK`7@_<$$P'QV0AUK+XHI[_&DWU.'C!:5[TH0Y M/ZS\&>X*V8/G!T088B/^'KII$'4\^2$;(X>/:9M'!^]EZD+"H&44#]/X\GQ3 M>3@8/?C2^9SZ`[K\<>ES70I;?OBFR%UB(HPQ@0YBO86+UC$B#6$J8\XVO.$+ MWCN^3I(/,C*ADBL_=#S((]=%]A@](K)"J0NL9/+\\)S?0;)`0W(!L>NOX$?S M8/A<8GB+';ZF2\.8042.469)70__Y4?^T;R/;KT^9GYP&Q$>AOD6S\.W#KJF M'KJ!+_#6237U[A)+BO.YQ/MRX_Y4F"D5<#IGX1'6#*@1QPZ;HV5M!)Q6U`6M);UY&X+O(*O8]#!ZZRXNXQ5K\:BQXX+48H!Y^3(W; M6>44'DL,C6W&71;:SMO@=LK&VWT;WF[9>(V'W(BCDB,?^1T7X5JK6]2T,1]=S$\:!@^*6E9* MP<1K<=)60--*%%`\;OFPIDV7$&<$'>A7B\KM)"GU#&)YG#E>#L/RI!]$S/_&!,L8LPE_^\&;KYS0L1&=HA< M",SAC)-_+.2TV^T.:(*0(_HC)#98LX,-_B*1)Q]C2JA=CD^>U/"?SWJ7O>OS M`9A\'0RFDQ*A)1^Y29P'6IS@PP;[OXK%G7*\*3$?;F&>3'O3P=7@FN,=78#1 MS6#M_YP.NA7@CS%]$<[J%&=0W0'HE*E8ZU*D^GH_+]?1Y?] MP7CR3]`?7`S/A],-)P6ZA-HXU-I0P1'E&M1-C(Q^1)M#=NN'M15K+B!\X"&R MTVTAQV/A)V+)U&VV.T%]QD_!QS.)FML-#?F/+Q<39P_*?QF0PMHJ)UZ MSSAU?"7SY.JZQ&6SUE6;3DARDT[5!*]5ZI\MK/U@&9[H%P5MKOZ([PBTSM": MFJ9"5_FDVW[?3IEU$A3(RR_AHOA-`>]-CO/54_GNH%K?<:A+2OREPE6P3TST M6XQNEKO+-G>K2>[0OQ8T!6T](]I6GH<%B9X49VAX"GB98:M^1L.*S6 M$]%M_EI'Y3YEFW#VJ0(_F&XB$\$J`U2U+KB#+F)#QE:OR9IMXT=(ZFSV;9C* M\)/O9.R[^PPR9(L7E"_=-_+)20,Y1EQGJZH!J^Q[E*]]A4=%AGDTCRR-+Z@K MVA%Z2W'BJ+!U.F.-[6X(7N6#X_)\L'[O=O#!FO&=^B`"7N6#3Y4&]FOD#8E% ME^B2,I5W-FAJ[(@X3I7-/T?.*%I;&O!'W)=T?A%OE9*G%I^TIQ;GO9*^CTH"_RP.03$3^>Z5B\3IG>0K[R`TL<%*0ORR#=$G!Y*^T.,KH_ZJ M$&JGO0TUP@]>!8!7"46"UW9>2;^LXLB?@@-BH$)PA8_=*#5^8B$:=W:DG,A]N87WF!SPRBW(6;6=V] M)1$?)5LYY`01UD++411=71+G\3;.D`-(EB+Q9>GHDI@_;6->2P&8`"%G?3\$ MH/-P'(.(K$(CW.Y]75*WV`P8%2IT$F)!*!?PSR*2@1`-I.S*IB+UE!2;/5.F M)/`A_*G@!8I!9UBH1#1[*,?;UTC6T"G[&LG\3N+"63IH MDR4+;0&+@KK6!9`:S'D'K10;3_EVU44V-C+Q)G&]:[8TF)7CN"`;#S@5X0\W M&\=;U/4NQM*!5IEYYX*L%#.?\U4^#Y/\;9+);2.#*_EF1^_!]'KX*B<<%>0$ MD0%>9X3%U*4O!=7RS#Z_!^.KH:L,_[D@PV\<#)G9/8EEUJEU?7HZ=.7\F7>! MNH2"W$=LF9I\@WC6>1?!/0FTTLP5E]N.1?I=L].-_+ZNN]J8"G6KI_4!ZHO\ MHQ05[%;C)MRV[R;\VNU',YFXMGM/4S?4N0/OBEMQN5IJ?;%!4TF#5]*8ICJ` MROA=;6BY@L_IUH[25-+3E6;M&$!EE*G6VN$$WR/V&"_N/#9:>?X7PO#-1,I" M)HEEUJEO>6TZ;I6/JI'_Y2.H\0BHS1TD9/Q]\K,LE MKM]9NGXWR,74'A)+M.*A/EK_NZ7UX)DOB#%#-R[?.W1T8[`R4+4?CA5;)N_M MAV)D#IX?\/J&IS\05,WZFT1U]EP24N7BMLI>CFS7[X9U%@?QLGZ#.HNRRG>R M7\DK]8H5)FJ*O"NJ2S*_JE=J%:M05!6")ZI4@S*&V+NVKXW9U\;L?%-%.Y@43+R'.Q/C4)7S3-YW)+Y>V:*]H29&-SNN;?8L&6M)AS.QA_O]FZ96 M]8G?DVE?`9=T!B&3S'Y&6IGIC1+5V)X)0$O*F*^7M@*@+,"-IN^U"W& MZ1+9XNNG!OYWKFDWQLG$U91!&J5A-8"5+TC.VXY+OD8D#%V@E"Z-&%TES7=F M9DW&JK)HWCUW-RZU5Y;GET5H31HGK*2KSLRF"K`JH^[<0Y=/'-_:7=I;#6^(]<(ND&JJ/Q]8)9O?I:[P=@%5ADN%Y,W#=5@D[7?'.XWA_O^ M/DU75-UV;OO^OEJ9N+Z[KGU_7TTZSLS[^ZH-+?]O_7U%G9]I3GDV3T:JV,!F M/#V3.`U6[GD8\0JZ]\@++OKU3T-[WH#8H[GV5#*%J\:&-D%>SX6(O)"YQ]AJ MN>XO$;?=6GPKW\>/V.8;L3$W@<)EINPU]ETF%911J+9._$X=OBT6.]8=W;@I MX)TZ,D$)Y6*I=JX<8W9_X2(TY.M&%S$OHR.3V-^9&Y4J*).QN;=/^L/H$L\Y M!M%SJ-H<)U#6V-8JM,IT;`']TNP;X;*=%]'4'52>1!IKSQW(&)YC9/=8F'O# MRBJ\W076V$EO5$KER^/JDK4&WP:17L@3NZP_>^JVO&\AR/RU,>GZQZ[XW_EK M9-3V"`:&^$O[O%[C_`^^^!;H+)#/)S.S';-NWOSKY"./:3((R7?_GJX\/IZ.%R,OD*9;D7!UZ4Q/@O7\7)5W_]W__[ M?Q#YWY__W^DIN@YQ%/R(KA+_=!(ODC^A.V^%?T0W.,:IER?IG]#/7K2A/TG^ M?G%_2_[)/_OOJG8].3PT*^QG'09)^O)]4A3WE^?K'UZ\_??KT*DZ>O4]) M^GOVRD_,BGM(-JF/J[*N;O\Q_^W\[-_GKSXO"-PK+R<_?'-V_O;UV;>OS]_- MS[_[\>S]C^_>&1:>>_DFJPH_^WQ6_(^K_SD*X]]_I/]Y]#*,2/O'V8^?L_`O M7]6J].GMJR1=OGYS=G;^^N\?;A_\)[SR3L.8]H./ORJU:"DBO?/W[]^_9K\M M13N2GQ_3J/S&V];>)[.:.1]C-(*D'_=5J*G=(? MG9Z_.7U+>B8+OBH;G[5@FD3X'B\0J^:/^TKQ0@PF2M/7 M5/]UC)>DLP/ZH??T0^??T0_]3_'C6^\11U\A*DFH)ZW7^T99A=)KVV!G.`V3 M8!P/0]W6=@2?C)TTWZ$"=7WK59@GN1<-`E_7M`[[#@]K\:V>_98F,P@>UM(U MS2;LB/[PEORM`1Q_SLG4@X,2.BU+8>#8IYC=+G]">G9^>%=?R?XL>_77II^D+F[WN\3E)2 MY=$JV<3YM1>F;$:Z"C,_2K)-BC_@U2.N(+#Z_^6KP:6\;M>8EC=*RVI[J:]I MNT+BM9^0B66=GT:\E[CZ(DU6.X`KFCX97,1OT6.%A?<@@2NI=$,LQ1ES-GH1 MJ%[SW?JEP+V*2#G4I'K_Z7&1SD%V5Q5P7]RE7^^>?7VP^[HW%5I8N7 M"R^BSL;#$\;Y39ILU@3SMJ*3'*]X*V2CSV$F:;?AQ=DD]JZ5KC-\:%E@J+YC M!=J<'U(<^I46"&U$3.+U)L]N\3..SI5&7*GAA-=RZ$+J=L7AL5.*443`PM1R M'<24T#E0+.93_^F%03:SLTIE1U;5H$(2&ZK0A,=)$[@*^RA1!F\- MW_2VAF^@6,,W_:SAFR.PAF\&6<,W4*UAK69O>_/L+12>O>W'L[='P+.W@WCV M=F\\"Z*7G++G[=G;@CML0_D7LKKRB`\Y)VA2'(1"SB@E;7#%`"KEB$+,.3?T MV-J<*(51*0W,YM`C!+S"<3[^]R;,7RZ3U3J)L7J!J]&Q:7>,X-)*#X/CWLR8&A?0)J6G(;%N/6:1Y[/I<+0D_RE_JJ>'6L\Z5TRJ MT2&.2@D6BPR02BE5Z2*FC*I?6&+8F$C%Y#L&-JVBJC2M$4G MZD"1[Q^+_/2!L\>1DV M8(U8WCII5+`[G!$)PZ*,`J&4,4P'54K6"(/3Y]`WHDI+TCY)A%"[]&B(`2.& M")N<$H4TL&WC#V$%42\;FMK`07GT;N"'@G!\J5&UF%#+`^'!/(&+% MD4'M]S9YT(%5YT#U2S#]WT;4[GOV>U"A$1^\SWH[T)2Q:@=$\!IVH"X`A@(6V.BA9(*X%;'*I3C9O<+),O?53Z'NJP$"%O).S:1ELX;ET M6]@YR4P1MME5%SOL^?/,R_SDDD91OUQ'21H&GMPPR66M62,=W,H$R02=4\($ M79L.3!QQ>50H''KRN@B3%0XH`<=Q'N:*^4HF:8T4:J@5)<1B,`BAQ-:FPU88 M828-;,ZYQQ&[ZTGFQI'@5871+UKEACS62L[9R3 M@R%W5EU<##&YP\YDDSC'483]?.-%LS19XU1EM%32U@R7'G)EO.2BSLEBAJ_- MC+H"6A<:P`S9`_8W*0ZN\*/X+%(A9]59EL%L.,EM(>>\T2'K!&ER.40%@1'E MDD8GY]>>'T:AW^KIQ5LLA@-KC2%H)#%0FR#E.8'#]`A,(/>O"=AX\1I@?AVIXA8J%`[D_UYZZS#WHGC\V<=9-ET0EYO=IY+[P#H- M:WZP&?3*%U:+.^>+.<8.6[@2"F/$]>BV,M'D%^-@V*9[G'MAC(.QE\9AO!0' M/NB$[2[:58";"W21I',^&<%K4VGD^YO5AB^^K_`B],,7&!*836:TA`!10XQ,PHU"&#%I1,1=L*.T8W-2K*!:S5_; MXH((5$F!^N]`]+P`D'2RH#(N>[E*DD]?B%#4I25GN]^%,-L$:`B!8H((F902 M7)BX$`%[ML,%.T8$2$#!7$?>4E"OUN]ML4$(JV1!XY<@>E^$J+/U7,H@*N2B MKR\W:4HQAIGO1?_`7BHW!G)16PS0@2W)(),#P0L-N,Y!%Q='7!Y1!:?&@3LK MO^`H^EN?H[546E+N+*?W5'JI^3:!/G7OIR'48X;<>%*>3LDD@"LTF>EA`@THB1J$$)N4:8@`8HH(EV3G@XFB4M:A>=F&03X\ M>:1)IINU![^RT2,]4_)ST5FF1-#>C6,5T.V% M8Y&4QI%`?T#_KB MQ[,78?K60UX^W,IN7$CJ;JAK]ZG='M5I/K!KH`B&=7W0=B_79$^(+(^03_^" MM^HP"#GR??:6Z3WV,4%&+YGAO!A?LC&H5+%JU`S`-VR;0AX,V0Q`"F[=\`=I MTTKG!,4X1U^'L1]MZ-*<_(K?REFSE!A;07;9ZP]OWY^?O'WW+2/J'\Z0EZ,/ MI/I/Z.WY":(.,_O%%5&B`9OE3]^G=!M>.\RY_#X:1`E"B&&\F`H,#LQ2OO3`8?U[36R?$=$_S)YPVG`=) M78TT;3*F1U7J1#)0`\,O#8I:H1P*<\<,1@LJYG5.]*M1EL7&AV;/#."7R>:4@$,TTQ0 MMJDVG?\TOB\V-GZ$0:XKO$ZRD*R*6S61U%HN;I-2.M!U-LEDP1!)`[!SS%*( MPZ#/=1B'.;XE"\E@$N<$)\UW4]1$.@?JE*P^IVY4@<:+ZDH-,+0R@ME-'9S3 M/2Z^"Y$LD%?+"^*M:/#2?]A=/K;Y`_G'VY/OWW\W;`OB0`>$ MS'&LV6G1T597QMJQH`Q>=2+8%H#ANJN@B5UW)H=&@!QW(1_:O[2_AI,OWF!T MO1!3I\^G\]$MJ-.;V]![I&D=0YR1)0$+@WI*H@"G&7^^7>-+FZO;9$S?2M4Y M9:H+9C+K";B3QF8RNIC<3N:3\0,:W5VAA_GT\F\_36^OQO+)_QL$0:EKO`"$_#!/7[& M\48S%\N$[6ZVJ@`WMUI%DF!HI(0GNW/.;NSQ#:^@T">VBA4`@T_&MLFU43*S M1H[-D';KP]@(\:VODD8U-7"T,3Y4U.@X(I/9H:)2`8R),D'9V=R8WMV$%7A2^FVC#V%#1VN9[KXI4._)&6E;9](S3QR3# MTHWZ/HB/W%EOS>\&9]E2>8?^E>XT6R(,QH3I$';/LYM>577VZ#<],!@<$QKH M/L8 MS=+"F+)*J2ZE"24MQ\?+H+;BX=MB8)@CQR:(=R\FN8R*_@G]X>S5V3G=RT?/ M5.U/Z/SLY.R,_1]E/#^'M\F?DC3\#P[^A*H?AC0_6<##Y0^3OV,OSQ0JKT-V MQ!P]4BB_Y-B2`4,X"3#)*W(93_?2H=J;,R77OOWVY/OOOC\Y>_\]HQGYYYOO MWYW\O3_YX8=WY3_/SK\_^>[L72E;(ZF5B*]:"Q4G;J(UD4C* MWNMU4HC;%^LZ(LXIJ,:E8F!Y5@G#2(V"(*2K"2^:>6$PB8LW]&HUDYU!&"A: M/>(QKDCCK$>KY9QIO:$JGD7$U;.(E?V#0*Y_\Z:&"]96(W",$D12I_JY.Z8 MER,_R?(3].;;[T_>G+\M7'48+.J.!^-=&]?;8&;;7S!LCQ:?>#^U+OY'6.\$ MZP+$]7O*$C5((?V:C7NA#BS"&:(57RFQ$L5ODFMRYM&CAR>>E&BY MR4*IK((X):50Q;F?W@^G.EDE:JBJF'1`([#GZ_)OH$0C](/;N3G/KA#RW!_` M+E400W:7Y+B9^$NVJ:'6<7'%0@E?=--"J.#<#O1!:9J'#0;/%!>Y:WL,H]KM M;$G3#"D(R%5\344-K^=+2@'#W<'0AU[C=S3%[>VJ(+C)S0"K+-`\VJH"F^"* MLYXB9I#X2$;W8`Q4'=XH5%9&<;]0J`?&@/0`N_O=0T?&8V\!2.",AP'63BQ2 M8T>F.&8`8CZ:X3&$A-.4/GN%`[99.<,I>XC&*+9&KNPN9$E7(7D4DTP3C!GI M!5<3ZP3MY+59-_X6TJ@*?S%JD*Z2.Q;**B!G7UL#*.LD,'5LZP0TP64=>VNT M#^-*!==L:P+7,8U+@V99`Z(APW@4'%QVR9_M,]9RS3/)PWV&*J`9IW^Z3T([ MR%&_/5T\(TU'L<%]G#L#-3!<-,>J">D$Y=-U7L;4.G1*#4><,W'E%.(0.6;H MQ#6X!=2#Z]1*Z;Y)I9UR2^ZX243A62-(D-=,T@)"26=QF4VHTL!,+@:&17)LFIC,_81@2L/#B8]'G[3( MIHOI&J?LY$_Y7JY.PV(HN`GT6@"X2MPY3U%%#+)Y+:4IXYPQ&F!MFMR/?Q[??1P#.?]Y\"(:?L.0WR1)H'@00BQJ M-9Y;`;9QGBB0`T,3!;B.1?$T)[@V0[=]EJ6Q`"Z-K&A)V0W,%D)L1JDT1*"= M+8OA=5*)<2FTP%#(4:>TF?UP:CH,K(9M@Z&_!"($)PS!A\&)RR3+IPMFX.@E M`IP^$]IF#TDDWXV1*]A=.NN`-Q?.,FDP$XX68F?1/'V8H^DUNIE.KQ[0P_3V M"@:E;M(DRV9ILI!>O&Y(V"2-`%J=);5?PS(K76!M,MS<3Q\>T(?1_M-4M:13R5E]8U,%N7!>1"8.Q*CJ$G;LAL_']:#ZYNT'CO\_&=P]C M(,\.W>,,DR9\(J;QBDRO4<(>%BTJ)5WI*77LKI@-X#>7SPH%,.PR0=E96!K1[)5IXF,<\) M<$3*7-[@F`S!B#31*%B%<4B''X6IYJZILE7GO%>%&CZ[D2886O>"V]D-X,HG M:,G5&4V]1@$5U6$0M3-'F,XECF=FHQD9EB,G@R>^I`UU,JYJ,8G]9(5OB7.J MJV]=T@EINE"%M-F*@;%&G)W.?TP_N90:2F?R*?Q)+[VPI0%VTT7 MOW@I]0_+"X/M!"7F:O825YI78IO)4J_CG$D]@7:VM)@FS3:X(+H\+)(Z^Y^X M>G6O\U`I3^O7@:>+JS!C]_BF\642DZ5(3J\0TXOPBG2H?4NP]T;'H*IM'^OH MI0Z#AX,P=^YRMEYJ#XIB$/FGORT(Q:0D6.E9)W&.27MJ-DDZ4C;G4PG$^NS9 M$H&6.4X,KTVB4JI<^$$AR#/!1/=7^&1?HI16529NES)JT$WNB&6=FR=#@%(: MA4P:!HND3F-?)Q.(*]_+A8>UNZ"#*=EE.(CWOB=RX5R[Q]"2L4HB$;P&<>H" M8,R."%6;&W?C.:+["3!XL(5[33J`.'"$XAO"\FWXY@RG5V&T(=.UZI[<@'+L M3FX#J]F<]7H6`H:70Y'+N(MFQ+`1:_9A>H<>?AK=CT_0Q>AAINXOXPG-S\14J+1S^/[TQ8J5_8N`0<[!N/<780+#V:W&V%RPRRP3LINP7P2P MF2JN+N&<7TI84A.'?F5B_P3&BMLPQA/R5]EZ6"3HA!T=H$*&5%+P6-*&IF`* M%45,5DD7&\W.TQW21\J3F$[4H\^AN@=$"A`S.IK`;7<1%T9;:?0KE7?720.? M.K';'<2M"Y.`M'B:J[M$BK/S.`!>AC%]]`L5SP2X^?,/?"RW!`+0-Q"D6YWI62=I]PDT)M/MC6$7,^ MI^JQ"=/PHDA8HM> M!09SC'%VCDH+1;K*\^O9919)BGRBO:_Y9P"MA+ECC+5`T*J;4\90!3ZME+EF M#&BEG[?@'$B"<_+%\#KG.SA'$1$X-B?^K0/O;!PKXY<4*#M+*7:`T<=_A^(3 MNU@\Z=I=A$_7X@=VB;=G`]0.7D?))^/,5@(%)R,/LM4W6P9T8N;_"5+S7V0`059#@@:6-'6 M)-VS%.?$W1EZYRK`Z.$G='T[_:5YH^GN!HTNYY.?VR-NZ,O-D/_P_S*>LOAUUP,9JO#5U@.^`&64'K%SG_L/V4RA/Z*N. M_&/L")4ZX?2G].]T]<-.7-E?,/$EG[V(J7V](=_^AM[>9UC0XPNJPE215P$! M,IJO\)I4,F1[3O3JM_XM2*6&S;%E`+T^1!3B8)BNQ]@F;%V#W[TW?*31\FF# M;O=9)VS]!$*Y!ZV6!$,G)3S3G>A]W>*1;1W&/JDVOL+LC]X777NIV]M,[%^I M[:ZBN2Z4_:R!N('?ARU>T;E-O)AFJQ-N86M57-UXE8&777%MRSNW83U`:B^Q MEN\A1421V#:B:?5&-9G)+W#,7MCT(GX=-R,"U]C+-RF>QNRU\=ZWK/N5ZOCF M]9`FT-S&[E,D*$.YM^I\29>W??JL`9\\/#I[;)=N_!%S]49!#WW+%YSZ5:MU ML]>WV,?D]6_/'C93-4M,>65 M47.RJP>8CE*PTB?-TTH2*@NG^1-.MQ62A4F;*#HVC9**:&QB2PLP^R10.^FE MJ%B->$`.M;KUH>D<8O*UL`?I&CIN^2:`KZ9:30&*/]D';#>]!I<`DC^V6X59 MBM=>&)2KOC(Y6QRP$<(]"N/V,"O,+2/[5%A-59.2`%O*'O`%CQ]3U>KR&]L3 M3YA)]9@>5+97KG*Y2Z8_'NU;")"ECZ*"ANL?00F`V6P`NVN;B^7/U^5"Z)MC M6`D5VQ/TY,KWTPT.:C7N[:2K"X.Q6C*IL-GZ25428&[W@"]=8Q4[4?STDFL# M2QG>K?=XM8Z2%XSO<<1RY@W@N:H(M^S65T[-:;D^?+]9BUU`8\;8QI$II7+* M2T"/;%<7KN-1>EGJ1_0,]-R25E(--5-;2H`-K1AI-QJD..E*N1@,SIE'2>X< M9@DU_G6WN%=@>1?[XA9=:&%AB(!F`9#;(7V:D$C0^@M[88ZFM3)M%48!3 M4FHKIF2G5!L\377(.YNY!-03Y6NRH$X"TV5K*UPJPF"N^82Q\XP#U178S04X M"@=7CEOJX%+_EGJU8:EZ+%[M=1A[L;\'KU99$``J&U34@-**4J![M7KH.J_V M>G(WNKOE66$)7+3.-5=VFQ9%7 M1IT;IZOGW#H.`&N:):?*N[M?UMF>]W>>3J#.\[O-[T?ALLIQ2UW6^F;LHE0' MY[:RC&AQ0/\8;^]>SU@NFO;AB:3)^A5AD\)#*EM,V` MITI::*)E;2O!O`K5+H)>Q3EA^N'LN*Q4D>:4JE315A>&;9FF2R\N;I5?)G&6 M1&%0)BB:T50?Q+;RJ^R"ZM/;[5&2;5(\QY_S"P+S=\F`V_]G;-JX0S52W4[N M^QO.A\Z!*R8::^@6G^,D^] M.*.'%L2=,)])>Y5@T\8-J%K=T/50=T[2X9B%K/V6L+8H"K&R4+VP0[ZW-5VS M3Q`?MDA_*)U=#77LOL%E`+_Y&I="P3FI^J`4TN@[.G.R!*E%`6P#NRSB0#2: MXW1%%CR$N@]>A+/1,L5\S:,DDHF6-2J95Z$BDUX%!IV,<0H)]3TAU+8$Q(I` MVS(.:9C*J.KJ:WJ[I%*Q:Y;TX)M622X/@T5F((44^N%589*J,/E*'X9#UKJS M:NZ'F2C:S31O6I%FPGF=EG,*]H8J).)[8LNJF\?W^[EY+#%@/$6T,KFTTIKU MT[=FVH94J[)S?92=,VXH8O%F[AEAWC9K."T._5QF#2]*1+>6LX8_YF5*WVE\ MN:%/".:64L-ID^ED2(T7O8!?439ZHL4TV;&42YN-UQ5#;H9NBJ6A<8N#4[@J<&E M:4/,:&6N;C4I3,]*-5+"&.J"\?9Z`NXF]8:;^^4F28)/81216K6S,+7_K9R! M!Y1CDZZ#JUGG;>]"P!!X*/*N92V%8:6C7ZV],*6#:IJ2]?XZR;QHNKA-:,[R M9QS4*Z:=Q`<5976"WZ&RCXCY#>5R$9G@3(_FC> M+A$LW<55'TS[9G''27]A';HGG_$I;@R%4ZA#X1YGF+3[$\M,]HRCA*U*B]!X M)>6--.TZ&<95:;H96C4P5#7'VG4UN";;?0BVNLTWQI8LV&2=)C[&`1`7^"9Y MQFE,L5XF,3N53=)B%C+SA?L48'0!+*@B&6!J#@/0,BCG+O,Y38D+&7TIQD-&\=\XW- MF*35LDDHPRK4>:51`4,O,YR=E7FAA;Z.DBS[AF8G0QE5AT&Y*YR&SQY=967W M>$VC1>,EC4(M?UJD_I3-HN;J=F]<]*M4\]Z%F2X86O8$W'WTK10L$[9"G%SO M\*=:T&B:Q.2O/J[Y"V:FLG\Q=I,/#ZMD,P5QOS+`T'@@\.YRFVX:T9=@R^#@ M=:.L@P>V"S,DT*`JPVAV$WT'(>SFU1+$K>N5G=-P*&+9@ZZE)D]Q@;@N#%OZ MX#_A8!.1Y5?WM>6YZH;1D`*L;K'WKEAC1]U8VSE9!T.6L;6Q%YDPQN[K#6W] M32!)8H4>-M.P"!E?9(F6[R+"?VFOJX_-0_*9/+%,4`&2K" M:H_HH%XRG_SB92M2/+PT^N2E0=$H/^,LQP$-^R4SDD_^.D_HC\:?<>J'&6LI MHX%E'8;[Z(+#-[(^).%P&.`,<3<5%P0_H&=6%-]@+$(?UOR#T*S"UBQ2V_64 M1`%.,QK9G[_0B^CEK#]-[\/EDSQIU1[*GDYDTTLE,!>ED]K2:Z4U4]0Y/ M7V4`Q%3L[/33A$Y$LQV=;3ZC!27@-V`X`E+B_REA.WYH,7 M>\MB*Y^%$]&Q+6#,88FC5Z&_^&L90%F+JN.%<"/EW7R[VS MMY$YBJ+DDT=8=)VD5\GF,5]LHFX&)HEA-U6VN479KT+UJ=1,TSF'!\'M^*^E M,GN^,RC4R[@S(*?4TL0Y9>K$X&.&"6R:M$&6G[)G&2"2(*FJ9Y0)250`&-X. M06V6$ZG*E1F@#2L"1>$"B)V]#N,PQRR]2"MG3EG;AG5HS*-BUX& M>F!XV@-LAYZ$@S3DYR!\E/BY_)OUC-E%#*?(!5((6_--M8`KKU,JZ9PK1O#$ M[$!>/;EY$:X(W59E@EK>X<_Y_!..GO&'),Z?9!/QKH7"L&]]&L#,\IF4Z)SG M>ZU&YU+L)B=K,>%X0"_82U$2'^7`^`?!/O^4[*4IJ[+@#H-6=8>SORCH2$G? M1-^;Z_FGY&BY3C[?WX?5E`:<[_4J[\AX6M0Q<[Z&OS_KJ?*Q\OZ:M/S>FI$7 M!IOU]0KO1GI:TA%SO@:_-^471/=H&4]D]]>(K##@C*]5>$?&$]EC9OP6?G_& M@SGT&,=YF+_\$@:XR*3ZP?M7DEYNLCQ9X72&4WH)VUO*.&ZN;C5U2<]*-7*8 M&.J"86Y/P)TMF$H`I7A-P-%_,,:&,?G)(1_QK",O#VDR,_X-T+>VFS>D6M4& M7Q]EYQ0:%GO.E&'=6V`ZV:**E72Y*+GN99+DPI$XI;I$&6M`U0DAE85@&/4#CM+X^53H0 M46ZH`9H528)'2X^FZ5)F)A;R9T@IUF@UO(H5V_H7`8.$@W%WKD4TDDDCCQ>% M4ETF:AAKR];CFJ/\DDR\+V3>9M>A),L9G9+M)U'U%6B_A2K7<,[.7C"%<H'( M\I0$;M+O%9'#P_/O=0H`DH!/4C'##'PM;2@,ZP_9,`=?H7P@"HK@BBHHEK-& M*!7,BCBAEBFC--6&XS`\T#YB7!F3Q$&S\O-RI&O&-*HDWIU.R MFA;'J`+-:YLJ#>>TZP53QKM/Y8[C7O84]K0Z*QZ0(>BGCU&X9(-"MEX0RUI= MBZG@-I9@(D$P-%*AZRRXMK(HJ80=W<'NYJ6]W*0I60>*^D`J;"OS@=[[,(>J M; MFZ?H8.6@>D%0[^,6%^?CY2WV,OHD1K5=>H?;'#?4L3EA&<&O&TVE@G-6]D'9 MY=YV;[H\A?L/#F#0K+PH//->:)`!6X&VIK;NE"'7L'K!6P^]-2O+Q,'02X]1 M,!TS#9H>E:JP:]Q4_E#S,EY@@B=X\"(O)>X"39G$*#SDUZK8FV'- MP&^G4;6\<]KT`-E]+HEKH:Q00YCIL4.U#=,\[-82H3BI5U2;WT/Q28=:WO:6 MDA)V>SM)*`R#-08(99[_FNNX>E"CURF(:1EPGM0P/PLQ*P`&W0:B[O&JQIY. M1?845UZ\W?Z`T^?0QY+$ZLMERG*F;1M'QNH]EFLU$GU?S=`(4=^U4.8GLZ0-M,^W\;H?,3J8"2+]S`)'G+BYJ@V10]5R>X.=RVBI#XZOXQQ=YVD M"QSFS&"Q-T'"(L'C))ZQCCA0\QM\]YC&I7$S[G.<:C\*9A*U55/UX%WP4G#P M&M,2U+M[@,GF:!*P>R[&IX%QK,Y5?+!*JAY`\W+T@<4VOST_071Q#'DJX'&3 MHTW^E*1T1_MC'."TMKYCJ?"+UY_P+"4N[CUM/-XGK:I%Z_(M3J%/AE[V0-:KZ7B;#+]5!KJT!'$R$ MQE\_IBFO9Y/NTRH8?OK+LPG]*K[+S+5=,N_7',B2(='O/@[9(>AN$-0,9]%L MK;:ZQRLOC/E#DN55ASE.5Z(`"B#`["5R@E'?5O`-"%20UMO@6D5K:])2'_FU M"T8Y*0%]'<8L067VC=@I.4$7>+GDRA=>1%]-LNQ)PVENH$,#D/\-L%4..SC& MW',W&!E`)NCNSCV0"7H'8$_<$0>Q0H-1?<$V:-F4_^.D_HCVK&OXH(G9`&"N,L]%49Q1SB.:9=A)V;?9_["H/!0%H: M0&F,SC664AJ%I3AZIO)0G7[G#0F+XH!L1'H/GZ4]/]#E33FC.99B/)5AT.(0?C,5F_PT M`5^GH4H>TG*[!UX!OPIZ%?>!3Q!7I!-YH?IEK`C8BP)5T-U-FF3][ISL^*5C M\N(53;5/_USP&>4A.V;W]>VM^8?#`,!Q?7+72 MR)IKJ@?%X'PH.JZX].9I.9]LQ_MMN`"WN=2M/WFWUN\PFYP`%D#UVV@-0RE%F)J!S(,VYR0_\!>^X4:H82U@2.& M5A&Y^6L8Q!)BZN;C+H40E7)\/:GG.]:]"P-W7:G/*]8]2X)!PEWA#[C&!.P- MZTXZ$?8&LBJB5"!L/=17"K@3Q-N1=$X\(WAB8OFU*;A\KAH(C?82ZUANQAXZ MQD+ZM:,XB#!KLOW?T.Y\"LY0.FC]VF-QGN1>A!9T0[-]EYIOC,(8DD9/5U:; MN:PY,E:U^N\ODRR_2_)_X/P>^\DRIFFH))UPP.^!>Q!UEV;K_5#JD(^!&9J' MKF%[<'Z,TTJDNFC+GU(M[N2*)E'^!BOY99Z@N':5M_X"Z^%6E45P_P7>UJ[P M!HI'O^?)]KIRS4^5+*N&%V=SO;IKI>N+VZ%E.1\E>ZJ`8-G,2J1T?J3DWHX( MYWRG&[YA3#_^X$4X&RU3S*;H7HOL`858X_;@"E:,[ET"#!X/A=WQKZIR$"L( M;4O:_RI:GD*!_'H3!S0KSA5>)UE(YQY,OMCV?PSD;29/T,*N7[&2"L-@E`%" M073"5@4%7(=:0*94-X5>1O[UC..#12GSYV>9N>9W;D55%`A98XL48$61C@0, M7LA@R1X`9M,:7Z+9ZFO1]H52TEVO=[8-%&)`^U^U7!>0X(0OW`_FT1='6*(7 MU(42%OUN$;2:*UW_-8R^%F*2O-N*$0^O.U#'3M@JE3HBY:Z^ZD4H,Q5K76\( MON*"1AX&.S67>$%3E,YV'=3:TM43Z.@^E"[F%H5:SUOB'XB@\:>>?FH`?(-EFX5NW0B+FD7DX#Z.F_ M]^.\[&<^J@[!1EFV6?$=P7);\2I\#@."^=[+92>TYNHVYZ>^E:K/4Z:ZS@DZ M$+!T#SDH9%%*A.&3\^QZ#BH)! MRIWQ=Z)->33;IBH1?2K#F&LO$B&_*I0>ID7;8@]UR/)$X_DF<663IXNBJF65 M7OH$$>Q4G+WCFMTKO3W3&5X6#*;O7H'.Z1`K$4WBV@UU-%V4?@?%LDX75SA MQYS>9TDV<3Z-+VE()?GM8X3ODAS/O!<>0V%N'O=9NC4>[K])*MKNKV@8+-][ M?3J/C]4^0$TJ_00JOX&F,:I]!='/H.([UDRMO`GZ-1@(@O<@+'0"FA"*V-F` M$BHH=%PD-6_7@!\0WB8>BUCO+C0T\K\%B6^M6\BW6(H@!L:D>\1@]7W$]5!$ M%)%/-0'T5,&941QJ7<`Z`=[;*?#=:60Q;4L'K4'+!DH1S&K9N/O18[$$),0/6'"%JG MY3=9GJS0.&)W(%ZY:%^6M*7(V9+U'",]=&'U37_@[9[K48*+7MUW:`ZHWC,# M"W"L[?NE)%"]8@868*\460-H6G.Z4F7/ZK%U$'&0R[71=$'^9.GM1(N_WB7` MZKFA\-M]V;L<%[U]3\PUD7UBF)YQE*PIYN)*;G:'\^GB)B&>:TQ_S++<=KJ[ M?Q&P^GLP?H"#]P%'Y$?+&[+63+V(U&@4K,(XI+N7='>QJ)0@`:"9'JR.ZP<: M8F]!>I-"'"P`!1TPY@%LFB^)WU]DEM,O@\'[;`NHE/TO3,@-CYQ.&N!H&,D# MUT:;_"E)Z94[%A/72;18&W/WM.V*G]"-YZ*I#-O'D*.641T#:]TTB83'^`OA M<6V``^+Q8%1?+H]W;1*(/*9U?DHB4OVL=.?]:$.K.*>>SR9]82)=JADJ`F-# M/]3"=+X&ZLYZLIL)>XX_YQ>1M`<5"@![3H^VFU%@0A MK8X771/2Q#ZQJ!\P/6/J-+U6`U9?F,(%N%8KH1-G)MM$.4%<#6)-WT@U8/:- M#B[@OAD_I3@F2'6CI24'LQ_$(`&WOJFM.@H+=71VB?IVV]#63-,'0FF8/:&" M"K@_R*+99RA&RUIF-TVWJ)1@]HX!8L"==)\\/L[3#4O,CS5](Y"%V25RH(![ MHGA:03=`FF(PVU^($7+3T\V`&6F.)R_3=X!`&&@WR)$"[HPYP97B(-1T0U,, M9@<(,4)L^N:V=1G-R5,N\US+M;WNJS#:Y()$](-*`=9Q.U0!8K\FZ>_T],%; MA[D7=3NL\6M@/2'"!K")1[Z?;EI'^7%0//?"K]R);I"::,'JD#Z0`?93+=>\ M[(I?5P16#TCQ`6QN&@_N$9'2=C+4+-I8'5UOJ`>K8_J!!MA;Q=@NH\)YV*;T MY$DI#:MG3*`"[(]++WN:Q-,UYH]F"QYT:0G`:G4).H`-/2.35YS7KS8+'B)6 M2\)J>AU,@'T@OJ$BGAX4LK#Z00\48$^P\/M9FO@8!]EHZ85QEJOO#W4ZJ'\1 ML/IM,'Z`W?DQ9,],$HN07>&UE[('5I+%.,;I\D6RNV*@`ZO#S`$#[*&9E_G) M)))ND0G"Z@L-2H`=4-Y4??`B+PUQ-O;2&`=DH'^,UU[8W>+2 MR,/J#C.P`'OE(DQ6.`A]+QK'>9C+;)58#%8?*#$";'J:"SV*,(M4)M,@<>&E MS2\7A=4%6IP`NV%_#\""Z@H#I``[0[2)8+0I`JOQ%0CA-OH]7A97WI/XGI[- M9#,<>Y$@/Y%.`61GZ-`"[)BA[SZ`:GXY0(`M#N.)!%#]MW,]`':S\IE-L02L M3I'!`]C6A?F=>2]$/"H.,6=>*APT*F%8/6"`%&!G[)JMX6>6B8RL:TNK/D_H MCVJV@,=Q[#]GAO&78='$=K4!^PLCMFA6*PND")$6#3"P,8KI.4'N2.5L)7"?0JL+K$&.^1=0_WA'MU M#U5L>8@078*P8ITN5=U$<95G\-0`ZP\_H_ M:J0(5QM>%JRNW;TB`'M:SM=LKNY78TU8O=@7-L`^XT>9OX0!YH)W4>1$*S.4"`$V.BW MH4\/W:ZQ]'9A1P)6<\O@`6SK69H$&S]G689DX50=$5BM+<4'L+GW\Y(AJ.;7 MX@38#?MZN1=41PQXWLI]3]0V,"2S:T<"5JO+X!U#6S.VZ!NN_AM7F0FPPF[@X5[ZHA9,4D8M%6,,\N4MB?A)=SP4KZH^A98'KO!TK`JNG M-]GITO/6O_%DHY>;-,7--8-0X+VXI#Y;(!8E7Y@.V/"1-O]D"%^@&\T:K:",`>.`)]R[&SEO\SW,X`,HMYX M!S]$CWZ]P@MO$^7HEG[_GX[&5J-6G6TFN12@4:4`UWD+H!#E[V2<(";MJ.6[ M5!.U?%?JMV_!M+P"G.I-F3\B+HQ&>9Z&CYN<'CFC/$$SSX&!$QAG,O.9]8Y. M!]`H,8:JF(;8@S)W7@-I7A*K=MDP&<2%' M;5MD:XN7HM1.4B%`[2S'UF[M2A*5HH[:G&:F(,V0"W+.240`M;<,6;NU2[FR ML1VU-5D6)F6_DY5*LL**5I<*`VI_/<;NVW=;#<15T->%TC>NIDYVU$UO?S3O M.XM^#V#IJX35\>29T`GB8FX.D'V"@+]:GJDO!0@.DXUU`73,8,@=Y$$+[.6;%#O>JA`%KQ6!:V0EO4@H#-EC33K6%>% M/EL2!OS%`&?^AD^W=?@`\>@(H4$8<9ZDH=C?4RH`F@O-<'8]$RZ-OB[UOJ'; MD355,/TT7JVCY`67Q_R2%"]#]$'WH@%LPTXM2T)%4:A6EBN/%.?T=BM9]3V' M`0XN7CYF.*C29L?+D9^'S](^-M<&U,,#0(O,+"T#E86@QQ?T-2V'=/,W:+NV MVY;EJ'^+Q!G9/!GY_]Z$*>%S3FI"K^C)(P2T2H!ZTQQKNQ-+3;J57>BBK3)R M&G;0J569,W)&JD!=!;JMRS)`&_6?5!MR1^I!F_1H6VF$+;Y9SGZ5NY]F0U>_/]"X! MRLIF.'#94#8N"=9(KIXM'C22!=KP1[(*=,^17!7EWG]BF7GB@/Y!)XUG+Z*L MG"51Z(LS=_12!-2K_?!VXFAH9]*9E?VE5@"9=ED1Z-?B3UH68H6YBZ'Q`DRJ MRD-Z?;;YDFTOTW.2'LKL4DBH1O"+H\1=\AH MVDE=*CV+W.='`/3ZX>LF/!4]?:3EH/JW4.UCU">MRQ4?1.R+)ZCX)OG+]JLG MB'\7%`'Y"?!HDS\E*;5)+&%Y[6(>W1=I7GN]ITU0/CM=_(;.]X+;C98_#6AJ MMEUC4PJ?<-)F:`L";2@*'D5=\);MAA'REE`0PX(8F)+%]/2Y!JAD/"AR#S(. MK0?6I??9+7_ZR[3$1C6V9I]+-*B`TQH`1\KMVBBUS6W#3X,WW(>K\2&Y7<," MC=O;)/^/0R;)[AQ9&\=%_5O-?X]77ABS#>$X3SWVUMH.1\1 M`!NC/5@J3GL%I].R!!KY5A:!D;ZKEDW`M*MI".?0!TG4,( M`V`P*@#N#L#&V/L`P%M(1^K=Z%]Z&2V7*5YZ.0W^2,,X"WWIW5AG8`#0'4X; M'-(GXNAXG$>!CP:$T!^W%@,52E3!='O'^##]4C-*[@>*'LP7M%38O0V<#93& MR@+*0"G?[WUFR(N*E'MGLMQK&GDH?K@I3,&%*I7>L9FR,HU'EJ7%9O[*^+<_JAEZMN2(.NTJM)UD!:AV/U?;5&MV!J&_OE;_T2WY&_EQ^2/R M'TH$\I/_#U!+`P04````"`"VA:]"Y+5^.8DD``#`3@(`%0`<`&1L>70M,C`Q M,S`S,S%?<')E+GAM;%54"0`#]_.34??SDU%U>`L``00E#@``!#D!``#M75]S MVSB2?[^J^PZ\[,/-59W'?Y*9W61G;DN1[*QJ'4ME*Y.=IRE:A&1N*$`+4DX\ MG_X`BI0HD@`:)"&`'L_#Q''08'?_T$`#Z&[\]+=OJ\A[1#0."?[YU?GW9Z\\ MA.?[DX&=\/Q^)47)SX._(A@]/,K3%[][?_^\S\\]M]/_W5RXEV% M*`K>>2,R/QGC!?FK=^.OT#OO`\*(^@FA?_5^\:,-_PWYY_O;:_;7[>?>>:^_ M?S/W3DX`G?V"<$#HI]OQKK.')%F_.SW]^O7K]Y@\^E\)_1)_/R>P[N[(AL[1 MKJ_1]:^SW\[/_GW^_;<%8W?D)^R7%V?GKT_/?C@]?S,[__'=V=MW;]X`.T_\ M9!/O.C_[=I;]MR7_*0KQEW?\?_=^C#RF?QR_^Q:'/[\JB/3U]?>$+D\OSL[. M3__Y\?IN_H!6_DF(.0YS]"JGXKW4T9V_??OV-/W7O&FEY;=[&N7?>'V:L[/K MF?UK*&E?X"0.W\4I>]=D[B?I,%)^QA.VX'\[R9N=\%^=G%^/Q/-C!V7PW\,/:Q'STEX9P-B-4I;W#*0-JL$$X&.+C$29@\<<3H M*F68"9'V^$#1XN=7`:,\X>"?O=Y^]D\0VN1IS4PC#E?KB"GEM`6G[_V(:_;N M`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`/)N^27AH]IWU<,;SP/_6B,XX1NBFBKN=;HY*B^E:[^ M6W1I_@EH/]FO=S=G9V M[IUX.47Q1Q\'WI;<*])GG.>\1V1^P&[$KW^(\A`LO6N#\!GY]RA*N_V-T\A) M3ILPEZDRO8"*T?S[)7D\#5!XROB]X#]PQB].SLZSZZ<_L5_]MOWV+5J&S'K9 MH.=7?@*.ZYN6.2T.@0&=>X0&B#)X\DY].C\`OGIEEK4X7:?W`2?SAS#:C9D% M)2NH#C-]$94$1;VR;Q]=^4,F`>7S9X"^_0,]2;5?:0M4_[E#^A?(:P.`7(`9 MZU9AI]LF0'5?.*'N.NEL:GG*G`;"6`]X0()"W:6V0+V_=DKOM?+:`&#`N`DX M1U>1OQ0HOM0&J/`W3BB\5CX;BAYN*)?MBKE6?O0K\JE\L(N;`]7_@Q/J5TEM M;VG]C*+H'YA\Q7?(CPE&P3B.-_M+RMHE5D@#Q.1')S`!R6\/F%](Q+8>/GVZ M"B-$8RD@E;9`(/[L$!`">2TZG5N;O45KOB_$RVV0G]SW%)``X?B+0W#(I;>' M2CHZAFSJ7!(JWPB46@(Q>.L0!K6R6C0(LEH1G!XBWCTPD>/))DFCA-GPD)N% ME!"\/W,(&8@J;.XCMH[&UKN^8K\335N2]E!8W-@W*P6WCP9W^^!8%%I#D7!K M2RT0N@:'GTYK3T:-'IO61U'OSDDOO!-O%RC*?GX_N![<#"^]N[]?7L[NNCP7 M/6!D<,]/W>:)8(0(VK8>SPL_OD^'QB8^6?K^>CNH493$^6_*HSO[]6^#.%:S M76YD\SQ4JNZ##7.M9%W.(FVUGGEH(.57VEH]%!7HMJ)]@81N@,!CQ]FI:I"T-.`&:%G84GR+YH@QS*_S M4)(-,Y$!24FLGKH"[`@@KQO(C/$CXXGM-S0]I6CM MAWDP'#/@-!SN8,85``"BM'HNJ\9%0WHWX((`TPP",\>PFHM[C;(9N]N`G^NM ME$*F4HX2DOA1VM*R59$UHLG3-/*W>R6V(J[Y[D$\G\E)K![A0NQ(+:\;!E0P M\!N"YR"O64%C]3P7O(4!">X&1B.T)G'(Q"EQ*SHJ$3:W>LH+4SB!R.$2.%0HJ:+E9G=OC96SPNA/)`Y1#PWH5B\@/LUR9/"78"30U$V'&0E7@&G8X*B.`(F7F@$$;@'KPG#Y!S0^GLFAZV#%"&UB54MWD0(D:0U$RRC09HY.M(%62N[<0J<$1]`6"HR9TPYM M8*02]WV9TS[4ZN`8Z\+,X0AX@>O+P=4T'U`IP[+(L=J64#3,G('H^9$24=W` MHA#:+PWAJS2#HF#F0$,/!9&0AIR]PN=*)0;%6MTUA.K5S*%#8[W6UE*T/;@' M01!RO?G1U`^#,1[ZZY"M3@6V12XW@!`*E)ES!\WS(+`BW`#NEI>:P2BX]"D. M\3)FFX7-:I-N#4KEM4O`00BAP)DYE=`##JX(0W-9E=TQGD<;GODUH\B/-_1) M9DAPL"*!=6'\.T60HR6Z;6)=1"K MF@#;+!Q$,V<.;:WSN=BAZD2[8;P&'%XS)Q>-C^:E2N@4;.M)F_5OH>PR.%]+ M,SB][P[(_\=81N?!9W32.P6$?\@X:O.'2%*8VL14]_1P/H]-8?,)KW=YF#^F MB-`1T%C-.-4/;X0HP(VMH20TN;`Y*E8W%0#8I".K*:I=1G$K5.4&U#8"'(\0 MB0J>?;4B&WL^]6;GAX57`""16P!2JXFS``3%(9)27;AAH39NV5O#:[!) M'@@-?]_O2:7858FLINRVP4PDO[M8I54Z=7#*":RF[K;'Z%!N=_%1EP944EE- MY6V/E.&*@)T$.&BN72!*NSFG+:[K^[!L5>I.*MTFP_:XG+]4%1' MRJ3N;M#BR6*R1M0_?!]\=]OVIG3;=C<;S"X_7M[,[KS)E3>97MX.9N/)S9WW MW:>;P:?1>'8YZO3.K9Y/Y=&+G,AJN%>:&J"2H-K,YHT:#(3#8*YZ,=V8B=)7 M'C,6/Q`22*K=U#>U>N4EU"U1L>T2!M?A/'VRM_1.?.6:H]3*ZK441/,"N?I_ M.%H<4C![T3$5,\ZNKJG46TDO`ZB&)$XFB]3V>>P0HH]L8,9W)!+O5\0$5F^6 M(""JI75CUOM`21Q/*5D(P[H/6EB])X+HO4:>OAM.YN#@9?ZHO"H22MS>\E6/ MKM.FE-P-&[IE2F0\\`KE(S9$(Y)6)\UX%OK34AJK]SMJM1.P("[A=(J`XQ0R&>S MDHWQG*S0-5NJ5?@56UHNY-H(PJJD;AC2#<'DD,>\3KW!D\=FG_$GT/(1-E%P"HK1[\P97+M&4RR@FQ<#Q?7 M""6!I/W/J^1/W\0)G^VWNL@%%6(I:F[W+J\AJ'+9W3`RH6BZ_H7M,JZ-,%)* MWW>/_@8E2E^^U,9N9==F,-9)Z89][?FZ8G*R99<)MF&R[5W?*:*C,-JP^5H6 M<->@'[O%7QO.F0VU9D"UJ7'UCPX@5_>L?&% M^:\_\*UGDX-\04?NAIT=W-)L-__'UR/;J\ MO?MO;W1Y-1Z.9ZUCS[K*$,RX/I04F"P(HK6:_YAQ.),II^05(O0R':3-H>\C#A3F\6W M.8J9'\R\__2:3:Y]!5$OU:^0J1`+[%!%7BE,HL9]A$CP]?A9*94$UCJ]D!&F8DE-/0-0\?`;S"57Y'D3)Q1>C0 MCQ\&*QXQ([J5`Q"Z$=,O53I1K3;6,/TLO+X>#N[][5]>3ST>IEK%C4R,FH(;&[K+$&9I2\A@RN-X_?8IY M>>==LL=@GH2/V]<1%%D4#3IR)6A`"&-IJ6NHJ>?N@)B9#UOH^_D[*(/@7YMM MI'0\([=H3O`\3*OK[X6=D6X,V\RGW#B>@MJ^276[,3N,$$-@'OK9P]F`!P^D M%%9/LHRB18`:<`G:P0`=7?4;%NV2KQ'.`W+Y<_E M\D")F#6X0GZRH6B"BP$3,'`;=6SU>-<2_BT0Z/]V(9T-_6PZ]/E\N%?F]@$G M^1Y`@]Z-0VNH8Z^M&#<G$51Y[/CMG70@T(#VCLWDATC%Z--I[CRCJE:.V'0>YP MYLF?."@\N`@>#;#.[-;#Z7B8Z.C/5'??$XW;/+:RZ+M?\D[LUNCIR%\(+\,HD17!\+E:AV1)Y0_KMD$?ED7 M=FOXF`!=K;#GZ!/DBYF\$#^`SF[!(!,#0J`:-PP>?@?=.BK"=A6A]MCJ*^L9 ME(JJDWA;QJR#X!EI1W9K%745/@/0E1M3`?-2LC/KP?S?FY#RXG0^7O(T1^F> M#D!GN5Y1@]7(?;QO`/O0=H1=,@X$H#77%>& M[O?S.>V*T!&Z3]*`_#2N(*TBMAV,DP7[DS$GB]5HT`\4.D,UM9LC4;,D:*O/ MYLJ@DXF7EHV##``P-11V0T6Z.X%=4U5N>/YPT5O/SW"4#57M[@1E?87U?2E/ MLWYQP/_@ONRC'_');9HF5Y4/5@2#1*\+Z#`Q5#B\DV'21&ENS`CUG`^84BA] M8O*G@:9:.%=HH0`;*BEN$&"!FFP7D>C)R-#(4[TP5*7\>&/CF64D;];K*-WU M^%&^Z1GC!:&K+7**%%(H-71TF#E-U-[9:6K%C04@?YADZH>BY/+#)N!\*#.@ M:.JXYIV=HJ2.E+U^[\^_+"G9X*`@RX['7;[X7[P3CT=_1R3>4,3^LJ?SBH0= M[@C3(/(9R:9$/]H;A?(I.C6AS<<.Z=+'64C]D."81&&09[]-"^A.%C42[#&8 M,;#?,S:_"+30_6=L)IK#!\/!:XN&5.V([7X@Z5X?SQ&M,=FW99--FWMY^Q=+ M55KJ=D>3F M<7Y6-H\"O;?OP-OU\&(P:N=,4WH9J>?CP-L1/VN3DE5BKBI2Z58IR?IG#5!5.&(",T173$#^ M=J@?H7BPI&@K8]4(WI2-8$_KI<1>@?J/:`5"7:KL`$+8/TN`J\,16TA-=[JA M\P<_1CMVJX;P0_UJD%/NS>`/:07U6@0M!3*J_HU_H"(<&?RB-*W=J/^Q/.IS M"B\G>=:CO:LJC`=:AN\A((3],Q&X.ARQDN&#CY?`:G,[R_ESV7*VO7@A]G@_ M7MJ11Q;Y'L+;]_6L34KTTIM:QRIKT>NB?W;31$6.6%"Y:M]]DE=NF^#2RX+E M*FT[@ZK<^!<[Y8;$N_7R?CWVNT+/'N_:R_O^(QJ8/@3*D^$V/?;/_#I0H"/6 M*+W^$5]05N[O%1>4WG?Y3YV^U+!G`22'P@P;]V;1G_P4LZG_,D["%1NWHO2$ M;]15U9?A.AR36BA2#>&0G;6S1]& M8+K@^H?A#J"S^NQ#AR"#5>0&HO5O"FUC0-+Y:LY4QT8G7[3D$WRCGJP^R-`A MZBW4V,-Q,`HIFC-&NAL/Y1ZM/O%@:US4J]6-\7'+],]X>$A+X#RBB*2>:Q9] M+!T'($J[+T%T.OV#]>0&L!\(VU%BSN20X%0L0K,9"K:VZW1@]\F(3EUZ7:VY M@7;ATG5W;S3&3,[-:G]R*0`:2&OWO8<.,=;2E1OP;E\IF_G?H,=PHN9V'W#H M]!Q.KA$W<+OT*6:"\?I"J<<`@T])9?=9A@Y1!.K'#3!'B(://O?JXENTYK?M M>,EOVO/?9C5H1-,LG-SN`PP=PJNK,3=POD%?"^)2@MF/^V/1B*-1&S#`XP@71A\R!C_H"" M3<22T"%Z52]02<9&7$8P%+HO!9&O1SG%PLV$9`@]ZF4]$8+5A2EMM[@6*IQA%* M_#!*YX>-']686:42RD'E1N^[K`/OADO.SYT,[0.*3+.I\B,3:YF=>J37P%LV M=ER`=P:-^[5ZK\R8PFSSFIWPLKWH9K5)B_*,T"*C4XXM96/#"1OUK3T!%'M$.HQ.IP MT+QX$M+N0=M"<;V:#*W#9HZD7'2(FT@5CC@MTGL3I1=3*66ES%\]EE\#D4O? MJVG8J\59=!!%Y"M_28P_($0L+T0V#B-U MQ)_J#&L=A;6%6/@P:L*/H0LE,+)+4Y%UBML[XC5U9XDJU;AN=7$-[S?,BYI] M1=$C^DAP\B":A-MVVH<,U6XL54?)?1PPOR*?SKZ23L;)KJ\^Y+&:&QXEE?9V M5+#/ZZ_GBM[ZD-EJ>&04U=K7L7%%-K2SH;'MK`_IL&9'1E&IO1T8K&UW`R/M MK`\9LX8'1D&I;@R,2R9]\O0Y#%"6_?W1_Q>APTV_%`T%.'D? MTF)UP-=5G*%M89&-_*@I;HZANHM>I+LV!1*J04-@WJ&(-5I^0!A1G]=<&00K M-L=PWKD4V41R+KK8@E+W(I55Z[)+3V^&T#LLG_'[_EY%6E$D;=>+Q%.]VWZ! M+FP6#Q/B5I?W/B1Q(CITD5+T(O]4#TNE?@Q9U`<>Q36E9(Y0$`^6?HCC1%JE M0`18DXYZD8&J@V-S;;KAJI9*E0Z2(9/ZB2DCC?J3Q`S(B'J1B*H;0*#6DB&# M'871AC,X)*L5P6D0O<@DZYOV(C]4!PZ91AR)Z:C+P*8(F9" MPO!"-9DC@1#M4%2JQ0V?X2[Q<>#3@+D]P6:>9(D!3ZD0PD!>%9$CT0T-`82I MQ`WX\@I5C+')?10N4Q6+/+WZMHX$.S0$2ZH`-S"JIN`/-Y0K1CY!UK5W)!BA MW*JXUAYQU#\//KQPGZAXH!=2OT.+5IN%F6.E]?(CWG] MHMW._P:)1%70N.&@-H6U:,T@Y3@S`Z?!QMFC5^E\I9R#Q12.^*==@`C0C*F3 MD&Q^O_,CG[*E@*>]I34#/N&U'XJN!I14CKB>76`#U)`A?++%F@T,)GQ4D"<4 MGEC)21SQ,SNR&J5N'#F[$I1N$!Y?5=Z$E554,GN")6>];4VE;LZQ.HHQ6:TC M\H30':*/X1P)RJ\LES1-,-R+IE)"!_VZX:_H#86#X(6N5.N&)].V,L]DD\3\ M>(.Y;3>;U;WP=-7`=QSQFIH/)6.Z;[SM91YX2(*[A*T\]M\,:ZN>*T(7*$Q2 MVTLK1X59AN\83U,Y#0U5P'<=<2KM#5TP-B^S9*OO_';AC)_LT#S)M=+)3'F) M6Q5G,#DXMQ??@TWR0"@/!_O$_'Q:P""MDY`5T$-3RER96Z[.K8(FBT)IO4R+ M6D/6P-<=.:KN>A@;P^GY#NU&EO\9\3M3%`P>$?67Z$"CYF=C^===R=]Q88:& MX/3BWX)\*`M#OB5/KN0KN>L7:YI'CX=W+^9N#?_:>)Z5Z[/W'\'KABNMX+A9 M&-[@KSN3?&9M=&L"97=LB]+U9U'P=HS#974T&NGU%NN&BOQA",]XT'!KS^73]-@57_)TCF$+U%,H=4VC! MFS,)B4X80FN07]Q^X4LVA4EF%SLP9DH,<1S.9=F6%OEQ)G/0VM:@-9BVO:07 MF^B4'QWGZ?D>YK=2W\M*`7_SS`FK@/`#M8GG>Z[?&LS.+<*]V.%]M:!=\/!? M&@0/>^=6PH?/.XH?/F\90"P0XX;@[1C<[PCR89H]_/DY3![RX-;85TC3O+L^ MQ/]6L#QXA[RE)@VE5S"V'E.V,JGR`!%Y](Z2JA>1BBJ\((IY<<6Y-M**1;O+ MY@^4Q'IQ7RV_U(M01>EH,PB`(]?Z7#?C.-Z@8+2AO$;/=ORG1TKUTF=!#<+R M?.VZ[$5\%M].QL,+F\;[O2N%]>W./-EA]3E#2\;Q]?G&,F1XWZ:.`:1KZ[,''N=IR-99N,-+5=\0VX;NGC;N>ESIE MK1?ADF:F+`,0O^P`J@[HT>VC*1>]",(\XLZAR:AWPG%4&O;.]06+>G'T2;P1 MC_T(M;0TG;=`W9%]LS'5;-UV:S-V]_PY\UJ"BX;0$.WG;@3/PJ/7B1]P^,3= M%57^86Y.][+N;D[?-KDYO;!RGR*"2?0*]"[.-YB)($KA_L2$TM,]QW1#YP^\ M]#M(Y_4D?51YO23%@QXC*M\6L`4JN]2XEVHNR5!\:-"B"Y[F5DKV0H5_=T#K MZGU/@=]"<+!M!4M'^4$+!Y1<&1(5_9;&L%T%?PQQN-JLI"HNM7%%R8<\%]5< M8MB-H?S1_Z;6]&&;'FCZD.%"C+=%3>>+Q@`'V\?V"E&0BK6RGL1FWHOX_+-N MG92);#):I%*FH'IC="^(?1%7(!/5)'@MNP8\-B=6*]G#!H=%A%R+4*I*M+V+ M'^,YY2]7C=#V3UFU,%/Q[FV9LIKNI3$2K>-F:%#N*W[^BGS1"E]N9#5K"@9: MO5R]>-)(_,+BZ[,FE^RF7U@$2M/1I;M;[RM6:ABESP<*+QGK&_(H(-&K.`N#'J0(]X[8+-4O'B&4G\J/CO0Q(G-R3Y M%26W:$Z6F%=2$ZW8YK[7BP1]T,@S#HHYGRW+EGR/]A_-9MOL+<<9V9>-*&A* M[.`U[[$7.?2P`=%>L8YXF'P_&V+.[YT?H7AWI0GP,<_+/N:^+R_MS-OW9MK) M!(NA<"X;]--Q?C'[YPT.^!7&"*U)'/+9`K$/BB9P.8E-C[$Q)J6T8J5&'#&E M@\O2G;1J.[JHWZOE/>VMR+01P0106)!N)R[$?_8L(+H93B_1T$<`IL?1T*+7 MPM\_%?]%%@Z@T4$OP-(1R(V@Z2)?THCINH8.8*(_!D5X=10XW0TLXW1G2*CT M=KS0)$U[=R/PA$*9^CTLO(]V?V)J'$/`ECD MM*^<]AXVZD$,1KU7F*W53]*]JJBQ8_H6[UA%`K3-0A$H]YJY;3A&5TB1 M=UG3KC'=4,[\E))@,T_2BV^I.NL:]D:?=6F[/Q31<&HR M]X]IH*([LS>CX6/J.F>H7AD MD8>Y>]>A?Q]&;![=;=T,1;F#!`+'N&OVYL(VHF\;NG;(O6SP'-@SN+S!>_9% M%&SOOEZ**+P441`H^:6(@@.:[K:(@NH^2W+QTNR:Q87++,&=BE[5Z$=$[TF, MVCP$(U#^1Y]^04GJ,')>W!/K*L+]Q'\A41,P7R'VQ##<@<]N(;6UX>[ M.-Z&\9%MPP3[+:T&H:-3G"E"Y&$)@O9Q)\P$SUZXO5ULEB10J&38>3'<;@(43"(\R.Z4!@WUZ9# M($)FGMC4*"#32E^.'.IN#V/'>&?;DT4FR^X85AV$\T/[(UY#T3D-Q%,<^+;J ML4N3E3"@6HSJ*&SNL3I`J7:=$FO&$>L;K`A-PM_3_B:+$;I/N!F1#4XF>%M` M.0GO(\3K*4_]IVUBK%+'O^4EWW+M'&VEUYA MJUU^H$O3%?.E+8A=P^T>P:(=J]6D9<;9O_#_\0J#[#?_#U!+`P04````"`"V MA:]";&9'H2$/``"6G@``$0`<`&1L>70M,C`Q,S`S,S$N>'-D550)``/W\Y-1 M]_.3475X"P`!!"4.```$.0$``.T=77/;-O+Y;N;^`\\OE\Z=+$M.TL:-VY$E M.=&=;6DD.4G[TH%(2$)-@2I`VE9__2W`#U$D09&T'2&5\I`XP.YRO[#8Q9?? M__RXL(U[S#AQZ/E1X_CDR,#4="Q"9^='MZ-::]3N]8Z,GW_ZQ]\-^//^G[6: M<4FP;9T9'<>L]>C4^=&X00M\9GS`%#/D.NQ'XQ.R/='B?+D87L%_??IGQNGQ M:].HU0H0^X2IY;#;82\B-G?=Y5F]_O#P<$R=>_3@L#M^;#K%R(T=',=4]G!X[ M;%9OGIPTZE^NKT82[L@'/'NT";W+`F^\>_>N+GM#T!3DXX39(>G3NNB>((XC MRM!+`W=;]S`Y1D@K[U04D(:N$$',?F\: MM9-&[;01@GN\-D-H&:%,$9](TD%'-@IS;,PS<61/!A)U*/46V=JQ7%9W5TM< M!Z`:0&%&S`AO.](F`O`@FK.YDST9W(FQ$B%8B'!$D;URB0F#;R'@3T].!32V M\0)3]])ABPZ>(L\&\_WA(9M,";:.#!>Q&7:%Q_,E,G$!BN'0090Z,,(@@`0M MHFVY)#"$H.%O[X6OG0G=CD$"0_P`84--7P#480QZ@ML6M;K4)>Y*#$BVD%\Y M,HAU?I0+(;X+7,@O6WA**)'LP9!OC1(W_B*AE^'2,&*'W]22)&&&/8ZM/ M?Y(_+QGF0$8B74%#@!B`*)!,9)N>70YGS4HF2M`0:KNR_B^0+8;[:(ZQRWV% M;S:I-=P$M8J(BP,57[2N6C?MKC'ZV.V.1P>-"O4-$`/9YA@@D)VAWLU^M:Y/ MZCY2$>]/^TN1!,$7`[=6]*EU_CJA\]&X->Y>=V]`W_U+HS_H M#EOC7O\&M'][T[KM],;=SD'SF]K-'H7T:G>]EK]\:'H9,P2QOQ^:7M M/&3$K'67V@3?YYJ@W1I]-"ZO^I\/(LS8J`5-\I+LCO5*C]-A15!P@AHR%69D,K> MJGR,V8)0X8@C9&/>FC'L)W^^TM7=:K6_3JI]3<205(PUF;W5NW3%@(X MTD?,T]-]:HV_R7;TD,1:WWNK;J@D,6/8&N)[3#TI/@YAZ1="$V,1=^VC&WJ"I1?Q6HPU*5[Y8ZS'@5 M_K2_*SI9A==8."Q7%V9!O](0S51!K"C/C%<^J?U5OZ(JB%L@'T1MA%2-K"X? M#G8H,+W';5(<7&V?5$5=."ALCTSVQ@M6V#41DFM!^3E M9GL_9O+5W"ABBT:.,5)%?@%C&(V#.;(UW2QBCF:..=)5?`%S-`_FR-9T8D(I M"JPTSVEZL[N`>0[SB7JG*MM0Q<'5IDJM`.3L9!ULM75W*V=$;8=56RFU#J#: M_3J82+TCEFV;;4!JHZ16`I([9@=C;!B#D7NI@TL(+]0DR.Y1[C(O'K%"DQ0! M51LF5?Z76#7;^T2ZP+)E]D"J@JBV86JYH+P-#Z.NR@YIMG&?@8[:UJGEA\H[ MJ']MVXN_Q*73(9X:\K+JF;C3>'[$R6(IMK;]MCG#T_,C"QRA%EXU_`U$.WY< MV"&(()US655Z3E(;P8=#$HB9*2JIR[1`Q%D*.V%>#YD/";C$%>B#V&<,\1V8 M`^K/(;*-)F5%!A1LOZ"L5X+^LPH)WE=6R(3#OI"H[?57GE5@&#IE!=X<;2\D M;R?Z2%SQ`<0IY!4]>'\ZZ2^Y?@KQQ3DLI!$?^KA7@U MT51K-&NGC>-';JTY+Z%=P44FCOBAMD8N^OW=98N0!ZB--$-G,ADSC[LB3\R6(QM$&PFV6$%CW0]L&)7RD8D9 M_!6V9HNQ!58;F;J0EE#@26&-=+(N:+;F78I MC-K5IA#%0'TP8J%-,7+Z=\[[!7$6D`9!6>H_'[3)N;)W MYWSWJ(MM&YOB+-K`KP\3O.="[)S_-EH2%]FT^PB#D_>G`^2OVF[*L!5JYW)< M07"A'%_B9`#*ZM@YM^`'EF>ZG;.;_X[8C[G^3`(OLR0Z88RE)?) MAP`JD)`\1\")/Q35"KB+XDUVIW9"C!T8E?*\9(MS^<28SW]&^U96_84A-^R: M^"H`$?!$O%X3YW_A4.PBMGH&"8+CGVUG(8Y_2EV!`P4'#R\PQ5.R%JLH<&59 M35&*OYRPP#A0\Q.Y\"):$&"S>G05(_YP4?ZX('2+J=(CMN>*UUJ!& MK8A<71LO.Z<6>`2PV-#^5L+7$'.,F#F'9*"#[['M+$5_>*/D!KO]Z0<'C$M% M\P?Z%G%O("3`:1=B(&,51Q1Z6#Y3Z&4HAR* MMMZ9///E'VZ]/+C$R/48[E.1&/%" M^51)2KJJ"3B4XQ7"C3B()T(1EJ:54051V]&0&8%EGI`I M>W%P7PUX$[&=*+0&H7US,?+<&/[H4=6\#8!E1U?=8-:3Q7\I?Q M]D=2E@)P.HBCO-24$J@0I`XB95__R390+I@.PA1YUB0I64D<'<0L?^`]'3R> M1$('):P/Y1=Z=BLY+U1&UVZR6$NB?NM*+7T1'(U%SGU<*L?FQ="T$[SPNTU) MT2L@?D/"^X8K$=K3"'J%M/CS3^"?UXBBF9\_#""_3MVA5CMZ94+:6?^SP^Z$ M+/ZACVB5/-FJZ8ZR6$WJT?CO)PK/L*3:=:VY"LZ8Q7VS(AGM/',`:3Z($,NH M@METO=:@!M#5VOYIF<_$PD-L8G(O)X=K]+O#VAYWG05F`\Q,<3MN%LE9$J=\ MR(5XN_0I/$?E@VT;',#_S:DV!,>6!24;$@#DFQA9OS9#PD?Q]P%#>2IC:+F7* MC6P83\'*Y,9&DZ*O^'A[D9VE_%HJF,?*%6`I).WFO.S?A*->F-3X%%7`[A#/ M@F#NT*$X>L$'F")[O7-6`$[3R+]VMJ+O,:K=M3P%[7PWW-X9@?89I)I=Q"BV M(%3>TB4BT;2X'4QSCQZ@%7-L.V8Q@I.G5E4P&L\/6]9PM@;LAX8+CPV&_PW M)N$6L!T7%5+SJ7.1+>&"_OKMQ6H-$AKG`;%0(-]^XM839.$F_#AV1%,LTOHB M-S8BQU?ZX,[/`E:5-;PG$KWWYV^7S1$-M'#IL"F&SUL].I#R)$*FK-4[D&I% M6Q+-)QO@A9BJNCHGF?R*$;Q9-8(W-8[@V?-XVADFBM$8&W8%)^W3_!3BI3^] M\X3AJ?$O)K8_R.1!6Q2>+0H_F8NR=GCF00^3!_%-^@M&T8)2 MJK7BY/S5CA^4V`,K2T"[4+6>[R]B6PC!XE^PKC!VUBEE3."8?9]`0M<5_<(O MH">]HP*B=EX!QF)XZE'+?VYUZ7#B^IN"ZWVG+3#:+D$5>S$]?;>D')9V)HV= M%=_;7TNFJ@E+^O`F6BMJ/9GS*-ZLK`6;=&K8_$< M8WT-:1O8SNN/_+?W4U-Z47#MQO4Z&2GTMKTZERF)KITB,AU5-[>\1NP.N\%I M1AG!6FZ76OWI9F38#K9K0<*D[XI,<4\F]JE\<+-K]['-GRODZKF]$O5M$+IB M55?;1IR3*8$*BXGX`Q0````(`+:%KT*#YCW73'`` M`.>Z`P`1`!@```````$```"D@0````!D;'ET+3(P,3,P,S,Q+GAM;%54!0`# M]_.3475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+:%KT*V>C$\L`P``+J5 M```5`!@```````$```"D@9=P``!D;'ET+3(P,3,P,S,Q7V-A;"YX;6Q55`4` M`_?SDU%U>`L``00E#@``!#D!``!02P$"'@,4````"`"VA:]"3]);&30-``#U MJ@``%0`8```````!````I(&6?0``9&QY="TR,#$S,#,S,5]D968N>&UL550% M``/W\Y-1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`MH6O0JE\5];3/P`` MUK<#`!4`&````````0```*2!&8L``&1L>70M,C`Q,S`S,S%?;&%B+GAM;%54 M!0`#]_.3475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+:%KT+DM7XYB20` M`,!.`@`5`!@```````$```"D@3O+``!D;'ET+3(P,3,P,S,Q7W!R92YX;6Q5 M5`4``_?SDU%U>`L``00E#@``!#D!``!02P$"'@,4````"`"VA:]";&9'H2$/ M``"6G@``$0`8```````!````I($3\```9&QY="TR,#$S,#,S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``?_\````` ` end XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Purchase Agreement (Details Narrative) (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Warrant [Member]
     
Common stock shares 123,070   4,375,000
Investor [Member]
     
Common stock shares 492,280   17,500,000
Common stock shares, value $ 49,228 $ 19,255 $ 17,500,000
Exercise period 5 years   5 years
Exercise price $ 0.30   $ 0.30
XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
BALANCE SHEETS (USD $)
Mar. 31, 2013
Dec. 31, 2012
ASSETS    
Cash and cash equivalents $ 18,174 $ 294,150
Accounts receivable, net (including related party receivables of $391,345 and $0 at March 31, 2013 and December 31, 2012, respectively) 451,163 512,842
Inventory 353,505 292,443
Prepaid expenses and other current assets 46,304 45,945
Total current assets 869,146 1,145,380
Property and equipment, net 92,748 95,557
OTHER ASSETS:    
Deposits 2,280 2,280
Patents, net of accumulated amortization of $159,803 and $153,796 at March 31, 2013 and December 31, 2012, respectively 117,507 107,230
Total Other Assets 119,787 109,510
TOTAL ASSETS 1,081,681 1,350,447
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Accounts payable, including related party payables of $86,261 and $82,195 at March 31, 2013 and December 31, 2012, respectively 554,596 559,946
Accrued compensation and related benefits    10,000
Accrued expenses, other 159,091 140,975
Current portion of deferred revenue 169,764 189,094
Total Current Liabilities 883,451 900,015
LONG-TERM LIABILITIES:    
Accrued compensation and related benefits 1,515,045 1,484,739
Deferred revenue, net of current portion 1,863,537 1,894,627
Total Long-Term Liabilities 3,378,582 3,379,366
STOCKHOLDERS' DEFICIT    
Preferred stock; $0.01 par value; 10,000,000 shares authorized; 0 shares issued and outstanding      
Common stock, $0.01 par value; 200,000,000 shares authorized; 55,767,097 and 55,274,817 shares issued and 55,509,884 and 55,017,604 shares outstanding, respectively 557,672 552,749
Common stock payable    19,255
Capital in excess of par value 35,792,064 35,723,001
Accumulated deficit (38,257,976) (37,951,827)
Total (1,908,240) (1,656,822)
Treasury stock at cost, 257,213 shares (1,272,112) (1,272,112)
Total Stockholders' Deficit (3,180,352) (2,928,934)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 1,081,681 $ 1,350,447
XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) (USD $)
Common Stock
Common Stock Payable
Capital in Excess of Par Value
Accumulated Deficit
Treasury Stock
Total
Beginning Balance, Amount at Dec. 31, 2012 $ 552,749 $ 19,255 $ 35,723,001 $ (37,951,827) $ (1,272,112) $ (2,928,934)
Beginning Balance, Shares at Dec. 31, 2012 55,274,817          
Stock based compensation       24,758       24,758
Issuance of common stock for cash, Amount 4,923 (19,255) 44,305       29,973
Issuance of common stock for cash, Shares 492,280          
Net loss          (306,149)    (306,149)
Ending Balance, Amount at Mar. 31, 2013 $ 557,672    $ 35,792,064 $ (38,257,976) $ (1,272,112) $ (3,180,352)
Ending Balance, Shares at Mar. 31, 2013 55,767,097          
XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Change in Fair Value of Warrant Liability (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Change In Fair Value Of Warrant Liability Details Narrative    
Fair value of warrant liability $ 0 $ 587,930
XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Change in Fair Value of Warrant Liability (Tables)
3 Months Ended
Mar. 31, 2013
Change In Fair Value Of Warrant Liability Tables  
Change in fair value of the warrants

The change in fair value of the warrants is recorded in the statement of operations and is estimated using the Black-Scholes option-pricing model with the following assumptions:

 

    For the Three Months Ended March 31,
    2012
         
Exercise price   $ 0.25  
Market value of stock at end of period   $ 0.19  
Expected dividend rate     N/A  
Expected volatility     167% - 174 %
Risk-free interest rate     0.19 %
Expected life in years     0.70 – 0.84  
Shares underlying warrants outstanding classified as liabilities     13,401,333  
XML 28 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
Amortization of Debt Discount on Convertible Note Payable (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Amortization Of Debt Discount On Convertible Note Payable Details Narrative  
Amortization of debt discount $ 358,555
XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Significant Accounting Policies Details Narrative      
Allowance for doubtful accounts $ 2,576   $ 2,576
Property and equipment estimated useful life 5 to 7 years    
Patents estimated useful life 15 years    
Patent amortization expense 6,000 4,400  
Future amortization expense year one 24,000    
Future amortization expense year two 24,000    
Future amortization expense year three 24,000    
Future amortization expense year four 24,000    
Future amortization expense year five 24,000    
Percentage representation in revenue 94.00% 67.00%  
Percentage representation in receivables 86.20%    
Warranty accrual 94,100   92,900
Revenue recognition 50,420 20,500  
Research and development costs 114,300 158,800  
Grant proceeds against research and development expenses   67,200  
Cash equivalents $ 336    
Dilutive common shares 38,543,711   54,463,590
XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (306,149) $ (18,383)
Adjustments to reconcile net loss to net cash and cash equivalents (used) provided by operating activities:    
Depreciation and amortization 14,627 13,292
Stock based compensation expense 24,758 41,584
Change in fair value of warrant liability    (587,930)
Amortization of deferred loan costs    15,224
Amortization of discount on convertible note payable    358,555
(Increase) decrease in:    
Accounts receivable 61,679 291,289
Other receivables    73,648
Inventory (61,062) (65,123)
Prepaid expenses and other assets (359) (27,820)
Increase (decrease) in:    
Accounts payable and accrued expenses 61,787 147,920
Accrued compensation and related benefits (28,715) 1,667
Deferred revenue (50,420) (236,959)
Net cash (used) provided by operating activities (283,854) 6,964
CASH FLOWS FROM INVESTING ACTIVITIES:    
Increase in patent costs (16,284) (12,709)
Purchase of property and equipment (5,811)   
Net cash used by investing activities (22,095) (12,709)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments for loan and offering costs    (4,650)
Issuance of common stock, net of offering costs 29,973   
Net cash provided by financing activities 29,973 (4,650)
Net decrease in cash and cash equivalents (275,976) (10,395)
Cash and cash equivalents, beginning of period 294,150 262,740
Cash and cash equivalents, end of period 18,174 252,345
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest    $ 233
XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
BALANCE SHEETS (Parenthetical) (USD $)
Mar. 31, 2013
Dec. 31, 2012
Other assets:    
Accounts receivable, net $ 391,345 $ 0
Patents, net of accumulated amortization 159,803 153,796
Current liabilities:    
Accounts payable, including related party payables $ 86,261 $ 82,195
Stockholders' deficit:    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 10,000,000 10,000,000
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Common stock par value $ 0.01 $ 0.01
Common stock shares authorized 200,000,000 200,000,000
Common stock shares issued 55,767,097 55,274,817
Common stock shares outstanding 55,509,884 55,017,604
Treasury stock shares 257,213 257,213
XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Change in Fair Value of Warrant Liability
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 10 - Change in Fair Value of Warrant Liability

The Company has accounted for certain warrants in accordance with ASC 815-10, Derivatives and Hedging (ASC 815-10).  ASC 815-10 provides guidance for determining whether an equity-linked financial instrument (or embedded feature) is indexed to an entity’s own stock.  This applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative under ASC 815-10, including any freestanding financial instrument that is potentially settled in an entity’s own stock.

 

Due to certain adjustments that may be made to the exercise price of the warrants issued in December 2007, January 2008 and August 2008 if the Company issues or sells shares of its common stock at a price which is less than the then current warrant exercise price, these warrants have been classified as a liability as opposed to equity in accordance with the Derivatives and Hedging Topic of the FASB ASC 815-10-15 as it was determined that these warrants were not indexed to the Company’s stock. As a result, the fair market value of these warrants was remeasured on January 1, 2009 and marked to market at each subsequent financial reporting period. The change in fair value of the warrants is recorded in the statement of operations and is estimated using the Black-Scholes option-pricing model with the following assumptions:

 

    For the Three Months Ended March 31,
    2012
         
Exercise price   $ 0.25  
Market value of stock at end of period   $ 0.19  
Expected dividend rate     N/A  
Expected volatility     167% - 174 %
Risk-free interest rate     0.19 %
Expected life in years     0.70 – 0.84  
Shares underlying warrants outstanding classified as liabilities     13,401,333  

 

All warrants issued by the Company other than the above noted warrants are classified as equity.  For the three months ended March 31, 2013 and 2012, the Company recognized a change in the fair value of the warrant liability of $0 and $587,930, respectively. All of the warrants underlying the warrant liability have expired as of March 31, 2013.

XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
3 Months Ended
Mar. 31, 2013
May 14, 2013
Document And Entity Information    
Entity Registrant Name DAIS ANALYTIC CORP  
Entity Central Index Key 0001125699  
Document Type 10-Q  
Document Period End Date Mar. 31, 2013  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   55,509,884
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2013  
XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Amortization of Debt Discount on Convertible Note Payable
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 11 - Amortization of Debt Discount on Convertible Note Payable

On March 22, 2011, the Company entered into a 10% note and warrant purchase agreement, secured convertible promissory note and patent security agreement (“financing agreements”) with an investor.In connection with the financing agreements, the Company issued a stock purchase warrant to the investor to purchase 3,000,000 shares of the Company’s common stock at $0.45 per share, exercisable until March 22, 2016. The warrant was fair valued on the date of issuance, which amounted to $1,204,787. The warrant value was recorded as a debt discount based on the relative fair value of the warrant to the total proceeds received, which amounted to $435,240. The warrant was fair valued using the Black-Scholes-Merton valuation model. In addition, the debt contained a beneficial conversion feature, which was valued at the date of issuance at $1,762,163; however, since this amount is in excess of the net value of the debt less the warrant discount, the beneficial conversion feature will be limited to $1,064,760 and recorded as a discount on the loan. The total debt discount of $1,500,000 is being amortized using the effective interest method over the 12-month term of the Secured Note. For the three months ended March 31, 2012 the Company recognized $358,555 as amortization of this debt discount.  The debt discount was fully amortized as of December 31, 2012.

XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
REVENUE:    
Sales $ 569,622 $ 1,018,983
License fees 50,420 20,500
TOTAL 620,042 1,039,483
COST OF GOODS SOLD 486,593 683,137
GROSS MARGIN 133,449 356,346
OPERATING EXPENSES    
Research and development expenses, net of government grant proceeds of $0 and $67,240, respectively 114,329 91,598
Selling, general and administrative expenses 325,371 434,765
TOTAL OPERATING EXPENSES 439,700 526,363
LOSS FROM OPERATIONS (306,251) (170,017)
OTHER EXPENSE (INCOME)    
Change in fair value of warrant liability    (587,930)
Amortization of discount on convertible note payable    358,555
Interest expense    77,786
Interest income (102) (45)
TOTAL OTHER EXPENSE (INCOME) (102) (151,634)
NET LOSS (306,149) (18,383)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED $ (0.01) $ 0.00
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED $ 55,422,501 $ 37,774,817
XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party Transactions
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 5 - Related Party Transactions

Timothy N. Tangredi, our Chief Executive Officer and Chairman, is a founder and a member of the board of directors of Aegis BioSciences, LLC (“Aegis”). Mr. Tangredi currently owns 52% of Aegis’ outstanding equity and spends approximately one to two days per month on Aegis business for which he is compensated by Aegis. Aegis has two exclusive, world-wide licenses from us under which it has the right to use and sell products containing our polymer technologies in biomedical and health care applications. As a result of a $150,000 payment made by Aegis, the first license is considered fully paid and as such no additional license revenue will be forthcoming. Pursuant to the second license Aegis made an initial one-time payment of $50,000 and is to make royalty payments of 1.5% of the net sales price it receives with respect to any personal hygiene product, surgical drape or clothing products (the latter when employed in medical and animal related fields) and license revenue it receives should Aegis grant a sublicense to a third party. To date Aegis has sold no such products nor has it received any licensing fees requiring a royalty payment be made to us. All obligations for such payments will end on the earlier of June 2, 2015 or upon the aggregate of all sums paid to us by Aegis under the agreement reaching $1 million. The term of each respective license runs for the duration of the patented technology.

 

The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Rent expense for this building is currently $4,066 per month. The Company recognized rent expense of approximately $12,200 and $11,400 during the three months ended March 31, 2013 and 2012, respectively. At March 31, 2013 and December 31, 2012, $85,637 and $82,195, respectively, were included in accounts payable for amounts owed for rent.

 

The Company also has accrued compensation due to the Chief Executive Officer and two other employees for deferred salaries earned and unpaid as of March 31, 2013 and December 31, 2012 of $1,466,024 and $1,494,739, respectively. During 2012, the Company determined that a portion of the accrued payroll, $1,484,739, is a long term liability, as the Company does not believe it will repaid within the next year.

 

The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.

XML 38 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses, Other
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 4 - Accrued Expenses, Other

Accrued expenses, other consist of the following:

 

    March 31, 2013     December 31, 2012  
Accrued expenses, other   $ 46,838     $ 29,946  
Accrued registration rights penalty     5,000       5,000  
Accrued warranty costs     94,053       92,829  
Contractual obligation     13,200       13,200  
    $ 159,091     $ 140,975  
XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Going Concern (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Going Concern Details Narrative      
Accumulated deficit $ 38,257,976   $ 37,951,827
Working capital 63,326    
Stockholders' deficit 3,180,352   2,928,934
Cash in operations $ (283,854) $ 6,964  
XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2013
Significant Accounting Policies Policies  
Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage reverted to $250,000 per depositor at each financial institution. The Company's non-interest bearing cash balances were fully insured at March 31, 2013.

Accounts receivable

Accounts receivable consist primarily of receivables from the sale of our ERV products. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company’s collection experience, customer credit worthiness, and current economic trends.  Based on management’s review of accounts receivable, we have recorded an allowance for doubtful accounts of $2,576 at March 31, 2013 and December 31, 2012.

Inventory

Inventory consists primarily of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.

Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 5 to 7 years. Gains and losses upon disposition are reflected in the statement of operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. Property and equipment are evaluated for impairment when events change or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.

Intangible assets

Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company’s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 15 years. Patent amortization expense was approximately $6,000 and $4,400 for the three months ended March 31, 2013 and 2012, respectively. Total patent amortization expense for the next five years is estimated to be approximately $24,000 per year.

Long-lived assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company uses market quotes, if available or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether or not the asset values are recoverable. There have been no significant impairments of long-lived assets during the three month period ended March 31, 2013.

Revenue recognition

Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from a related party) and 67% of revenues, respectively.  During the three months ended March 31, 2013 one customer, which is a related party of the Company, accounted for approximately 86.2% of accounts receivable.

 

In certain instances, our ConsERV product carries a warranty for two years for all parts contained therein with the exception of the energy recovery ventilator core which, in such circumstances, typically carries a 10 year warranty. The warranty includes replacement of defective parts. The Company has recorded an accrual of approximately $94,100 and $92,900 for future warranty expenses at March 31, 2013 and December 31, 2012, respectively.

 

Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of $50,420 and $20,500 from license agreements for the three months ended March 31, 2013 and 2012, respectively.

 

The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

Employee stock based compensation

The Company recognizes all share-based awards to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

There were no awards granted during the three months ended March 31, 2013 and 2012.

Non-employee stock-based compensation

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC 505-50, Equity-Based Payments to Non-Employees.  Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The fair value of common stock issued for services is based on the closing stock price on the date the common stock was issued. During the three months ended March 31, 2013 and 2012, the Company did not issue any non-employee stock based compensation.

Research and development expenses and grant proceeds

Expenditures for research, development and engineering of products are expensed as incurred. For the three months ended March 31, 2013 and 2012, the Company incurred research and development costs of approximately $114,300 and $158,800, respectively.  The Company accounts for proceeds received from government grants for research as a reduction in research and development costs. For the three months ended March 31, 2012, the Company recorded approximately $67,200 in grant proceeds against research and development expenses on the statement of operations.  There were no grant proceeds received by the Company during the three months ended March 31, 2013.

Government grants

Grants are recognized when there is reasonable assurance that the grant will be received and that any conditions associated with the grant will be met. When grants are received related to property and equipment, the Company reduces the basis of the assets resulting in lower depreciation expense over the life of the associated asset. Grants received related to expenses are reflected as a reduction of the associated expense in the period in which the expense is incurred.

Financial instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

    Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
    Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
    Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2013. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities, which include cash equivalents of $336 at March 31, 2013. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities.

 

The respective carrying value of certain on-balance sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued compensation and accrued expenses.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are computed on the basis of differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based upon enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2009 through 2012.

Earnings (loss) per share

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. At March 31, 2013 and 2012, the Company had 38,543,711 and 54,463,590 potentially dilutive common shares that were not included in the computation of income (loss) per share.

Derivative financial instruments

The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 “Derivative and Hedging” (ASC 815) to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.

 

Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.

Recent accounting pronouncements

Recent accounting pronouncements issued by FASB, the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Purchase Agreement
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 8. Stock Purchase Agreement

On October 17, 2012, Dais Analytic Corporation (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with an investor, Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Company will offer up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock (such offer being the “Offering”).Pursuant to the terms and conditions of the SPA, Company agreed to issue the Common Stock and Warrants in three tranches. The Warrants are exercisable for 60 months beginning on the date of their issuance. The warrants have an exercise price of $0.30, and are subject to standard anti-dilution adjustments for stock splits and other subdivisions. Pursuant to terms of the Offering, officers of the Company and the Investor have signed lock-up agreements restricting the sale of Common Stock. The Investor does not have any registration rights with respect to the Common Stock or Warrants. No underwriter or placement agent was used in the sale of the Common Stock or Warrants.

  

On December 28, 2012, Dais Analytic Corporation (the “Company”) amended the SPA, dated October 17, 2012, with Green Valley International Investment Management Company Limited (the “Investor”) pursuant to which the Investor will purchase up to $7.0 million of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 17,500,000 shares of Common Stock. Pursuant to the terms of the SPA, the Investor has purchased $1,750,000 of Common Stock and Warrants and the Company as recorded a common stock payable for an additional amount of $19,255. The amendment requires the Purchaser to purchase the remaining Common Stock and Warrants on or before January 31, 2013.

 

In 2012, the Company sold and issued, in connection with the SPA, 17,500,000 shares of its common stock to the Investor for $1,750,000. In addition, as part of the purchase it issued the Investor a warrant to purchase 4,375,000 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $.30 per share.

 

During 2013, in connection with the SPA, the Company sold and issued 492,280 shares to the Investor for $49,228 in cash, of which $19,255 was received in 2012.  In addition, under the terms of this agreement, the Investor also received a warrant to purchase 123,070 shares of the Company’s common stock with an exercise period of five years from the date of issue at an exercise price of $0.30 per share. The SPA expired, per its terms and conditions, on January 31, 2013. The parties are in discussions to permit the Investor to purchase securities on similar terms and conditions

XML 42 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 6 - Stock Options and Warrants

Options

 

In June 2000 and November 2009, our Board of Directors adopted, and our shareholders approved, the 2000 Plan and 2009 Plan, respectively (together the “Plans”). The Plans provide for the granting of options to qualified employees of the Company, independent contractors, consultants, directors and other individuals. The Company’s Board of Directors approved and made available 11,093,886 and 15,000,000 shares of common stock to be issued pursuant to the 2000 Plan and the 2009 Plan. The Plans permit grants of options to purchase common shares authorized and approved by the Company’s Board of Directors.

 

There were no options awarded or exercised during the three months ended March 31, 2013 and 2012.

 

The following summarizes the information relating to outstanding stock options activity with employees during 2013 and 2012:

 

   

Common

Shares

   

Weighted Average

Exercise Price

   

Weighted Average

Remaining

Contractual Term

(in years)

   

Aggregate

Intrinsic

Value

 
Outstanding at December 31, 2012     18,647,332     $ 0.29       6.06     $ 26,345  
Expired/Forfeited     (99,999 )   $ 0.32                  
         
Outstanding at March 31, 2013     18,547,333     $ 0.29       6.03     $ 356,486  
                                 
Exercisable at March 31, 2013     17,589,137     $ 0.29       5.84     $ 296,041  

 

Stock compensation expense was approximately $24,800 and $41,600 for the three months ended March 31, 2013 and 2012, respectively. The total fair value of shares vested during the three months ended March 31, 2013 and 2012 was approximately $27,400 and $87,300, respectively.

 

As of March 31, 2013, there was approximately $110,700 of unrecognized employee stock-based compensation expense related to non vested stock options, of which $55,900, $32,300 and $22,500 is expected to be recognized for the remainder of the fiscal year ending December 31, 2013, and for the fiscal years ending 2014 and 2015, respectively.

 

The following table represents our non vested share-based payment activity with employees for the three months ended March 31, 2013:

 

   

Number of

Options

   

Weighted

Average

Grant Date

Fair Value

 
Nonvested options - December 31, 2012     1,235,555     $ 0.16  
Granted         $  
Vested     (138,473 )   $ 0.20  
Forfeited     (138,886 )   $  
                 
Nonvested options – March 31, 2013     958,196     $ 0.16  

 

Warrants

 

At March 31, 2013, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:

 

Warrants  

Remaining

Number Outstanding

   

Weighted Average

Remaining Life

(Years)

   

Weighted Average

Exercise Price

  Expiration Year
                           
Warrants-Financing     7,000,000       3.99     $ 0.34   2016 – 2017
Warrants-Tangredi     3,000,000       .25     $ 0.36   2013
Warrants-Ehrenberg     250,000       .59     $ 0.30   2013
Warrants-Consulting Agreement     825,000       1.77     $ 0.30   2014 – 2015
Warrants-Note Conversions     2,302,538       1.42     $ 0.39   2014 – 2015
Warrants-Stock Purchases     6,218,840       4.22     $ 0.33   2014 – 2017
Warrants-Services     400,000       2.06     $ 0.50   2015
Tota     19,996,378                    

 

XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Terminated Sales Agreements
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 7 - Terminated Sales Agreements

On August 21, 2009, we entered into an Exclusive Distribution Agreement with Genertec, under which we are to supply and Genertec is to distribute, on an exclusive basis, three of our nanotechnology-based membrane products and related products in Greater China, including mainland China, Hong Kong, Macau and Taiwan. The agreement provides that during the initial five year term of the agreement, Genertec will order and purchase these products in the aggregate amount of $200 million. A minimum quantity of said products is to be purchased by Genertec during each contract year of the initial term.

 

In April of 2010, the Company entered into a technical and sales agreement with CAST Systems Control Technology Co., Ltd. (“CAST”) and Genertec with a value of up to approximately $48 million over a twelve month period. Under the terms of the Agreement, the Company will supply to CAST, through Genertec, key system components of its nanotechnology clean water process.

 

During 2011, Genertec expressed a desire to limit its participation in this endeavor as they find NanoAir and NanoClear to have engineering requirements they are not best suited to undertake. During the three months ended March 31, 2012, we terminated the Genertec and CAST agreements and recognized $150,000 nonrefundable deposit received from Genertec as revenue.

XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Deferred Revenue
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 9 - Deferred Revenue

The Company entered into a licensing agreement during the year ended December 31, 2003 and received an initial fee of $770,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 10 years. In addition, the Company received royalties of $100,000 in each of the first three years of the agreement. The Company recognized revenue of approximately $19,250 for this agreement during each of the three months ended March 31, 2013 and 2012.

 

The Company entered into a licensing agreement with a biomedical entity during the year ended December 31, 2005 and received an initial license fee of $50,000. This fee is deferred and recognized on a straight-line basis over the life of the license agreement of 7 years. The Company recognized revenue of approximately $1,250 for this agreement during each of the three months ended March 31, 2013 and 2012.

 

On October 30, 2012, the Company and MG Energy LLC, a Delaware limited liability company (“MG Energy”) , a company in which a shareholder of the Company holds a position, entered into a License and Supply Agreement (the “Agreement”), effective October 26, 2012, pursuant to which the Company licensed certain intellectual property and improvements thereto to MG Energy, for use in the manufacture and sale of energy recovery ventilators (“ERV”) and certain other HVAC systems for installation in commercial, residential or industrial buildings in North America and South America in exchange for the cancellation of $2,034,521 of debt due to MG Energy. MG Energy also agreed to purchase its requirements of certain ConsERV products from the Company for MG Energy’s use, pursuant to the terms and conditions of the Agreement. MG Energy will also pay royalties, as defined, to the Company on the net sales of each product or system sold. The term of the Agreement will expire upon the last to expire of the underlying patent rights for the licensed technology.

 

The Company has identified all of the deliverables under the Agreement and has determined significant deliverables to be the license for the intellectual property and the supply services. In determining the units of accounting, the Company evaluated whether the license has stand alone value to MG Energy based upon consideration of the relevant facts and circumstances of the Agreement. The Company determined that the license does not have stand alone value to the licensee and, therefore, should be combined with the supply agreement as one unit of accounting. The initial payment for the license agreement will be treated as an advance payment and recognized over the performance period of the supply agreement. Royalties will be recognized as revenue when earned. The Company recognized revenue of $29,920 in license fees and $475,287 in product sales relating to this Agreement during the three months ended March 31, 2013.

XML 45 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Change in Fair Value of Warrant Liability (Details) (USD $)
3 Months Ended
Mar. 31, 2013
Exercise price $ 0.25
Market value of stock at end of period $ 0.19
Expected dividend rate 0.00%
Risk-free interest rate 0.19%
Shares underlying warrants outstanding classified as liabilities 13,401,333
Minimum [Member]
 
Expected volatility rate 167.00%
Expected life in years 8 months 12 days
Maximum [Member]
 
Expected volatility rate 174.00%
Expected life in years 10 months 2 days
XML 46 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants (Tables)
3 Months Ended
Mar. 31, 2013
Stock Options And Warrants Tables  
Outstanding stock options activity

The following summarizes the information relating to outstanding stock options activity with employees during 2013 and 2012:

 

   

Common

Shares

   

Weighted Average

Exercise Price

   

Weighted Average

Remaining

Contractual Term

(in years)

   

Aggregate

Intrinsic

Value

 
Outstanding at December 31, 2012     18,647,332     $ 0.29       6.06     $ 26,345  
Expired/Forfeited     (99,999 )   $ 0.32                  
         
Outstanding at March 31, 2013     18,547,333     $ 0.29       6.03     $ 356,486  
                                 
Exercisable at March 31, 2013     17,589,137     $ 0.29       5.84     $ 296,041  
Non vested share-based payment activity

The following table represents our non vested share-based payment activity with employees for the three months ended March 31, 2013:

 

   

Number of

Options

   

Weighted

Average

Grant Date

Fair Value

 
Nonvested options - December 31, 2012     1,235,555     $ 0.16  
Granted         $  
Vested     (138,473 )   $ 0.20  
Forfeited     (138,886 )   $  
                 
Nonvested options – March 31, 2013     958,196     $ 0.16  
Warrants

At March 31, 2013, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:

 

Warrants  

Remaining

Number Outstanding

   

Weighted Average

Remaining Life

(Years)

   

Weighted Average

Exercise Price

  Expiration Year
                           
Warrants-Financing     7,000,000       3.99     $ 0.34   2016 – 2017
Warrants-Tangredi     3,000,000       .25     $ 0.36   2013
Warrants-Ehrenberg     250,000       .59     $ 0.30   2013
Warrants-Consulting Agreement     825,000       1.77     $ 0.30   2014 – 2015
Warrants-Note Conversions     2,302,538       1.42     $ 0.39   2014 – 2015
Warrants-Stock Purchases     6,218,840       4.22     $ 0.33   2014 – 2017
Warrants-Services     400,000       2.06     $ 0.50   2015
Tota     19,996,378                    
XML 47 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party Transactions (Details Narrative) (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Related Party Transactions Details Narrative      
Rent expense recognized $ 12,200 $ 11,400  
Accounts payable for rent 85,637   82,195
Deferred salaries earned and unpaid 1,466,024   1,494,739
Accrued payroll     $ 1,484,739
XML 48 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Statements Of Operations Parenthetical    
Research and development expenses, net of government grant $ 0 $ 67,240
XML 49 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies
3 Months Ended
Mar. 31, 2013
Notes to Financial Statements  
Note 3 - Significant Accounting Policies

In the opinion of management, all adjustments necessary for a fair statement of (a) the results of operations for the three month periods ended March 31, 2013 and 2012, (b) the financial position at March 31, 2013 and December 31, 2012, and (c) cash flows for the three month periods ended March 31, 2013 and 2012, have been made.

 

The significant accounting policies followed are:

 

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and cash equivalents - Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage reverted to $250,000 per depositor at each financial institution. The Company's non-interest bearing cash balances were fully insured at March 31, 2013..

 

Accounts receivable - Accounts receivable consist primarily of receivables from the sale of our ERV products. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company’s collection experience, customer credit worthiness, and current economic trends.  Based on management’s review of accounts receivable, we have recorded an allowance for doubtful accounts of $2,576 at March 31, 2013 and December 31, 2012.

 

Inventory - Inventory consists primarily of raw materials and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration and other factors.

 

Property and equipment - Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 5 to 7 years. Gains and losses upon disposition are reflected in the statement of operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. Property and equipment are evaluated for impairment when events change or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.

  

Intangible assets - Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company’s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 15 years. Patent amortization expense was approximately $6,000 and $4,400 for the three months ended March 31, 2013 and 2012, respectively. Total patent amortization expense for the next five years is estimated to be approximately $24,000 per year.

 

Long-lived assets - Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company uses market quotes, if available or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether or not the asset values are recoverable. There have been no significant impairments of long-lived assets during the three month period ended March 31, 2013.

 

Revenue recognition - Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable. During the three months ended March 31, 2013 and 2012, four customers accounted for approximately 94% (77% of revenue is from a related party) and 67% of revenues, respectively.  During the three months ended March 31, 2013 one customer, which is a related party of the Company, accounted for approximately 86.2% of accounts receivable.

 

In certain instances, our ConsERV product carries a warranty for two years for all parts contained therein with the exception of the energy recovery ventilator core which, in such circumstances, typically carries a 10 year warranty. The warranty includes replacement of defective parts. The Company has recorded an accrual of approximately $94,100 and $92,900 for future warranty expenses at March 31, 2013 and December 31, 2012, respectively.

 

Revenue derived from the sale of licenses is deferred and recognized as revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized revenue of $50,420 and $20,500 from license agreements for the three months ended March 31, 2013 and 2012, respectively.

 

The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

 

Employee stock based compensation - The Company recognizes all share-based awards to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

There were no awards granted during the three months ended March 31, 2013 and 2012.

  

Non-employee stock-based compensation - The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC 505-50, Equity-Based Payments to Non-Employees.  Stock-based compensation related to non-employees is accounted for based on the fair value of the related stock or options or the fair value of the services, whichever is more readily determinable. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The fair value of common stock issued for services is based on the closing stock price on the date the common stock was issued. During the three months ended March 31, 2013 and 2012, the Company did not issue any non-employee stock based compensation.

 

Research and development expenses and grant proceeds - Expenditures for research, development and engineering of products are expensed as incurred. For the three months ended March 31, 2013 and 2012, the Company incurred research and development costs of approximately $114,300 and $158,800, respectively.  The Company accounts for proceeds received from government grants for research as a reduction in research and development costs. For the three months ended March 31, 2012, the Company recorded approximately $67,200 in grant proceeds against research and development expenses on the statement of operations.  There were no grant proceeds received by the Company during the three months ended March 31, 2013.

 

Government grants - Grants are recognized when there is reasonable assurance that the grant will be received and that any conditions associated with the grant will be met. When grants are received related to property and equipment, the Company reduces the basis of the assets resulting in lower depreciation expense over the life of the associated asset. Grants received related to expenses are reflected as a reduction of the associated expense in the period in which the expense is incurred.

 

Financial instruments - Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

    Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
    Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
    Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2013. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities, which include cash equivalents of $336 at March 31, 2013. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities.

 

The respective carrying value of certain on-balance sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued compensation and accrued expenses.

 

Income taxes - Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are computed on the basis of differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based upon enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2009 through 2012.

 

Earnings (loss) per share - Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. At March 31, 2013 and 2012, the Company had 38,543,711 and 54,463,590 potentially dilutive common shares that were not included in the computation of income (loss) per share.

 

Derivative financial instruments - The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 “Derivative and Hedging” (ASC 815) to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.

 

Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.

 

Recent accounting pronouncements - Recent accounting pronouncements issued by FASB, the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 50 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options and Warrants (Details) (USD $)
3 Months Ended
Mar. 31, 2013
Stock Options And Warrants Details  
Common shares outstanding 18,647,332
Common shares forfeited/expired (99,999)
Outstanding at March 31, 2013 18,547,333
Exercisable at March 31, 2013 17,589,137
Weighted average exercise price of shares outstanding $ 0.29
Weighted average exercise price of shares expired/forfeited $ 0.32
Weighted average exercise price of shares outstanding at March 31, 2013 $ 0.29
Weighted average exercise price of shares exercisable March 31, 2013 $ 0.29
Weighted average remaining contractual term (in years) of shares outstanding, Beggining Balance 6 years 21 days
Weighted average remaining contractual term (in years) of shares outstanding, Ending Balance 6 years 10 days
Weighted average remaining contractual term (in years) of shares exercisable 5 years 10 months 2 days
Aggregate intrinsic value of shares outstanding, Beggining Balance $ 26,345
Aggregate intrinsic value of shares outstanding, Ending Balance 356,486
Aggregate intrinsic value of shares exerciseable $ 296,041
XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 49 196 1 false 19 0 false 4 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://daisanalytic.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0002 - Statement - BALANCE SHEETS Sheet http://daisanalytic.com/role/BalanceSheets BALANCE SHEETS false false R3.htm 0003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://daisanalytic.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) false false R4.htm 0004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://daisanalytic.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (UNAUDITED) false false R5.htm 0005 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Sheet http://daisanalytic.com/role/StatementsOfOperationsParenthetical STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) false false R6.htm 0006 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) Sheet http://daisanalytic.com/role/StatementsOfStockholdersDeficit STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) false false R7.htm 0007 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://daisanalytic.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (UNAUDITED) false false R8.htm 0008 - Disclosure - Background Information Sheet http://daisanalytic.com/role/BackgroundInformation Background Information false false R9.htm 0009 - Disclosure - Going Concern Sheet http://daisanalytic.com/role/GoingConcern Going Concern false false R10.htm 0010 - Disclosure - Significant Accounting Policies Sheet http://daisanalytic.com/role/SignificantAccountingPolicies Significant Accounting Policies false false R11.htm 0011 - Disclosure - Accrued Expenses, Other Sheet http://daisanalytic.com/role/AccruedExpensesOther Accrued Expenses, Other false false R12.htm 0012 - Disclosure - Related Party Transactions Sheet http://daisanalytic.com/role/RelatedPartyTransactions Related Party Transactions false false R13.htm 0013 - Disclosure - Stock Options and Warrants Sheet http://daisanalytic.com/role/StockOptionsAndWarrants Stock Options and Warrants false false R14.htm 0014 - Disclosure - Terminated Sales Agreements Sheet http://daisanalytic.com/role/TerminatedSalesAgreements Terminated Sales Agreements false false R15.htm 0015 - Disclosure - Stock Purchase Agreement Sheet http://daisanalytic.com/role/StockPurchaseAgreement Stock Purchase Agreement false false R16.htm 0016 - Disclosure - Deferred Revenue Sheet http://daisanalytic.com/role/DeferredRevenue Deferred Revenue false false R17.htm 0017 - Disclosure - Change in Fair Value of Warrant Liability Sheet http://daisanalytic.com/role/ChangeInFairValueOfWarrantLiability Change in Fair Value of Warrant Liability false false R18.htm 0018 - Disclosure - Amortization of Debt Discount on Convertible Note Payable Sheet http://daisanalytic.com/role/AmortizationOfDebtDiscountOnConvertibleNotePayable Amortization of Debt Discount on Convertible Note Payable false false R19.htm 0019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://daisanalytic.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) false false R20.htm 0020 - Disclosure - Accrued Expenses, Other (Tables) Sheet http://daisanalytic.com/role/AccruedExpensesOtherTables Accrued Expenses, Other (Tables) false false R21.htm 0021 - Disclosure - Stock Options and Warrants (Tables) Sheet http://daisanalytic.com/role/StockOptionsAndWarrantsTables Stock Options and Warrants (Tables) false false R22.htm 0022 - Disclosure - Change in Fair Value of Warrant Liability (Tables) Sheet http://daisanalytic.com/role/ChangeInFairValueOfWarrantLiabilityTables Change in Fair Value of Warrant Liability (Tables) false false R23.htm 0023 - Disclosure - Going Concern (Details Narrative) Sheet http://daisanalytic.com/role/GoingConcernDetailsTextuals Going Concern (Details Narrative) false false R24.htm 0024 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://daisanalytic.com/role/SignificantAccountingPoliciesDetailsTextuals Significant Accounting Policies (Details Narrative) false false R25.htm 0025 - Disclosure - Accrued Expenses, Other (Details) Sheet http://daisanalytic.com/role/AccruedExpensesOtherDetails Accrued Expenses, Other (Details) false false R26.htm 0026 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://daisanalytic.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) false false R27.htm 0027 - Disclosure - Stock Options and Warrants (Details) Sheet http://daisanalytic.com/role/StockOptionsAndWarrantsDetails Stock Options and Warrants (Details) false false R28.htm 0028 - Disclosure - Stock Options and Warrants (Details 1) Sheet http://daisanalytic.com/role/StockOptionsAndWarrantsDetails1 Stock Options and Warrants (Details 1) false false R29.htm 0029 - Disclosure - Stock Options and Warrants (Details 2) Sheet http://daisanalytic.com/role/StockOptionsAndWarrantsDetails2 Stock Options and Warrants (Details 2) false false R30.htm 0030 - Disclosure - Stock Options and Warrants (Details Narrative) Sheet http://daisanalytic.com/role/StockOptionsAndWarrantsDetailsNarrative Stock Options and Warrants (Details Narrative) false false R31.htm 0031 - Disclosure - Terminated Sales Agreements (Details Narrative) Sheet http://daisanalytic.com/role/TerminatedSalesAgreementsDetailsNarrative Terminated Sales Agreements (Details Narrative) false false R32.htm 0032 - Disclosure - Stock Purchase Agreement (Details Narrative) Sheet http://daisanalytic.com/role/StockPurchaseAgreementDetailsNarrative Stock Purchase Agreement (Details Narrative) false false R33.htm 0033 - Disclosure - Deferred Revenue (Details Narrative) Sheet http://daisanalytic.com/role/DeferredRevenueDetailsNarrative Deferred Revenue (Details Narrative) false false R34.htm 0034 - Disclosure - Change in Fair Value of Warrant Liability (Details) Sheet http://daisanalytic.com/role/DerivativeFinancialInstrumentsDetails Change in Fair Value of Warrant Liability (Details) false false R35.htm 0035 - Disclosure - Change in Fair Value of Warrant Liability (Details Narrative) Sheet http://daisanalytic.com/role/ChangeInFairValueOfWarrantLiabilityDetailsNarrative Change in Fair Value of Warrant Liability (Details Narrative) false false R36.htm 0036 - Disclosure - Amortization of Debt Discount on Convertible Note Payable (Details Narrative) Sheet http://daisanalytic.com/role/AmortizationOfDebtDiscountOnConvertibleNotePayableDetailsNarrative Amortization of Debt Discount on Convertible Note Payable (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 0003 - Statement - BALANCE SHEETS (Parenthetical) Process Flow-Through: 0004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) Process Flow-Through: 0005 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Process Flow-Through: 0007 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) dlyt-20130331.xml dlyt-20130331.xsd dlyt-20130331_cal.xml dlyt-20130331_def.xml dlyt-20130331_lab.xml dlyt-20130331_pre.xml true true XML 52 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses, Other (Tables)
3 Months Ended
Mar. 31, 2013
Accrued Expenses Other Tables  
Accrued expenses and other expenses

Accrued expenses, other consist of the following:

 

    March 31, 2013     December 31, 2012  
Accrued expenses, other   $ 46,838     $ 29,946  
Accrued registration rights penalty     5,000       5,000  
Accrued warranty costs     94,053       92,829  
Contractual obligation     13,200       13,200  
    $ 159,091     $ 140,975